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Abstract 
Various recent studies have suggested that regular intake of some non-steroidal 
anti-inflammatory drugs (NSAIDs) have a preventative effect against several types 
of tumours including breast cancer. The term nanotechnology refers to technology 
in which one-billionth of a meter is used as a scale for chemical particle size. This 
work aims to study the effect of both ibuprofen and aspirin on DNA damage using 
peripheral blood lymphocytes from breast cancer patients and comparing the 
results with those from healthy females as a control using the Comet and 
micronucleus assays. Western blot analysis (WBA) was used to investigate the 
effect of these drugs on XRCC3 and p53 proteins, whereas QPCR was to evaluate 
this effect on p53, cox1 and cox2 genes. Two hundred fifty ng/ml of ibuprofen (NP 
and bulk) and 500 ng/ml of aspirin (NP and bulk) were used to treat the 
lymphocytes. Both aspirin and ibuprofen caused a reduction in DNA damage and 
micronucleus formation. Aspirin, both forms, showed a reduction in DNA damage 
in the Comet and micronucleus assays. Ibuprofen both forms, by contrast, showed 
a statistically significant reduction in micronucleus frequency in the micronucleus 
assay, while its preventative effect with the Comet assay was weak or insignificant. 
NPs of both agents were more effective than bulk sizes. Using the Comet repair 
assay, aspirin and ibuprofen nano form catalysed DNA repair to a greater extent 
than their bulk forms. Also, both sizes showed better repair with NSAIDs compared 
to samples repaired without NSAIDs. In WBA aspirin increased the expression of 
XRCC3 protein in healthy cells. However, both NSAIDs decreased that expression 
in cells from BC patients. Furthermore, aspirin increased p53 expression in BC 
patients lymphocytes. With the QPCR method, results of both aspirin forms 
 ii 
 
increased the expression of the p53 gene in BC patient cells statistically 
significantly. Both drugs reduced cox1 expression in healthy volunteers and cancer 
patients lymphocytes. Moreover, cox2 reduction was only in lymphocytes from BC 
patients. The results of this work are consistent with the view that NSAIDs, 
particularly aspirin and ibuprofen, could have a promising role in cancer treatment 
including breast cancer. 
 
 
Keywords: Breast cancer, lymphocyte, aspirin, ibuprofen, nanoform, Comet assay, 
DNA damage, in vitro.  
 
 
 
 
 
 
 
 
 
 
 iii 
 
Acknowledgment 
I would firstly like to thank my supervisor Professor Diana Anderson Established 
Chair of Biomedical Science at the University of Bradford for her help and support. 
I gratefully acknowledge for the opportunity to do this project. She had always 
motivated and encouraged me. This work was impossible without her supervision.  
I would like to thank my second supervisor Dr Adi Baumgartner, and I wish to 
express gratitude for his helpful suggestion and guidance throughout the research. 
He has helped me with calculations and attention to detail in aspects of my work.  
I also owe big thanks to Dr Mojgan Najafzadeh, who has kindly provided blood 
samples from donors and consenting them.  
My special gratitude is due to my wonderful parents for their continual loving 
support from when I was born to the present. Moreover, I wish to convey my loving 
and sincere gratitude to my great wife for her patience and understanding for a 
precious family time that has had to be sacrificed and to my sweet and lovely 
children Mohammed, Hiba and Omer. 
Finally, I would like to acknowledge my country Libya for the financial support, 
without which this work would have been difficult to achieve. 
 
 
 
 iv 
 
Table of Contents 
1. Chapter (1) Introduction ...................................................................................... 1 
1.1 Genotoxicity ................................................................................................ 2 
1.2 Cancer ........................................................................................................ 2 
1.3 Breast cancer .............................................................................................. 3 
1.3.1 Classification of breast cancer ............................................................. 4 
1.3.2 Invasion and metastasis ....................................................................... 4 
1.3.3 Hereditary breast cancer ...................................................................... 6 
1.3.4 The molecular genetics of breast cancer .............................................. 6 
1.4 Oestrogen and its receptor ......................................................................... 7 
1.5 BRCA1 and BRCA2 .................................................................................... 8 
1.6 TP53 tumour suppressor .......................................................................... 10 
1.7 Ataxia telangiectasia (ATM) ...................................................................... 11 
1.8 Phosphatase and tensin homolog gene (PTEN) ....................................... 12 
1.9 XRCC3 ...................................................................................................... 13 
1.10 DNA Repair ........................................................................................... 13 
1.10.1 Base Excision Repair ...................................................................... 16 
1.10.2 Nucleotide Excision Repair (NER) .................................................. 16 
1.10.3 Mismatch Repair (MMR) ................................................................. 17 
1.10.4 Double-Strand Break Repair ........................................................... 18 
1.11 Nanotechnology ..................................................................................... 19 
1.12 Ibuprofen ............................................................................................... 22 
1.12.1 Mechanism of action of ibuprofen ................................................... 23 
1.12.2 Genotoxicity of Ibuprofen ................................................................ 24 
1.12.3 Ibuprofen and breast cancer ........................................................... 25 
1.13 Aspirin ................................................................................................... 25 
 v 
 
1.13.1 Mechanism of Action of Aspirin ....................................................... 26 
1.13.2 Genotoxicity of aspirin ..................................................................... 28 
1.13.3 Aspirin and breast cancer ............................................................... 28 
1.14 Bleomycin .............................................................................................. 29 
1.15 Reactive oxygen species (ROS) ............................................................ 30 
1.16 The Comet assay .................................................................................. 32 
1.17 The cytokinesis blood micronucleus (CBMN) assay .............................. 34 
1.18 Polymerase chain reaction (PCR) ......................................................... 37 
1.18.1 Real time-PCR or quantitative PCR (qPCR) ................................... 39 
1.18.2 RT-PCR/qPCR combined ............................................................... 41 
1.19 Western blot (WB) ................................................................................. 41 
1.20 Aim ........................................................................................................ 42 
2.  Chapter (2) Material and Methods ................................................................... 44 
2.1 Material ..................................................................................................... 45 
2.2 Blood samples .......................................................................................... 46 
2.3 Aspirin and ibuprofen ................................................................................ 47 
2.3.1 Preparation of aspirin and ibuprofen nanoparticles ............................ 47 
2.3.2 Measuring of nano-suspension particle size ...................................... 47 
2.3.3 Zeta potential analysis of nano suspensions ...................................... 48 
2.3.4 Aspirin and Ibuprofen Doses .............................................................. 49 
2.4 Lymphocyte isolation from whole blood .................................................... 49 
2.5 Comet assay ............................................................................................. 50 
2.5.1 Cell treatment ..................................................................................... 50 
2.5.2 Cell lysis ............................................................................................. 50 
2.5.3 Electrophoresis................................................................................... 51 
2.5.4 Neutralization ..................................................................................... 51 
 vi 
 
2.5.5 Staining and comet scoring ................................................................ 51 
2.6 Micronucleus assay .................................................................................. 52 
2.6.1 Preparation of basic culture medium .................................................. 52 
2.6.2 Lymphocyte cell culture ...................................................................... 53 
2.6.3 Culture start ........................................................................................ 53 
2.6.4 Cytokinesis block................................................................................ 53 
2.6.5 End of cell culture ............................................................................... 54 
2.6.6 Cell hypotonic shock treatment .......................................................... 54 
2.6.7 Fixation of cells................................................................................... 54 
2.6.8 Preparation, staining and slide fixation ............................................... 55 
2.7 Comet assay on BLM with and without recovery ...................................... 55 
2.7.1 Reagents ............................................................................................ 55 
2.7.2 Cell treatment of Whole blood cells .................................................... 55 
2.7.3 Treatment over duration of 1hour ....................................................... 56 
2.7.4 supplementation with NSAIDs during recovery .................................. 57 
2.7.5 Embedding of cells in agarose ........................................................... 57 
2.7.6 DNA unwinding and electrophoresis .................................................. 58 
2.7.7 Neutralisation ..................................................................................... 58 
2.7.8 Scoring of Slides ................................................................................ 58 
2.8 PCR .......................................................................................................... 58 
2.8.1 RNA Extraction ................................................................................... 58 
2.8.2 Preparation of cDNA .......................................................................... 59 
2.8.3 Quantitative real time PCR analysis ................................................... 60 
2.9 Western blot .............................................................................................. 61 
2.9.1 Cell culture and protein isolation ........................................................ 61 
2.9.2 Total protein evaluation ...................................................................... 61 
 vii 
 
2.9.3 SDS-PAGE gel preparing and electrophoresis ................................... 62 
2.9.4 Protein transfer from the gel to the membrane ................................... 63 
2.9.5 Antibody staining ................................................................................ 63 
2.9.6 Signal development ............................................................................ 64 
2.9.7 Western blot membrane stripping for restaining ................................. 64 
2.10 Cell viability ............................................................................................ 64 
2.11 Statistical analysis ................................................................................. 65 
3. Chapter (3) The Comet assay in lymphocytes after treatment with ibuprofen 
and aspirin………... ………………………..….…………………...…………………..66 
3.1 Introduction ............................................................................................... 67 
3.2 Materials ................................................................................................... 69 
3.3 Methods .................................................................................................... 69 
3.4 Scoring and data statistical analysis ......................................................... 69 
3.5 Results ...................................................................................................... 70 
3.5.1 Ibuprofen NP and bulk forms concentration responses on lymphocytes 
DNA  from female healthy volunteers ............................................................. 70 
3.5.2 Ibuprofen NP and bulk forms concentration response in lymphocytes 
DNA from BC patients .................................................................................... 71 
3.5.3 Comparison of Ibuprofen NP and bulk forms for concentration 
responses on lymphocytes DNA from BC patients and healthy volunteers .... 73 
3.5.4 Aspirin NP and bulk forms concentration responses on lymphocytes 
DNA from healthy volunteers .......................................................................... 74 
3.5.5 Aspirin NP and bulk forms concentration responses in lymphocyte 
DNA from BC patients .................................................................................... 76 
3.5.6 Comparing aspirin NP and bulk forms concentration responses in 
lymphocyte DNA from BC patients and healthy volunteers............................. 77 
3.6 Discussion ................................................................................................ 80 
 viii 
 
4. Chapter (4) Anti genotoxic of ibuprofen and aspirin on lymphocytes in the 
microncleus assay.........................................................................................……82 
4.1 Introduction ............................................................................................... 83 
4.2 Materials and Methods.............................................................................. 86 
4.2.1 Materials ............................................................................................. 86 
4.2.2 Methods ............................................................................................. 86 
4.2.3 Statistical Analysis .............................................................................. 86 
4.3 Results ...................................................................................................... 87 
4.3.1 Results of CBMN Assay following ibuprofen and aspirin (NPs and 
bulk) exposure to lymphocytes ....................................................................... 87 
4.3.2 Ibuprofen and aspirin (NPs and bulk size) concentration response on 
MNi induction in lymphocytes from healthy female individuals. ...................... 90 
4.3.3 Ibuprofen and aspirin (NPs and bulk size) concentration response on 
MNi induction in lymphocytes from BC patients .............................................. 91 
4.3.4 Comparing ibuprofen and aspirin (NPs and bulk) concentration 
response on MNi frequencies in lymphocytes from BC patients and  healthy 
females volunteers .......................................................................................... 92 
4.4 Discussion ................................................................................................ 94 
5.  Chapter (5) Comet assay on BLM with and without recovery ...................... 96 
5.1 Introduction ............................................................................................... 97 
5.2 Materials and Methods............................................................................ 100 
5.2.1 Materials ........................................................................................... 100 
5.2.2 Methods ........................................................................................... 100 
5.2.3 Statistics ........................................................................................... 101 
5.3 Results .................................................................................................... 102 
5.3.1 Aspirin and ibuprofen concentration response on lymphocyte from 
healthy female volunteers treated with bleomycin ........................................ 102 
 ix 
 
5.3.2 Aspirin and ibuprofen concentration response on lymphocyte from BC 
patients treated with bleomycin ..................................................................... 105 
5.4 Discussion .............................................................................................. 108 
6.  Chapter (6) investigating XRCC3 and P53 proteins in lymphocytes after 
treatment with aspirin and ibuprofen using Western blot technique ............ 110 
6.1 Introduction ............................................................................................. 111 
6.2 Material and methods ............................................................................. 115 
6.3 Results .................................................................................................... 115 
6.3.1 XRCC3 expression in lymphocyte from healthy female individuals 
treated with both forms of aspirin and ibuprofen individually......................... 115 
6.3.2 XRCC3 expression in lymphocyte from BC patients treated with aspirin 
and ibuprofen both forms .............................................................................. 117 
6.3.3 P53 expression in lymphocyte from healthy female individuals treated 
with both forms of aspirin and ibuprofen individually ..................................... 118 
6.3.4 P53 expression in lymphocyte from BC patients treated with aspirin 
and ibuprofen both forms .............................................................................. 119 
6.4 Discussion .............................................................................................. 120 
7.  Chapter (7) studying P53, COX1 and COX2 genes expression in 
lymphocytes using real time PCR  ................................................................... 124 
7.1 Introduction ............................................................................................. 125 
7.2 Material and Methods ............................................................................. 128 
7.3 Results .................................................................................................... 128 
7.3.1 P53 mRNA abundance in lymphocytes from healthy female individuals 
treated with both forms of aspirin and ibuprofen individually. ........................ 128 
7.3.2 P53 mRNA abundance in lymphocytes from BC patients treated with 
both forms of aspirin and ibuprofen individually. ........................................... 130 
7.3.3 COX1 mRNA abundance in lymphocytes from healthy female 
volunteers treated with both forms of aspirin and ibuprofen individually ....... 132 
 x 
 
7.3.4 COX1 mRNA abundance in lymphocytes from BC patient  treated with 
both forms of aspirin and ibuprofen individually ............................................ 134 
7.3.5 COX2 mRNA abundance in lymphocytes from healthy female 
individuals treated with both forms of aspirin and ibuprofen individually. ...... 136 
7.3.6 The effects of aspirin and ibuprofen both forms, on the expression of 
COX2 in lymphocytes from BC patients. ....................................................... 138 
7.4 Discussion .............................................................................................. 140 
8. Chapter (8) General Discussion ................................................................ 143 
8.1 Effect of aspirin and ibuprofen on DNA damage using the Comet assay 145 
8.2 Ibuprofen and aspirin effect on MNi induction in the micronucleus assay
 ……………...…………………………………………………………………. 146 
8.3 Comparing Comet and micronucleus assays results .............................. 147 
8.4 Comet assay on BLM with and without recovery .................................... 149 
8.5 Investigation of XRCC3 and P53 proteins in Lymphocytes from Healthy 
Female and BC Patients Treated with Both forms of Aspirin and Ibuprofen using 
Western Blot ..................................................................................................... 150 
8.6 The effect of both aspirin and ibuprofen on COX1, COX2 and P53 genes 
expression in lymphocytes from healthy female and BC Patients using Real Time 
PCR ………………………………………………………………………………….152 
8.7 Conclusion .............................................................................................. 156 
8.8 Future work ............................................................................................. 156 
9.  Chapter (9) References ................................................................................. 158 
     Appendix …………………………………………………………………..……… 183 
 
 
 
 
 
 xi 
 
List of figures 
Figure 1 Metastatic cascade. Metastatic cells detach from the primary tumor site, 
migrate and invade through the BM and ECM, enter the blood or lymphatic vessels 
(intravasation), travel in the blood/or lymphatic vessels, leave the blood orlymphatic 
vessels (Guan, 2015). .............................................................................................. 5 
Figure 2 shows p53 role in different cellular pathways (Bieging et al., 2014). ........ 10 
Figure 3 DNA several repair pathways ................................................................... 15 
Figure 4 Ibuprofen structural formula; taken from http://pubchem.ncbi.nlm.nih.gov
 ............................................................................................................................... 23 
Figure 5 Biosythesis of prostaglandin and leukotrienes. NSAIDs block 
cyclooxygenase (Pardutz and Schoenen, 2010). ................................................... 24 
Figure 6 Salicylic Acid and Aspirin structural formula taken from 
http://www.theodora.com ....................................................................................... 26 
Figure 7  The role of aspirin inhibiting inflammatory mediators  (Wood, 2015) ...... 27 
Figure 8 Aspirin mechanism of action (Gasparyan et al., 2008). ........................... 28 
Figure 9 A general protocol for alkaline and neutral Comet assay ......................... 33 
Figure 10 Several possible fates of cultured cells in the CBMN assay (Fenech, 
2007). ..................................................................................................................... 36 
Figure 11 Photomicrographs of the cells scored in the CBMN assay. (a) 
mononucleated (MonoNC cell); (b) binucleated (BiNC) cell; (c) multinucleated 
(multiNC) cell; (d) early necrotic cell; (e) late apoptotic cell; (f) BN cell with one or 
more MNi; (g) BN with an NPB and a MN; (h) BN cell with NBUDs (Fenech, 2007).
 ............................................................................................................................... 36 
Figure 12 shows the exponential amplification of the gene in PCR (Singh et al., 
2014) ...................................................................................................................... 39 
Figure 13 Concentration response of ibuprofen 250 ng/ml (NPs and bulk), SE, and 
significance on lymphocytes DNA from healthy volunteers using Olive tail moment. 
(N = 20) .................................................................................................................. 70 
Figure 14 Concentration response of ibuprofen 250 ng/ml (NPs and bulk), SE, and 
significance on lymphocytes DNA from healthy volunteer using % Tail DNA. (N = 
20) .......................................................................................................................... 71 
 xii 
 
Figure 15 Concentration response of Ibuprofen (NPs and bulk), SE  and 
significance on lymphocyte DNA from BC patients using Olive tail moment. (N = 
20) .......................................................................................................................... 72 
Figure 16 Concentration response of Ibuprofen (NPs and bulk), SE and 
significance on lymphocyte DNA from BC patients % Tail DNA. (N = 20) ............. 72 
Figure 17 Comparison of ibuprofen concentration responses, SE, and significance 
on lymphocytes DNA from both healthy volunteers and BC patients using Olive tail 
moment. (N = 20) ................................................................................................... 73 
Figure 18 Comparison of ibuprofen concentration responses, SE, and significance 
on lymphocytes DNA from both healthy volunteers and BC patients using % Tail 
DNA. (N = 20) ........................................................................................................ 74 
Figure 19 Concentration response to aspirin (NPs and bulk), SE, and significance 
in lymphocyte DNA from healthy volunteers using Olive tail moment. (N = 20)  .... 75 
Figure 20 Concentration response to aspirin (NPs and bulk), SE, and significance 
in lymphocyte DNA from healthy volunteers using % Tail DNA. (N = 20) .............. 75 
Figure 21 Concentration responses of aspirin (NP and bulk), SE and significance in 
lymphocyte DNA from breast cancer patients using Olive tail moment. (N = 20) ... 76 
Figure 22 Concentration responses of aspirin (NP and bulk), SE and significance in 
lymphocyte DNA from breast cancer patients using % Tail DNA. (N = 20) ............ 77 
Figure 23 Comparison of the aspirin concentration responses, SE, and significance 
in lymphocyte DNA from both healthy volunteers and BC patients using Olive tail 
moment. (N = 20) ................................................................................................... 78 
Figure 24 Comparison of the aspirin concentration responses, SE, and significance 
in lymphocyte DNA from both healthy volunteers and BC patients using % Tail 
DNA. (N = 20) ........................................................................................................ 78 
Figure 25 Typical comet image showing control lymphocyte cells (undamaged 
DNA) ...................................................................................................................... 79 
Figure 26 Typical comet image showing damage in lymphocytes cell DNA where 
the head represents undamaged DNA and tail reflects damaged DNA. ................ 79 
Figure 27  MN frequency in lymphocytes from healthy females exposed to 
ibuprofen and aspirin including SE and significance. (N=5) ................................... 90 
 xiii 
 
Figure 28  MN frequency in lymphocytes from BC patients exposed to ibuprofen 
and aspirin including SE and significance. (N=5) ................................................... 91 
Figure 29 Comparison between MN frequencies in lymphocytes from healthy 
females and BC patients exposed to ibuprofen and aspirin including SE and 
significance. (N = 5) ............................................................................................... 92 
Figure 30 shows (A) Binucleated, (B) Mononucleated, and (C) Multinucleated cells.
 ............................................................................................................................... 93 
Figure 31 shows binucleated cells (A) with one MN and (B) with two MNi. ............ 93 
Figure 32 illustrates the comparison of the aspirin and ibuprofen (both forms) 
concentration-response, (±SE), on lymphocyte DNA from healthy female 
volunteers treated with bleomycin using Olive tail moment (n = 15). ................... 103 
Figure 33 illustrates the comparison of the aspirin and ibuprofen (both forms) 
concentration-response, (±SE), on lymphocyte DNA from healthy female 
volunteers treated with bleomycin using % Tail DNA (n = 15). ............................. 104 
Figure 34 Comparison of the aspirin and ibuprofen (both forms) concentration-
response, SE, and significance on lymphocyte DNA from BC patients treated with 
bleomycin using Olive tail moment (n=15) ........................................................... 106 
Figure 35 Comparison of the aspirin and ibuprofen (both forms) concentration-
response, SE, and significance on lymphocyte DNA from BC patients treated with 
bleomycin using % Tail DNA (n=15) ..................................................................... 107 
Figure 36 showing the effect of aspirin and ibuprofen both forms on XRCC3 protein 
expression in lymphocytes from healthy female individuals incubated for 8 and 24 h 
individually. (A, B) Developed bands of XRCC3, and β-actin by immunoblotting. β-
actin was used as a control. (C, D) demonstrating relative expression of XRCC3 
after treatment with aspirin and ibuprofen both forms individually, SE, and 
significance comparing to untreated cells. (N=3) ................................................. 116 
Figure 37 Western Blot validation results illustrating the effect of aspirin and 
ibuprofen both forms on XRCC3 protein expression in lymphocytes obtained from 
BC patients incubated for 8 and 24 h individually. (A, B) Images displaying Western 
blot results of XRCC3, β-actin was used as a control. (C, D) Graph displaying 
relative expression of XRCC3 after treatment with aspirin and ibuprofen both forms 
individually, SE, and significance comparing to untreated cells. (N=3) ................ 117 
 xiv 
 
Figure 38 Western Blot verification results demonstrating the effect of aspirin and 
ibuprofen both forms on P53 protein expression in lymphocytes obtained from 
female healthy control incubated for 8 and 24 h individually. (A, B) Images 
displaying Western blot results of p53 and β-actin which was used as a control. (C, 
D) Graph displaying quantitative analysis of P53 relative expression after treatment 
with aspirin and ibuprofen both forms individually, SE, and significance comparing 
to untreated cells. (N=3) ....................................................................................... 118 
Figure 39 Western Blot validation results demonstrating the effect of aspirin and 
ibuprofen both forms on p53 protein expression in lymphocytes obtained from BC 
patients incubated for 8 and 24 h individually. (A, B)  Western blot results show 
representative examples for expression of p53, as well as β-actin which served as 
an internal control. (C, D) Eexhibiting relative expression of p53 after treatment 
with aspirin and ibuprofen both forms individually, protein levels were expressed as 
means in bar graphs including SE and significance comparing to untreated cells. 
(N=3) .................................................................................................................... 119 
Figure 40 Real-time PCR (qPCR) results expressed in relative changes of p53 
mRNA over the control, using β actin as an endogenous housekeeping gene in 
lymphocytes from healthy female volunteers. (A) Relative expression level of P53 
mRNA in ASP BULK treatment. (B) Relative expression level of P53 mRNA in ASP 
NPs treatment. (C) Relative expression level of P53 mRNA in IBU BULK treatment. 
(D) Relative expression level of P53 mRNA in IBU NPs. Results are expressed as 
mean ± SEM and significance compared with the 0 h treatment. (N=3) .............. 129 
Figure 41 Real-time PCR (qPCR) results expressed in relative changes of P53 
mRNA over the control, using β actin as an endogenous housekeeping gene in 
lymphocytes from BC patients. (A) Relative expression level of P53 mRNA in ASP 
BULK treatment. (B) Relative expression level of P53 mRNA in ASP NPs 
treatment. (C) Relative expression level of P53 mRNA in IBU BULK treatment. (D) 
Relative expression level of P53 mRNA in IBU NPs. Results are expressed as 
mean ± SEM and significance compared with the 0hr treatment. (N=3) .............. 131 
Figure 42 Real-time PCR (qPCR) results expressed in relative changes of COX1 
mRNA over the control, using β actin as an endogenous housekeeping gene in 
lymphocytes from female healthy volunteers. (A) Relative expression level of 
 xv 
 
COX1 mRNA in ASP BULK treatment. (B) Relative expression level of COX1 
mRNA in ASP NPs treatment. (C) Relative expression level of COX1 mRNA in IBU 
BULK treatment. (D) Relative expression level of COX1 mRNA in IBU NPs. Results 
are expressed as mean ± SEM and significance compared with the 0hr treatment. 
(N=3) .................................................................................................................... 133 
Figure 43 Real-time PCR (qPCR) results expressed in relative changes of COX1 
mRNA over the control, using β actin as an endogenous housekeeping gene in 
lymphocytes from BC patients. (A) Relative expression level of COX1 mRNA in 
ASP BULK treatment. (B) Relative expression level of COX1 mRNA in ASP NPs 
treatment. (C) Relative expression level of COX1 mRNA in IBU BULK treatment. 
(D) Relative expression level of COX1 mRNA in IBU NPs. Results are expressed 
as mean ± SEM and significance compared with the 0hr treatment. (N=3) ......... 135 
Figure 44 Real-time PCR (qPCR) results expressed in relative changes of COX2 
mRNA over the control, using β actin as an endogenous housekeeping gene in 
lymphocytes from female healthy volunteers. (A) Relative expression level of 
COX2 mRNA in ASP BULK treatment. (B) Relative expression level of COX2 
mRNA in ASP NPs treatment. (C) Relative expression level of COX2 mRNA in IBU 
BULK treatment. (D) Relative expression level of COX2 mRNA in IBU NPs. Results 
are expressed as mean ± SEM and significance compared with the 0hr treatment. 
(N=3) .................................................................................................................... 137 
Figure 45 Real-time PCR (qPCR) results expressed in relative changes of COX2 
mRNA over the control, using β actin as an endogenous housekeeping gene in 
lymphocytes from BC patients. (A) Relative expression level of COX2 mRNA in 
ASP BULK treatment. (B) Relative expression level of COX2 mRNA in ASP NPs 
treatment. (C) Relative expression level of COX2 mRNA in IBU BULK treatment. 
(D) Relative expression level of COX2 mRNA in IBU NPs. Results are expressed 
as mean ± SEM and significance compared with the 0hr treatment. (N=3) ......... 139 
 
 
 
 
 xvi 
 
List of tables 
Table 1 Chemicals with their corresponding sources and CAS numbers. .............. 45 
Table 2 List of primers ........................................................................................... 46 
Table 3 primary and secondary antibodies ............................................................ 46 
Table 4 Six different treatments which were used in the CBMN assay .................. 53 
Table 5 Second incubation for all 6 tubes incubated for 30 min at 37 °C. .............. 57 
Table 6 Various cytological scoring parameters, including cell mitotic status (BiNC, 
MonoNC, MultiNC), NDI and chromosomal damage/instability parameters in the 
form of NPBs and NBUDs in lymphocytes from 5 healthy female volunteers  
following exposure to ibuprofen and aspirin (NPs and bulk). (N = 5) ..................... 88 
Table 7 Various cytological scoring parameters, including cell mitotic status (BiNC, 
MonoNC, MultiNC), NDI and chromosomal damage/instability parameters in the 
form of NPBs and NBUDs in lymphocytes from 5 BC patients  following exposure 
to ibuprofen and aspirin (NPs and bulk). ................................................................ 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvii 
 
Abbreviations  
ALS                                Alkali-labile site  
ASP:                               Aspirin 
ATM                               Ataxia telangiectasia 
BC                                  Breast cancer 
BER                               Base excision repair  
BLM                               Bleomycin  
BLMR                             Bleomycin with allowing repair  
CBMN                            Cytokinesis Block Micronucleus assay 
COX                               Cyclooxygenases  
CPD                               Cyclobutane pyrimidine dimers  
CPT                                Camptothecin 
CT                                   Threshold cycle  
Cyto B                             Cytochalasin-B 
DDH2O                            Deionized distilled water 
DMSO                              Dimethyle sulfoxide  
dNTPs                             Deoxynucleoside triphosphate  
DSB                                 DNA double strand break  
ECL                                  Enhanced chemiluminescence 
EDTA                               Ethylene diamine tetrachloro acetic acid  
EL                                    Erythrocyte lysis buffer 
EMQN                              European Molecular Genetics Quality Network 
ER                                    Oestrogen receptors 
FBS                                  Foetal bovine serum  
GBM                                 Glioblastoma multiform 
H2O2                                 Hydrogen peroxide  
HBOC                               Hereditary Breast and Ovarian Cancer Syndrome 
HER2                                Human epidermal growth factor  
HO.                                   Hydroxyl radical  
HR                                     Homologous recombination 
Ibu                                     Ibuprofen 
IDLs                                   insertion/deletion loops  
 xviii 
 
LMP                                Low melting point agarose  
MAPK                             Mitogen activated protein kinases 
MMC                               Mitomycin C 
MMR                              Mismatch repair  
MNi                                Micronucleus 
NaCl                              Sodium chloride  
NaOH                            Sodium hydroxide  
NBUDs                          Nuclear Buds  
NDI                                The nuclear division index  
NER                               Nucleotide excision repair 
Ng                                  Nanogram 
NHEJ                              non-homologous end joining  
NMP                               Normal melting point agarose  
NPBS                             Nucleoplasmic bridges  
NPs                                Nanoparticles  
NSAID                            Nonsteroidal anti-inflammatory drugs 
O2-                                 Superoxide radical  
OTM                               Olive tail moment 
PC                                  Positive control 
PCR                               Polymerase chain reaction 
PHA                               Phytohaemagglutinin  
 PIP3                              phosphatidylinositol-3,4,5-triphosphate 
PTEN                             Phosphatase and tensin homolog gene 
PTMs                             Posttranslational modifications  
PVDF                             Nitrocellulose and polyvinylidene fluoride  
ROS                               Reactive oxygen species  
RT                                  Room temperature  
SSB                               Single strand break 
STM                               Scanning tunneling microscope  
TCGA                             The Cancer Genome Atlas 
TEM                               Transmission electron-microscope 
Trx                                 Thioredoxin  
WB                                Western blot 
 xix 
 
μM                               Micro molar 
 1 
 
 
 
 
 
 
 
Chapter 1- Introduction   
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1. Introduction 
1.1 Genotoxicity 
Genotoxicity can be defined as any alteration or damage by a toxicant in the 
genome, which under some conditions correlates to mutagenicity. Hence, 
genotoxicity can be divided into different gene alterations (insertion, deletion and 
point mutation), clastogenic impacts (breakage in DNA strands leading to 
alterations in chromosomes structures), and aneugenic defects (numeral 
chromosomal aberrations leading to the development of aneuploidy or polyploidy) 
(Eastmond et al., 2009). Genetic mutation and DNA damage can be introduced by 
different factors having genotoxic potential such as chemical substances and 
physical agents (UV and X radiation). This genetic alteration could be detrimental 
where it increases the chance of cancer, congenital defects, and inflammation.  
Consequently, genotoxicology research becomes an essential part of biomedical 
science that enable scientists to study and discover the impact of other chemicals, 
and physical agents. 
1.2 Cancer    
The term cancer refers to diseases in which cells divide and proliferate abnormally 
without any control and have the ability to invade other parts of the body. Some 
types of cancer have the capacity to spread to other tissues of the body through 
the blood and lymph systems or through direct invasion (Hanahan and Weinberg, 
2000, 2011). There are more than 100 different types of cancer. Most of them are 
classified depending on pathological criteria, where cancers are named according 
to the organ or type of cell in which they originate - for instance, cancer that 
develops in the breast is called breast cancer; cancer that develops in melanocyte 
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cells of the skin is called melanoma (Hoadley et al., 2014). However, extensive-
scale genomics is providing at the present detailed molecular descriptions of 
thousands of cancers, producing a systematic molecular-based classification of 
tumours. Indeed, The Cancer Genome Atlas (TCGA) Project Network completed 
genome-wide studies of ten different malignancies: the glioblastoma multiform 
(GBM) (Hoadley et al., 2014; McLendon et al., 2008). 
1.3 Breast cancer 
Breast cancer (BC) has been found as the most common type of cancer affecting 
females worldwide. It accounts for almost 1 in 4 female malignancy cases globally. 
In 2008, 1.38 million patients were diagnosed with breast cancer and this number 
has been estimated to reach 1.7 million by 2020 (Bhikoo et al., 2011). Despite the 
fact that BC is more common in the developed countries compared to developing 
countries, the overall survival from BC is increasing but survival remains poorer in 
developing nations. This was found to be due to reasons such as adaptation to 
western life styles by developing nations, less BC screening and also poorer health 
care services (Bhikoo et al., 2011; Osaro, 2016). Various aspects of BC 
epidemiology have demonstrated that sex steroid hormones play a crucial role in 
carcinogenesis (Henderson and Feigelson, 2000; Hormones and Group, 2013).  It 
has been shown that the frequent exposure to some risk factors such as 
oestrogens lead to an increase in breast cell proliferation. However protective 
effects have been noticed when there was a reduction in exposure to female sex 
hormones to the same cell types (Cuzick, 2003; Musgrove, 2013). The cumulative 
exposure of women to steroid hormones induces breast cell proliferation and this in 
turn increases the proportion of genetic mutation which is essential to cancer 
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growth and development (Jung et al., 2015). Some studies proved that many 
factors including sex hormones are participating in the emergence of cancer in the 
breast, for instance external environmental contaminants, oncogenic viruses, and 
inflammatory factors (Chace, 2015; Glaser et al., 2004). 
1.3.1 Classification of breast cancer 
BC is categorised into two main types which are: 1) carcinoma in situ breast cancer 
and 2) invasive carcinoma breast cancer. The In situ carcinoma is subdivided into 
ductal or lobular carcinoma in situ according to the tumour origin. In both subtypes, 
there is no invasion and the tumour cells remain localised and hence there is only 
a small chance for metastasis. However, invasive breast carcinoma is associated 
with metastasis and it occurs when in situ ductal or lobular tumour cells migrate 
over their natural boundaries, namely through their basement membrane with the 
consequence of spreading to the neighbouring tissues (Richie and Swanson, 2003; 
Ward et al., 2015).  
1.3.2 Invasion and metastasis 
Breast cancer has the ability to invade the adjacent tissue and this is the main fatal 
aspect of this tumour type (Figure 1). The new tumour may relocate to and grow in 
other, secondary sites of the body distal to the primary breast tumour (Talmadge 
and Fidler, 2010). The capacity of BC cells to migrate and invade surrounding 
tissues, and the process of reduced adherence to the main tumour are 
demonstrated and well known at the cellular level (Talmadge and Fidler, 2010). 
However, at the molecular level these processes are yet poorly understood. The 
invasion process begins when the cancerous cells head to the lymphatic system 
and blood vessels, then into the blood stream, and eventually to a new healthy 
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tissue where they settle down and grow to create secondary tumour sites in a 
process called metastasis. The secondary tumours have properties that are often 
similar to the original tumour. The majority of uncured tumours have a high 
potential to invade and metastasise. Nevertheless, some other cancer types have 
very low tendency to metastasis, for instance basal and glioma carcinoma cells. 
Metastases from BC have been seen decades after the primary tumour treatment. 
The majority of cancer deaths are caused by cancer metastasis and not the 
primary tumour. Cancer metastasis is the main cause of morbidity and mortality 
and accountable for about 90% of cancer deaths (Guan, 2015; Karrison et al., 
1999). Tumour cells can be present in three different states at secondary malignant 
sites: solitary cells in passivity, active pre-angiogenic, and micro metastasis. This 
means that there is no increase in tumour size because apoptosis is balanced with 
cell proliferation, so could be small and clinically unidentifiable, or could be large 
and detectable by existing technology (Demicheli, 2001; van Zijl et al., 2011).  
 
Figure 1 Metastatic cascade. Metastatic cells detach from the primary tumor site, migrate and 
invade through the BM and ECM, enter the blood or lymphatic vessels (intravasation), travel in the 
blood/or lymphatic vessels, leave the blood orlymphatic vessels (Guan, 2015). 
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1.3.3 Hereditary breast cancer 
The association between breast cancer and family history was first described in 
1866 by French pathologist Paul Broca. This was when Broca’s wife was suffering 
from early onset BC when she was in the early stage of her life and Broca followed 
a history of her family and faound that the BC could be traced back through four 
generations (Broca, 1866; van der Groep et al., 2011). Broca’s observation was 
considered as the first description that a predisposition to getting BC could be 
inherited and thereby passed down through generations. Since then the 
contribution of the family history and BC was established and considered as one 
risk factor for the pathology of the BC disease (Claus et al., 1998; van der Groep et 
al., 2011). 
1.3.4 The molecular genetics of breast cancer 
Breast cancer arises as a result of complicated genetic alteration and epigenetic 
formation, and these events take place during the tumourigenesis of breast cells. 
The consequence of genetic alteration or mutation can be the changing of 
nucleotide base pairs in specific places of genes, or complete gene alteration or 
gene loss, which in turn leads to aberrant RNA, protein, and loss of gene function 
(Sadikovic et al., 2008). Epigenetic changes can also be involved in the aetiology 
of BC where it prevents the transcription of some genes without any changes in 
base pair sequence (Buchholz and Wazer, 2002). The somatic mutation theory 
which was presented by Boveri in 1914 became the principal genetic guide in the 
twentieth century (Boveri, 1914; Suter and Marcum, 2007). This theory suggests 
that cancer is the consequence of hereditary and/or sporadic genetic mutations in 
germinal and somatic cells, respectively. Many cellular pathways are affected by 
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such mutations for instance, mitogen-activated protein kinases (MAPK), RB/E2F 
that arrest cells in G1, intracellular apoptosis pathway (P3K/AKT/mTOR), and 
TP53 pathways, which function as tumour suppressors. These pathways are 
essential in controlling cell growth and proliferation and hence disturbance in their 
roles due to mutation can cause cancer particularly breast cancer (Suter and 
Marcum, 2007; Zhang et al., 2015). BC is considered as a complicated molecular 
disease, where the mutations take place in genes, which are responsible for 
growth and proliferation. Sporadic formation of BC is the most prevalent and the 
oncogenes, which are initially mutated, in turn lead to dysregulation of cell 
proliferation and performance, which eventually lead to malignancy. Genes that 
have inheritable mutation tendencies are more responsible for familial BC, which is 
responsible for only 5%-10% of all breast cancer cases (Suter and Marcum, 2007). 
1.4 Oestrogen and its receptor 
The oestrogen hormone is an effective mitogen which induces cell proliferation in 
normal breast epithelial cells and ductal morphogenesis but also plays an essential 
role in carcinogenesis of BC through the over-expression of the oestrogen receptor 
(ER). However, scientists still debate the role of oestrogen in BC (Russo and 
Russo, 2006; Simoes et al., 2015). Epidemiological research show evidence that 
BC risk is positively correlated with post-menopausal levels of oestrogen. The 
impact of oestrogen mostly presented through connecting to two nuclear ligand to 
activate transcription factors, the ERs ERα and ERβ, which finally bind to 
oestrogen-responsive elements in the DNA sequence to regulate the transcription 
of specific genes (Simoes et al., 2015). In BC tissue the ERα isoform considered 
as an essential agent in mitogenic processes. This isoform is highly expressed in 
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the early stage of BC (Hewitt et al., 2005). Higher levels of ER are expressed in 
nearly 66% of BC tissues compared to normal breast tissues. A stable receptor 
dimer is formed by binding oestrogen to ERα and this phosphorylated dimer 
activates conformational change (Butt et al., 2005; Suter and Marcum, 2007).  In 
BC the mitogenic processes can also be activated by binding growth factors with 
ER, for instance TGFα, EGF, and IGF-I (Butt et al., 2005; Simoes et al., 2015). The 
way that ERβ participates in the development of BC is still unclear, as well as, the 
ratio of ERβ to ERα that is essential in BC. Many studies found that the level of 
ERα-positive cells in the Oestrogen-dependent breast cancers is higher than it is 
proportion in normal breast tissue, however, the expression of ERβ is reduced, 
demonstrating an antagonistic relationship between ERα and ERβ (Renoir et al., 
2013). This finding supports the theory that ERα play an important role in 
malignancies, and upregulation of ERβ may inhibit the promotion of breast tumour 
(Chen et al., 2014). Eventually, both ER-negative and ER-positive tumours can be 
found in breast tissue. A unique molecular subgroup can be formed by ER-positive 
tumours, whereas, the highly aggressive form of BC is often associated with ER-
negativity and a poor prognosis (Suter and Marcum, 2007).   
1.5 BRCA1 and BRCA2  
Around 10,000 to 20,000 women yearly are diagnosed with breast cancer that 
shows a family history of the disease. This suggests the probability of a germline 
mutation having occurred. In the 1900s, genetic studies using lymphocytes from 
these families led to the discovery of two genes BRCA1 and BRCA2. These genes 
show germline mutations in 65% of family malignant breast cases. BRCA1 and 
BRCA2 are identified tumour suppressor genes. BRCA1 and BRCA2 are the most 
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important and predisposition genes, inhibiting risks of breast and ovarian cancer for 
a lifetime (Pelttari et al., 2015). The proteins that are encoded by these genes have 
a role in the elimination of DNA damage and genomic integrity. These two genes 
are located on different chromosomes and have dissimilar genetic sequences; 
however, they share many similar functional qualities. BRCA1 and BRCA2 encode 
proteins which form a protein complex with Rad51 which is very important in the 
recognition and repair of DNA double strand breakage. But mutated BRCA1 and 
BRCA2 can function adversely and inhibit the repair of double strand DNA 
breakage (Cunningham et al., 2014; Zhong et al., 1999). Eventually, the BRCA1 
and BRCA2 encoded proteins are expressed through cell division in G1/S and 
G2/M phases. Additionally, the expression of wild-type BRCA1 is high in 
proliferating cells. BRCA1 has an essential role in a checkpoint response 
(Buchholz and Wazer, 2002). The cellular disorders in DNA double-strand repair 
increases the proportion of breast cancer formation in female with mutated BRCA 
genes in germline cells. The unrepaired damaged DNA in turn lead to additional 
mutations (Buchholz and Wazer, 2002; Zhong et al., 1999). Additionally, both 
proteins BRCA1 and BRCA2 are functioning in homologous recombination (HR), 
an essential DNA repair procedure that uses the undamaged sister chromatid to 
perform high-fidelity repair of mainly replication-associated with DNA double-strand 
breaks (DSB). HR appears to be the significant pathway responsible for  protecting 
the integrity of the genome throughout proliferation, whereas, other DSB repair 
mechanisms are error-prone and may generate chromosome disorders such as 
deletions and translocations (Schlacher et al., 2011). Interestingly, in the hereditary 
breast and ovarian cancer syndrome (HBOC) the BRCA1 associated with BC is 
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predominantly oestrogen-receptor (ER) negative, however BRCA2 correlated with 
BC have similar distribution of cancer subtypes as found sporadically (Roy et al., 
2012). 
1.6 TP53 tumour suppressor  
P53 is considered as a tumour suppressor and confirmed to be ‘the guardian of the 
genome’ due to its contribution in a variety of cellular pathways (Figure 2) such as 
DNA repair, apoptosis, cell cycle arrest, and senescence (Kim et al., 2015).The 
significance of p53 in cancer suppression is clear, where it is inactive in more than 
50% of all sporadic human tumours (Bieging et al., 2014).  
 
Figure 2 shows p53 role in different cellular pathways (Bieging et al., 2014).  
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The p53 role in the aging status is clearly understood in vivo. In a transgenic 
mouse model, a truncated form of p53 that enhances wild-type p53 activity 
augmented resistance to spontaneous cancer development. Recent researchers 
reported that the expression of p53 decreased in neural progenitor cells and 
mesenchymal stem cells depend on an age-dependent manner (Wilson et al., 
2010) and that p53 efficiency decreases due to  age at the organismal level (Feng 
et al., 2007). In general, these outcomes suggest that the decrease or loss of p53 
expression throughout aging may involve in the development of cancer (Kim et al., 
2015). P53 tumour suppressor gene has also been found as one of the most 
mutated genes in breast cancer and is found in approximately of 20-40% of the 
cases. This consequently results in the loss of its growth suppressive character 
and eventually leads to uncontrolled cell proliferation (Christgen et al., 2012; Ergul 
and Sazci, 2001). In addition, individuals with mutations in the genes BRCA1 and 
BRCA2 have a high possibility for development of p53 mutations (Roy et al., 2012). 
Furthermore, change in the genes involved in the p53 pathway are also linked to 
the development of breast cancer, for instance: G1 cell cycle checkpoint kinase is 
one of the p53 gene pathway and its mutation results in breast cancer due to 
destabilisation of p53, which ultimately results in proliferation of cells with damaged 
DNA (Bieging et al., 2014; Suter and Marcum, 2007).  
1.7 Ataxia telangiectasia gene (ATM) 
This gene phosphorylates various key proteins which activate the DNA damage 
checkpoint, initiates cell cycle arrest, DNA repair or apoptosis. The mutation of this 
gene results in a deficiency in the DNA repair system as well as a cell-cycle 
checkpoint with a net effect of evolving into breast cancer. The mutation of this 
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gene has been observed to increase the chance for getting breast cancer by 100-
200 fold compared to people with the normal ATM gene. Waha (1998) investigated 
the level of ATM transcripts in some breast cancer patients, benign breast cancer 
and normal individuals. They found that the ATM transcript level was the lowest in 
the breast cancer patients and the highest levels were found in the normal 
individuals. However, benign breast cancer cases showed moderate levels 
between breast cancer and normal individuals (Ergul and Sazci, 2001). Recently 
some studies suggested the ATM gene as risk marker in breast cancer, where 
ATMmvp2a hypermethylation can be detectable in blood previous to disease 
onset, and this hypermethylation is associated with increased breast cancer risk 
(OR=1.89). However, the mechanism of increased risk is not clearly understood, 
nor possible causes of increased hypermethylation at this region (Brennan et al., 
2013). 
1.8 Phosphatase and tensin homolog gene (PTEN) 
Phosphatase and tensin homolog gene (PTEN) is classified as a phosphatase; 
however, it differs from phosphatase  as it targets fatty acids instead of proteins. Its 
target is called phosphatidylinositol-3,4,5-triphosphate (PIP3) and PTEN has 
crucial roles in mediating cell proliferation as well as cell death and such properties 
make it dual functional in respect of cell growth (Leslie and Foti, 2011; White et al., 
2006). However, when this gene is mutated as in the case of breast cancer, it 
causes a disruption in the balance between cell survival and death towards cell 
proliferation with the overall result of production of uncontrolled cell growth. 
However, the contribution of this gene to breast cancer pathology remains small 
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and has been found to be responsible for about only 6% of breast cancer cases 
(Ergul and Sazci, 2001; Suter and Marcum, 2007). 
1.9 XRCC3 
XRCC3 is considered as one of the five RAD51 paralogs (i.e. XRCC2, XRCC3, 
RAD51L1/RAD51B, RAD51L2/RAD51C and RAD51L3/RAD51D) that have an 
essential role in the repair of double strand DNA breakage by homologous 
recombination (HR) (Thacker, 2005) in cells, by interacting with its binding 
supplementing Rad51C (Girard et al., 2013; Masson et al., 2001). XRCC3 
deficiency or mutation exhibit to a number of impaired DNA damage repair which, 
induced by RAD51 foci formation, increased chromosome aberrations and 
elevated sensitivity to camptothecin (CPT), various DNA cross-linking agents, and 
impaired HR (Girard et al., 2013). Human XRCC3 (hXRCC3) has 8 cysteine 
residues, and was identified from a cosmid library across its ability to complement 
the mutagen-sensitivity of  Chinese hamster irs1SF cells (Girard et al., 2013). 
Various association studies of XRCC3 have demonstrated debated consequences, 
however a meta-analysis by He et al. illustrated a correlation between common 
XRCC3 polymorphisms and BC risk (He et al., 2012). A prospective lethal 
missense mutation in the XRCC3 gene has been recognised in one breast and one 
ovarian cancer (Golmard et al., 2013).  
1.10 DNA Repair 
DNA is complex chemical structure that serves as the source and repository of 
genetic information in both prokaryotic and eukaryotic cells (Davis, 2012). 
Modifications to this complex structure caused by exposure to different elements 
from the environment and within a biological system could result in mutations that 
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related to the pathogenesis of several diseases (Boiteux and Jinks-Robertson, 
2013; Clancy, 2008) Hence, DNA stability and integrity are prerequisites to normal 
physiological function and life (Davis, 2012). The pathogenesis of cancer has been 
associated with many toxic environmental factors. For instance, skin cancer is 
majorly associated with environmental induced DNA damage, which is mainly due 
to by excessive exposure to UV radiation. Similarly, tobacco smoking leads to 
damaged DNA in epithelial cells, a critical process of lung cancer pathogenesis 
(Lord and Ashworth, 2012). In addition to exogenous substances that can cause 
DNA damage, by-products of cell metabolism lipid peroxidation have the potential 
to interact with and damage DNA (Kryston et al., 2011). Indeed, the free radicals 
by-products of cellular metabolism has been shown to cause oxidative stress 
through increase in reactive oxygen species such as, superoxide anions, hydrogen 
peroxide, and hydroxyl radicals. Interestingly, several research studies have shown 
that each cell can experience more than one million DNA lesions per day (Lodish 
et al., 2000). Therefore, the importance of well-regulated DNA repair mechanisms 
is crucial in resolving this magnitude of damage in order to maintain normal cell 
function (Clancy, 2008). Processes of DNA repair exist in both prokaryotic and 
eukaryotic cells, and many proteins involved have been discovered throughout the 
study of DNA repair mechanisms. Depending on the type of damage which can 
occur to DNA, cells are using various mechanisms to detect and repair DNA 
damage, regardless the damage accrued by the environment or inaccurate 
replication (Abbotts et al., 2014; Clancy, 2008). Because DNA is responsible for 
protection and transference of genetic traits it also plays a crucial role in cell 
division. Additionally, DNA repair is strongly correlated to the regulation of the cell 
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cycle. Throughout the cell cycle, checkpoint processes ensure that a cell's DNA is 
intact before allowing DNA replication and cell division to occur. However, suggest 
failure of these checkpoints mechanisms can lead to an accumulation of DNA 
damage, which in turn leads to mutations and fatal diseases (Clancy, 2008; 
Goodarzi and Jeggo, 2012) 
Depending on different types of DNA damage that might occur, cells have 
developed several repair pathways for their different types of damages. These 
repair mechanisms (Figure 3)  are commonly divided into five major types: base 
excision repair (BER), mismatch repair (MMR), nucleotide excision repair (NER), 
and double-strand break repair, which includes both homologous recombination 
(HR) and non-homologous end joining (NHEJ)(Houtgraaf et al., 2006; Klapacz et 
al., 2015). 
 
Figure 3 DNA several repair pathways 
http://www.bio-connect.nl/uploads/websiteimages/1%20Lev%20BC/GeneTex/DNA-repairs.gif. 
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1.10.1 Base Excision Repair 
Oxidative stress is considered as the main cause of endogenous DNA damage. 
The hydrolysis and deamination are eliminated by the base excision repair (BER) 
mechanism. BER involves the sequential action of five DNA-modifying stages:  
releasing nitrogenous bases from deoxyribose by DNA N-glycosylase enzyme,  an 
endonuclease enzyme that cleaves the DNA backbone at the resulting 
apyrimidinic/apurinic (AP) site,  a 39- or 59-phosphodiesterase enzyme that 
sweeps the remaining deoxyribose phosphate residue,  a DNA polymerase 
enzyme that fills the cavity thus created, and  a DNA ligase enzyme to seal the 
remaining incision (Boiteux and Jinks-Robertson, 2013; Hoeijmakers, 2001). 
1.10.2 Nucleotide Excision Repair (NER) 
Nucleotide excision repair (NER) is described as the essential repair mechanism 
from prokaryotes to higher eukaryotes (Morita et al., 2010). The most important 
advantage of the NER system is its extensive substrate specificity: NER can mend 
DNA lesions such as UV-induced pyrimidine dimers or further bulky adducts 
(Truglio et al., 2006). NER is a highly versatile and multipurpose used repair 
pathway that can identify and repair a variety of bulky, helix-distorting damage in 
DNA. Such damage results in pyrimidine dimers, for instance cyclobutane 
pyrimidine dimers (CPD) and 6–4 photoproducts, which are induced by the UV light 
after exposure to sun. An alternative notable substrate of NER is cisplatin-DNA 
intrastrand crosslinks. NER is mediated by the sequential functioning of repair 
proteins at the location of the DNA lesion. Despite similarities to BER, the NER 
pathway is more complicated, where it requires thirty different proteins to achieve a 
multi-stride ‘cut-and-patch’-like mechanism. These steps include DNA lesion 
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recognition, local unwinding of the DNA helix near the lesion site, removal of a 
short single-strand section of DNA containing the lesion, and sequential repair 
synthesis and strand ligation (Shuck et al., 2008). The biological significance of 
NER is supported by the fact that defects in the NER pathway can cause several 
human genetic diseases, such as xeroderma pigmentosum, Cockayne syndrome, 
and trichothiodystrophy, which all show sun sensitivity. Furthermore, these 
diseases show overlapping symptoms and clinical signs including cancer, 
developmental delay, neurodegeneration, immunological disorders, and premature 
aging (Cleaver et al., 2009). The NER pathway divided to two linked sub-pathways, 
which are termed global genome NER (GG-NER) and transcription-coupled NER 
(TC-NER). As the names indicate, GG-NER repairs DNA lesions throughout the 
genome and cell cycle, whereas, TC-NER is especially responsible for eliminating 
DNA lesions located on the coding strand site expressed active genes. Both sub-
pathways are acting mechanistically in the same way, apart from the initial DNA 
damage recognition step (Sugasawa, 2010). 
1.10.3 Mismatch Repair (MMR) 
The MMR pathway plays a crucial role in post-replication repair of misincorporated 
bases that have avoided the checkpoint processes of replication polymerases. In 
addition, MMR proteins also involved in accurate insertion/deletion loops (IDLs) 
that consequence from polymerase slippage through replication of repetitive DNA 
sequences. The importance of this pathway is established by the fact that 
deficiency in the MMR pathway leads to a mutator phenotype in cells, which is 
distinguished by constant microsatellite instability and an increased mutation 
frequency. Moreover, germline mutations in MMR genes are correlated to a variety 
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of cancers, such as hereditary non-polyposis colon cancer, also known as Lynch 
syndrome (Fukui, 2010; Larrea et al., 2010). The MMR pathway can be divided into 
three sub-type pathways: a recognition stage where mis-paired bases are 
identified, an excision stage where the strand mis-paired region is removed 
including oligonucleotides resulting in a gap, and a repair synthesis stage, where 
the cavity is filled by the DNA resynthesis (Larrea et al., 2010). 
1.10.4 Double-Strand Break Repair 
Double-strand breaks (DSBs) is one of the most biologically dangerous types of 
DNA damage (Dexheimer, 2013). For instance, a single unrepaired double strand 
break is sufficient to lead to cell death. Furthermore, defective repair can cause 
deletions or chromosomal aberrations, which are linked with the progress of cancer 
or other abnormal genomic syndromes. Therefore, the repair of DSBs is essential 
for both cell survival and maintenance of genome integrity (Dexheimer, 2013; 
Khanna and Jackson, 2001; van Gent et al., 2001). Mammalian cells are use two 
different mechanisms for DSBs repair which are homologous recombination (HR) 
and non-homologous end-joining (NHEJ). These two repair pathways have 
different requirements for a homologous template DNA and in the precision of DSB 
repair. HR-directed repair is largely an error-free mechanism as it uses the genetic 
information available in the undamaged sister chromatid as a copy template 
(Dexheimer, 2013; Li and Heyer, 2008). However, NHEJ is typically error-prone 
and repairing the DSBs by direct ligation of the broken ends (Lieber, 2010). NHEJ 
considered as the predominant and fast repairing pathway in mammalian cells, 
which is using in all phases of the cell cycle, whereas, homologous recombination 
(HR)  is limited to the late-S and G2 phases (Dexheimer, 2013). 
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The biological importance of DNA repair pathways is emphasized by the fact that 
the deregulation of these mechanisms can contribute to the inception and 
progression of tumours. By contrast, DNA repair can cause resistance to front line 
cancer treatments such as chemotherapy and radiation, which act to cause DNA 
damage to kill tumour cells. Thus, the sensitivity of tumour cells to DNA damaging 
agents is almost likely correlated to intrinsic disorders in DNA repair pathways. The 
capacity of tumour cells to distinguish DNA damage and introduce DNA repair is a 
key mechanism for therapeutic resistance (Abbotts et al., 2014; Dexheimer, 2013). 
1.11 Nanotechnology  
The term nanotechnology refers to technology in which one-billionth of a meter is 
used as the scale. It involves design, manufacturing, identification and use of 
substances by making their sizes at the nanometer scale. Once the size of the 
material is reduced to nano-size it shows new characteristics such as enhancing 
the physicochemical and ultimately biological properties compared to bulky 
materials (Ochekpe et al., 2009). For decades, nature has been a good source, 
which inspired mankind to make tremendous progress in innovations, design, 
discovery, and inventions. Scientists have long been promoting the idea of utlising 
the level of atomic or molecular structures and systems that have new properties, 
characteristics, and functions that led to a revolution named "nanotechnology" 
(Sharma et al., 2009). The oldest scientific illustration of nanomaterials and optical 
properties was given by Michael Faraday in 1857, and the title of that paper was 
“Experimental relations of gold (and other metals) to light” (Wilcoxon, 2009). The 
first idea of nanotechnology was described by American physicist Richard 
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Feynman in December 1959 at the American Physical Society. Feynman explained 
a procedure by which smaller groups of molecules and atoms can be formed 
through the manipulation of larger ones (Pierotti et al., 2008). Furthermore, in 1974 
Professor Norio Taniguchi demonstrated the term nanotechnology as the 
procedure of separation, integration, and deformation of materials by one molecule 
or atom (Khawaja, 2011). The real start of the nanotechnology and nanoscience 
was in the early 1980s, and as a consequence of this technology the scanning 
tunneling microscope (STM) was invented. The fullerenes and carbon nanotubes 
were discovered in 1985 as a result of this development. The United States 
National Nanotechnology Society was established in the year 2000 to organize 
nanotechnology research and its progress (Guzman et al., 2006; Tinkle, 2010). 
Nanoparticles (NP) are considered to be the stage between the bulk and atomic 
structure of materials. Substances have stable and known chemical and physical 
properties in their normal size; however, these properties can be changed to 
completely different ones at the nano stage (Ehrman, 1999; Hutter and Maysinger, 
2011; Perrier et al., 2010). Agglomeration or aggregation is another physio-
chemical advantage of NPs; because NPs are held together by soft and strong 
forces, as well as Vander Waals is electrostatic forces and sintered bonds. In 
addition, the solubility of nano-materials can be affected by the binding force 
aggregation under several different conditions (Allouni et al., 2009; Poizot et al., 
2000; Wokovich et al., 2009). The 21st century can be called the "nano century". 
As a result of the revolution in nanotechnology, most aspects of human life have 
been touched by nanotechnology development. This intervention was obviously 
seen in many sectors, including industries, consumer products, drug delivery, 
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optical devices, cosmetics, and sport accessories (Balshaw et al., 2005; Kango et 
al., 2013; Lee et al., 2008; Sharma et al., 2009). The essential reason behind the 
popularity of nanotechnology in the technological world at present can be attributed 
to the considerable increase in proportion between surface area and volume at the 
nanoscale, which brings quantum mechanics into display providing evolution of 
novel and improved mechanical, optical and electronic properties to nanomaterials 
(Oberdorster et al., 2005). However, these novel properties featured in the 
materials at the nano-range enable them to interact with biological systems, and 
this can lead to unpredictable outcomes. This has been proved recently by a 
several studies concerning the undesirable consequences of nanoparticle 
exposure (Brumfiel, 2003; Goldston, 2007; Magdolenova et al., 2014; Nel et al., 
2006). Different methods have been used to synthesise a variety of NPs with 
disparate chemical composition, differing in shape, surface coating, size, etc. 
These NPs have been confirmed to be cytotoxic and genotoxic to mammalian cells 
(Dhawan et al., 2006; Isakovic et al., 2006; Lewinski et al., 2008; Magdolenova et 
al., 2014; Papageorgiou et al., 2007; Singh et al., 2007; Wang et al., 2007). In the 
last 4 years the Health and Environmental Safety Department of Nanotechnology 
has shown an increasing attentiveness, after the first report which was published in 
2004 by the Royal Society and Royal Academy of Engineering highlighting the lack 
of required information that illustrates the impact of engineered nanomaterials on 
human health and the environment (Singh et al., 2009; Society and Engineering, 
2006). The mechanism behind NPs, toxicity is yet to be demonstrated (Singh et al., 
2014). Many studies have illustrated that NPs have the potential to induce DNA 
damage, apoptosis, cell membrane disruption through oxidative stress and lipid 
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peroxidation (Hsin et al., 2008; Li et al., 2008; Magdolenova et al., 2014; Sharma et 
al., 2009). Nanotechnology is also used as a means for drug delivery to its target 
tissue or organ. In doing so nanotechnology is used to overcome some problems 
associated with some drugs such as improving bioavailability, drug solubility and 
minimising or reducing side effects. Moreover, the presence of drug in nano-size 
gives better delivery properties including better membrane entrance or permeability 
and hence better intracellular drug concentration (Ochekpe et al., 2009). Recently, 
drug delivery based on nanotechnology has been developed as a dynamic strategy 
by overcoming various biological, biophysical and biomedical obstacles that 
emerge in the body against successful delivery of chemotherapy drugs to cancer 
tissues. The constant, organized and aimed delivery of anticancer drugs in 
combination with a nanotechnology approach enhances the influence of cancer 
therapeutic and elimination of side effects associated with cancer drugs (Parhi et 
al., 2012).  
1.12 Ibuprofen 
In Europe, non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen are 
consumed in amounts of over 100 tablets yearly (Heckmann et al., 2007). The 
discovery of ibuprofen (Figure 4) goes back to more than four decades when Dr 
Stewart Adams and his colleagues observed the anti-inflammatory effect of this 
agent on guinea pigs after its synthesis by Dr John Nicholson, as an attempt to find 
safer anti-inflammatory agents than ‘’ulcerogenic’’ aspirin. It has been found that 
ibuprofen is less irritating to the gut compared to aspirin with remarkable anti-
inflammatory effects. In 1970, the action of prostaglandin in mediating some 
inflammation and pain was established and ibuprofen was found as a good 
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inhibitor for the production of this  compound (Rainsford, 2011). Consequently, it 
has been classified as one of the non-steroidal anti-inflammatory drugs (NSAIDs). 
Ibuprofen has many therapeutic applications such as being anti-inflammatory, 
antipyretic and analgesic. In addition, ibuprofen has also been used as one of the 
medications for treatment of various joint and bone inflammations; for instance, 
osteoarthritis, rheumatoid arthritis and mild to moderate pain. (Potta et al., 2011). 
 
Figure 4 Ibuprofen structural formula; taken from http://pubchem.ncbi.nlm.nih.gov 
1.12.1 Mechanism of action of ibuprofen 
Ibuprofen works by inhibiting both cyclooxygenases I and II (COX-1 and COX-2) 
non-selectively (Figure 5). These enzymes are responsible for the biosynthesis of 
inflammatory mediators, namely prostaglandins. Ultimately, inhibition of such 
enzymes causes lowering of the levels of prostaglandins which in turn leads to 
inhibition of the various effects related to prostaglandins such as reducing pain, 
inhibition of the inflammatory process and also reduction of body temperature 
(Bushra and Aslam, 2010). 
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Figure 5 Biosythesis of prostaglandin and leukotrienes. NSAIDs block cyclooxygenase (Pardutz 
and Schoenen, 2010).  
1.12.2 Genotoxicity of Ibuprofen 
Despite the fact that ibuprofen is available as a non-prescription medication it can 
cause some toxic effects particularly it can act as a genotoxin. The genotoxicity 
induced by ibuprofen has been debated in recent years, for instance, the 
genotoxicity of ibuprofen on Salmonella strains did not produce conclusive results 
(Tripathi et al., 2012). Philipose et al. (1997) on the other hand, demonstrated the 
genotoxic effect of ibuprofen in mice where it caused a weak genotoxic impact on 
sister chromatid exchange. Moreover, also adverse results were found when it was 
reported that ibuprofen has no genotoxic effect after a short term two weeks period 
treatment (Ghosh et al., 2010). Conversely, Tripathi et al. (2012) conducted a 
similar study to investigate the genotoxic effect of ibuprofen on bone marrow cells 
of mice. Ibuprofen was administrated orally at different doses which were 10, 20, 
40, and 60 mg/kg body weight. Chromosomal aberrations, were used as a 
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parameter to assess the genotoxicity. It was observed that Ibuprofen led to an 
increase in the number of chromosomal aberrations that was more pronounced at 
40 and 60 mg/kg doses. 
1.12.3 Ibuprofen and breast cancer 
There are limited studies on the relationship between ibuprofen and breast cancer. 
Harris et al. (1999) performed a study to compare the influence of some NSAIDs 
including ibuprofen on breast cancer patients. It was found that regular ibuprofen 
consumption caused a reduction of breast cancer rate by about 50%. As a result of 
this it was suggested that NSAIDs including ibuprofen might be useful as a means 
for prevention of the occurrence of breast cancer(Bushra and Aslam, 2010; Harris 
et al., 1999). Sun et al. (2012) evaluated the anti-breast-cancer efficacy of 
phosphor- ibuprofen (P-I) 400 mg/kg/day on (MCF-7) and (MDA-MB231) breast 
cancer cell lines comparing with control, where, the phosphor-ibuprofen inhibited 
growth of MCF-7 and MDA-MB231 cell lines 51% and 26.6% respectively. They 
suggested that P-I induced oxidative stress, which disrupted the thioredoxin 
system by inhibiting the expression of oxidized Trx-1 and suppressing thioredoxin 
reductase activity.  
1.13 Aspirin 
The history of aspirin (Figure 6) started a long time ago; its discovery came after 
the optimisation of salicin which was obtained from the bark of willow trees  (Thorat 
and Cuzick, 2015). In 1853, Charles Gerhardt made a modified form of salicin, 
namely acetylsalicylic acid, for first time. However, its therapeutic application was 
discovered later in 1876 when some physicians like Thomas Maclagan started 
using it for both alleviating pain as well as in the treatment of rheumatism. In 1897, 
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a German scientist Felix Hoffman managed to create acetylsalicylic acid in the lab 
and after which acetylsalicylic acid was named as aspirin (Miner and Hoffhines, 
2007; Thorat and Cuzick, 2013; Vane and Botting, 2003; Wood, 2015). 
 
Figure 6 Salicylic Acid and Aspirin structural formula taken from http://www.theodora.com 
1.13.1 Mechanism of Action of Aspirin 
Although aspirin is an old drug, its mechanism of action became known only in 
1971 when John Vane found that aspirin blocks the COX enzyme (Figure 7,8) by 
adding functional group to it. As mentioned earlier, COX enzyme is a very crucial 
enzyme playing a role in the biosynthesis of various inflammatory mediators, most 
importantly prostaglandins. As a consequence of this effect on cyclooxygenase 
enzyme, prostaglandins and some other inflammatory mediators cannot any longer 
be produced from their bioprecursor arachidonic acid, as long as aspirin is present. 
Therefore, the inhibition of cyclooxygenase enzyme by aspirin results in numerous 
effects such as inhibition of inflammation and its associated oedema (Wood, 2015). 
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Figure 7  The role of aspirin inhibiting inflammatory mediators  (Wood, 2015) 
 
 In addition, aspirin also causes inhibition of other inflammatory mediators other 
than prostaglandins such as the leukotrine derivative 12-HETE. This compound is 
important in mediating the recruitment of immune cells such as eosinophils and 
neutrophils in the inflammation areas with the consequence of releasing some 
inflammatory mediators from these cells and causing tissue destruction and hence 
inflammation. Thromboxine is another important bio-mediator and is similar to 
prostaglandin in that it is produced from the same bio-precursor under effect of 
cyclo-oxygenase enzyme. However, thromboxane possesses a blood clotting 
effect and thus the inhibition of its biosynthesis by aspirin results in an 
anticoagulant effect (Fuster and Sweeny, 2011; Koester, 1993; Peixoto and Silva, 
2014; Vane, 1971). 
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.  
Figure 8 Aspirin mechanism of action (Gasparyan et al., 2008). 
 
1.13.2 Genotoxicity of aspirin 
Although aspirin itself does not exhibit a gentoxic effect, its protective potential was 
observed when it was combined in a treatment with the genotoxic anticancer agent 
mitomycin C (MMC). This was concluded when aspirin was used in a mouse study 
at doses of 0.5, 5 and 50 mg/kg combined with 2 mg/kg dose of MMC, it has been 
observed that aspirin led to a reduction in the genotoxocity produced by MMC in 
various organs such as liver and spleen and the reduction was in dose-dependent 
fashion (Baron and Sandler, 2000; Niikawa et al., 2008) 
1.13.3 Aspirin and breast cancer 
The use of aspirin in prevention of breast cancer is still a new subject and there are 
only a few studies in this regard. The effect of aspirin to protect against breast 
cancer was observed in some patients who are on regular intake of aspirin such as 
patients with cardiac disease who take aspirin (100mg) on a daily basis (Lotrionte 
et al., 2016). The reduction of breast cancer incidence by aspirin was linked to its 
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inhibition of the cyclo-oxygenases COX-1 and COX-2 (Fig 5 and 8) with the former 
being inhibited more strongly than the latter. This results in inhibition of 
prostaglandin H2 production from its bioprecursor arachidonic acid which in turn 
leads to inhibition of further prostaglandin production from its biosource 
prostaglandin H2 (Cazzaniga and Bonanni, 2012; Lazzeroni et al., 2013). 
Ultimately, the inhibition of prostaglandin production leads to the inhibition of their 
physiological roles such as inhibition of cell growth and angiogenesis which 
contributes to its antitumour effect. In addition, aspirin also causes stimulation of 
AMPK signalling pathway which also cause inhibition of cancer cell growth.  
Prostaglandin E2 has been found to elevate the level of expression of the 
aromatase gene which in turn is responsible for the biosynthesis of oestrogen. It 
has been observed that there is a direct correlation between the level of expression 
of COX-1, COX-2 and aromatase stimulation and hence oestrogen production and 
this eventually means aspirin indirectly inhibits oestrogen production and its 
associated breast cancer growth. Despite such effects of aspirin, it is too early for 
using it as a single agent in chemoprevention of breast cancer due to limited 
available results on its effect for protection against breast cancer and it 
consequently should be used in combination with other breast cancer therapies 
(Cazzaniga and Bonanni, 2012; Lazzeroni et al., 2013). 
1.14 Bleomycin 
Bleomycin (BLM) is a drug extracted from Steptomyces verticillus, and classified as 
an anti-cancer therapy drug which belongs to a group of natural glycopeptides. The 
drug was described for the first time in Japan by Umezawa in 1976. BLM has a 
unique structure and pathway of action among chemotherapy drugs (Sikic et al., 
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1985). Bleomycin is used to cure several types of cancers such as head and neck 
cancer, lymphomas and testicular cancer. BLM is used for therapeutic purpose 
because of it has the potential to cause DNA damage like single and double strand 
breaks (SSB, DSB) in the presence of cofactors O2, Fe (II), and a one-electron 
reduction (Chen et al., 2008). The actual mechanism behind DNA strand scission 
is still unclear. However, a hypothesis suggested that BLM has the ability to 
prevent the integration of thymidine into DNA. Furthermore, BLM may react with 
metal ions producing metal-bleomycin which in turn react with O2 to generate free 
radicals hydroxide and superoxide that break DNA strands. An alternative study 
proposed that BLM may link at particular locations in the DNA strand and induce 
cleavage by inhibiting the hydrogen atom from the nitrogen base to generate 
strand breakage as the base show a Criegee-type rearrangement (Chen et al., 
2008; Huls and ten Bokkel Huinink, 2003). Sikic et al. (1985) demonstrated that 
BLMs binds to DNA and worked as mini enzyme after forming a complex with iron 
and O2 that formed free radical formation and finally leads to DNA strand breakage. 
Some studies stated that BLM’s capacity to induced chromosomal breaks were 
significantly increased in the cells of both familial and sporadic breast cancer 
patients compared to the healthy controls (Hu et al., 2013). 
1.15 Reactive oxygen species (ROS)  
ROS receive considerable attention in genotoxicology science. They are defined as 
short-lived molecules that are capable of releasing oxygen atoms. In general they 
can be found in micromolar or picomolar different concentrations in natural 
systems  (Burns et al., 2012). In environmental systems, O2, 
.OOH, .OH, H2O2, and 
CO3
-  have the ability to oxidise a varieties of molecules including biomolecules 
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(Burns et al., 2012; Canonica et al., 2005). It is well-known that increasing levels of 
oxidative stress leads to damage to sensitive biological components for instance 
DNA, membrane lipids and proteins, and such negative influence may contribute in 
the aetiology of various fatal diseases such as cancer (Naveenkumar et al., 2013). 
ROS are commonly produced by photolysis, electron transfer or energy transfer 
reactions (Bartosz, 2006). Free superoxide & hydroxyl radicals can be created by 
reduction of oxygen (Gutteridge, 1994). The superoxide radical (O-2) is produced 
during the activity of enzymes such as NADPH oxidase and xanthine oxidase. 
Superoxide (.O-2) is considered the essential form of the free oxygen radical (Dohi 
et al., 2010; Floyd and Carney, 1992), and it acts as a reductant or an oxidant 
(Imlay et al., 1988). The superoxide radical, which is formed by organic agents has 
a high reactivity and is more reactive than any (.O-2)  generated in interior biological 
processes and might cause significant damage to DNA (Gutteridge, 1994). 
Hydrogen peroxide (H2O2) is an active form, which is enzymatically generated from 
the superoxide radical. A more effective and aggressive form of oxygen radical, the 
hydroxyl radical (.OH) can be created by the combination of (.O-2) and H2O2 (Ben-
Shaul et al., 2001; Sewerynek et al., 1996). The most reactive oxygen radical 
known to chemistry is the hydroxyl radical; it has a massive potential to cause 
biological damage once it comes in to contact with all biological molecules. All DNA 
components including pyrimidine and purine bases can be damaged by the 
hydroxyl radical (Gutteridge, 1994). Mitochondrial DNA is more sensitive than 
nuclear DNA to reactive oxygen species induced damage, and delayed treatment 
leads to constant mitochondrial DNA damage and impaired of mitochondrial 
function (Naveenkumar et al., 2013). 
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1.16 The Comet assay 
Methodologies, that can recognize and evaluate DNA damage, have been 
developed in the last two decades. The first expression of DNA damage in a single 
cell was developed by Rydberg and Johanson in1978, by lysing and inserting cells 
in agarose on slides in the presence of an alkaline pH ≥ 13, allowing the partial 
unwinding of DNA. After neutralisation, cells were dyed with acridine orange and 
the amount of DNA damage was indicated by measuring the extent of green 
(equivalent to double-stranded DNA) and red (equivalent to single-stranded DNA) 
fluorescence using a photometer. A microgel electrophoresis method, that is 
known as the Comet assay, was first developed by Ostling and Johanson, to 
increase the sensitivity of these experiments for detecting DNA damage in 
individual cells (Collins, 2004; Ostling and Johanson, 1984; Rojas et al., 1999; 
Singh et al., 1988; Tice et al., 2000). The Comet assay is a term referring to single 
cell gel electrophoresis. The Comet assay has been specified to be a sensitive and 
accurate technique. It can determine DNA damage and detect DNA integrity 
(Anderson et al., 2013; Tice et al., 2000). As a result, the Comet assay is typically 
used to determine genotoxicity, and consequently used to evaluate the 
effectiveness of chemotherapy compounds on tumour cells and their effects on 
germ and somatic cells (Anderson et al., 1997). The Comet assay can be carried 
out in two versions (Figure 9), the neutral Comet assay, which mainly detects 
double strand DNA breakage and the alkaline Comet assay, which additionally 
assesses single-strand damage and alkaline labile sites (Collins, 2004; Singh et 
al., 1988). In this technique, cells were embedded in agarose. High salt 
concentration and a detergent were used to lyse the cells. Under natural 
conditions, the released DNA was electrophoresed. Increased rates of DNA double 
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strand break (DSB) in cells increased the migration of DNA towards the anode. 
The DNA was stained using ethidium bromide. The damage was evaluated by 
measuring the ratio of intensity of fluorescence between two fixed points and this 
was throughout the migration step by utilising a florescence microscope, camera 
and capture system; software Komet 6 . The neutral pH, which was used in this 
assay led to the lack of efficiency of this procedure (Collins, 2004; Tice et al., 
2000).  
 
Figure 9 A general protocol for alkaline and neutral Comet assay  
As a result, using the Comet assay under alkaline pH (pH>13), it became possible 
to identify the single-strand DNA breakage (Singh et al., 1988). At pH>13 the 
migration of DNA depends on the increase in the level of DNA single-strand 
breakage (SSB), which is associated with inadequate excision repair process at 
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damaged sites and alkali-labile site (ALS). Most of the genotoxic agents induce 
SSB and ALS rather than DSB; the alkaline Comet assay provided additional 
sensitivity in recognition of more genotoxic agents. This single cell gel 
electrophoresis assay is the most beneficial method in genotoxic research (Collins, 
2004; Singh et al., 1988; Tice et al., 2000). In the Comet assay the image that is 
seen under the fluorescence microscope, is similar to a comet with a prominent 
head and tail; the head consists of integrated undamaged DNA and the tail of 
migrated DNA fragments (Collins, 2004; Kumaravel and Jha, 2006). Consequently, 
the DNA amount in the tail of the comet would reflect an estimated percentage of 
damaged DNA. Subsequently, DSB, SSB and oxidative damage of DNA base pairs 
can be successfully detected by the Comet assay (Tice et al., 2000). The Comet 
assay has several advantages such as the collected data are from single cells, 
providing more pronounced statistical analysis; it needs a small number of cells per 
sample (less than 10,000), it is a highly sensitive method for detection of DNA 
cross links and a convenient assay for any eukaryotic individual cell (Dixon et al., 
2002; Lee and Steinert, 2003). 
1.17 The cytokinesis blood micronucleus (CBMN) assay 
A micronucleus (MNi) is a small supplemental nucleus that is exhibited after the 
anaphase through nuclear division. MN is a remnant of a centric chromosome 
fragment or an entire chromosome. This chromosomal fragment is not incorporated 
in the daughter nuclei (Fenech, 2007). The first description of a micronucleus in an 
erythrocyte cytoplasm was by Howell and Jolly more than a century ago, and MNs 
have been called Howell-Jolly bodies by haematologists since that time (Kirsch-
Volders et al., 2003). In 1969 the term micronucleus test proposed by Boller and 
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Schmid (1969). MN can be seen in bi-nucleated cells in humans or mammals, after 
using cytochalasin-B (a microfilament ring assembly inhibitor) to block cytokinesis 
(Fenech, 2000). Hence another name for the MN assay is the cytokinesis block 
micronucleus assay (CBMN). This assay is considered as the preferred method to 
score micronuclei (MNi) because it is restricted to binucleated cells. The CBMN 
assay is the commonly used method to track DNA damage in human lymphocytes 
after being insulted by genotoxic and cytotoxic agents (Fenech, 2007), in medicine 
prevention, and determination of chemical and pharmaceutical safety (Bonassi et 
al., 2007). The CBMN assay has many advantages compared to other cytogenetic 
methods. It is relatively quick, inexpensive, and it can be used easily to identify and 
score MNs in cells that have successfully completed one nuclear division. The 
complete nuclear division is essential for the appearance and recognition of MNi, 
nuclear buds and nucleoplasmic bridges (NPBs) (Fenech, 2007; Umegaki and 
Fenech, 2000). The CBMN assay can be carrid out in human lymphocytes or cell 
lines after the cells have been cultured. Cell division of lymphocytes in culture is 
stimulated by phytohaemagglutinin (PHA). Measurements must be carried out in 
deviding cells because scoring should be in binucleated BN cells that indicate cell 
division (Fenech, 2000; Lyall et al., 2007). 
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Figure 10 Several possible fates of cultured cells in the CBMN assay (Fenech, 2007). 
 
 
Figure 11 Photomicrographs of the cells scored in the CBMN assay. (a) mononucleated (MonoNC 
cell); (b) binucleated (BiNC) cell; (c) multinucleated (multiNC) cell; (d) early necrotic cell; (e) late 
apoptotic cell; (f) BN cell with one or more MNi; (g) BN with an NPB and a MN; (h) BN cell with 
NBUDs (Fenech, 2007). 
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In the CBMN assay (Figures 10 and 11), DNA damage deletion rate can be 
measured by scoring the MNi in BN cells, detecting cytogenetic damage such as 
chromosomes breaks or loss of whole chromosomes. MN and NPBs indicate DNA 
disrepair. Nuclear buds and chromosome rearrangement reflect amplified DNA 
repair complexes (Shimizu et al., 2000). The generation of MNi, NPBs and nuclear 
buds occurs at the anaphase stage of cell division, chromosome fragments or 
whole chromosome losses lead to the rise of MNi (Fenech, 2000; Schmid, 1975). 
NPBs could result from di-centric chromosome or from chromatids that pulled 
toward the opposite end of the cell and lead to asymmetrical chromosome 
rearrangement or DNA strand break disrepair (Thomas et al., 2003); or telomere 
end fusion that occurs as a result of telomere shortening associated with the aging 
process (Blasco, 2005; Stewenius et al., 2005). Furthermore, nuclear buds indicate 
the possible gene amplification and are considered as evidence of genotoxic 
exposure, likewise the MNi and NPBs, and this could be an additional advantage of 
the CBMN assay (Fenech, 2002; Serrano-Garcia and Montero-Montoya, 2001).  
1.18  Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is a molecular biology technique that is 
based on the cells’ capacity to replicate new DNA strands complementary to the 
displayed original strands (Ngô and Van de Voorde, 2014). The American 
biochemist Kary Mullis developed the PCR in 1984 and later on in 1993 won the 
Nobel prizes (Bartlett and Stirling, 2003). The PCR technique soon became one of 
the most important methods used in molecular biology due to be simple, quick and 
inexpensive (Joshi and Deshpande, 2011). The PCR technique is a revolutionary 
invention in the history of molecular biology and medical sciences. The application 
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of PCR was a milestone in the field of molecular genetics research as well as 
animal and plant biotechnology, moreover, PCR has also demonstrated its 
importance and ingenious utility in various science fields such as forensic sciences, 
molecular epidemiology, archaeology, anthropology and evolutionary genetics 
(Singh et al., 2014). The principle of PCR amplifies one DNA molecule into two, 
then four, then eight and so forth. This incessant doubling process is accomplished 
by thermostable polymerases that are able to bind together DNA building blocks to 
procedure long molecular strands. These techniques, which produce more than 
one million specific DNA sequences also need primers which are small DNA 
fragments. Primers function by connecting the constructing blocks to form a longer 
DNA molecule to work as a template for building the new strand (Joshi and 
Deshpande, 2011). The basis of PCR depended on the certainly that at high 
denaturing temperatures approaching 95°C, the two strands in the target DNA 
molecule separated by breaking bonds between A-T and G-C. At the annealing 
temperatures in the range of 50-65°C, the selected forward and reverse primers 
bind at the 3’ end of the specific regions in each of the separated strands in DNA 
molecule. In the extension stage, Taq polymerase enzyme extends the new DNA 
strands in the presence of deoxynucleoside triphosphate (dNTPs) and the single 
strands rebind themselves during the extension temperature 72°C. These stages 
are repeated a 35 times to produce multiple copies and finally amplify the target 
DNA molecule (figure 12). The European Molecular Genetics Quality Network 
(EMQN) provide the best practice guidelines, which, should be followed for best 
results (Müller, 2001). 
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Figure 12 shows the exponential amplification of the gene in PCR (Singh et al., 2014) 
1.18.1 Real time-PCR or quantitative PCR (qPCR) 
The first description of qPCR was  by Higuchi et al. (1992) and co-workers (Singh 
et al., 2014). The development of real-time (q-) PCR characterizes has a 
substantial advance in various molecular techniques including nucleic acids' 
analysis (Rodriguez-Lazaro and Hernandez, 2013). The qPCR method has the 
ability to detect a fluorescent DNA stain, such as SYBR Green and measuring the 
amplification of the target DNA at each cycle of PCR. During the log-linear phase 
of magnification, the fluorescence level increases to a measurable point which is 
called threshold cycle (CT). Therefore, the qPCR results consist of amplification; 
standard curves log concentration vs CT, which is plotted by using serial dilutions 
of a known magnitude of standard DNA, the amount of DNA or complementary 
DNA (cDNA) in an unknown specimen can be detected as CT value by this 
standard curve (Singh et al., 2014). Major advantages of qPCR are combining the 
amplification and detection into one step therefore eliminating any requirement for 
post amplification processing of the targeted DNA (Mackay, 2004). Furthermore, 
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qPCR is a technique with a high level of sensitivity, accuracy, speed of analysis 
and real time detection of measuring progress (Gachon et al., 2004). This  is due  
to  the  availability  of  either  fluorescent  materials  or fluorescently-attached  
oligonucleotide  probes  whose intensity  reflects  the  amount  of  targeting DNA  
formed  (Wong and Medrano, 2005). Various categories of polymerases are 
utilised to assist different types of qPCR reactions, such as high precision, hot start 
and enzymes with high and fast activity.  Hence, qPCR machines are designed to 
perform these reactions that contain a thermic cycler needed for DNA amplification, 
an optical environment to stimulate fluorophores and capture generated 
fluorescence from the detection chemistry, and using special software to gather 
and investigate the quantitative data emitted. The most essential advantage of 
qPCR is that it has a low proportion of contamination caused by PCR products 
such as cDNA and RNA (Singh et al., 2014). However, qPCR has some drawback 
including expensive reagents. This technique is a very sensitive procedure and 
understanding the experimental design of this method is essential for accurate and 
valuable results (Wong and Medrano, 2005). qPCR has become the preferred 
choice in PCR techniques for diagnostic applications for several  reasons. It is 
more sensitive and can be more controlled compared to ordinary PCR and these 
are important characteristics for diagnostic utilizations.  qPCR additionally is 
preferred than end point PCR due to several reasons, including the amplification of 
short DNA fragments, the ability of fluorescent detection, which allow the detection 
of minor amounts of amplified products, and enhanced tolerance to inhibit 
materials interfering with DNA purification compared to conventional PCR process. 
Moreover, working as one process in qPCR instruments helps to avoid post PCR 
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contamination which could lead to false positive results. Finally, the absence of gel 
electrophoreses step in real time PCR makes the method easy to  automate and 
suitable for fast throughout (Ravnikar et al., 2016).  
1.18.2 RT-PCR/qPCR combined  
The (RT-PCR)  polymerase  chain reaction technique is used when  measuring the 
qualitative  expression of  RNA  by converting the RNA template to cDNA, 
however, both  RT-PCR  and  qPCR techniques are used for quantitative detection 
of  RNA  expression,  and this merger technique is named  qRT-PCR/  quantitative  
RT-PCR  or  RT-qPCR (Singh et al., 2014). 
1.19 Western blot (WB) 
Western blotting (WB) has become the most important technique that has been 
used in cell and molecular biology, which is often utilized in protein diffusion and 
detection. Since 1979, protein blotting has been developed significantly. WB allows 
researchers to measure and detect specific proteins from a relative quantities of 
individual proteins isolated from cells (Gürtler et al., 2013; Kurien and Scofield, 
2006; Mahmood and Yang, 2012). The principle of WB can be shortened to five 
major steps: 1. diffusion of the proteins depend on their sizes by using 
polyacrylamide gel electrophoresis (SDS-gel); 2. Transfer and relocate the protein 
from SDS-gel to artificial membrane such as nitrocellulose and polyvinylidene 
fluoride PVDF (Electroelution); 3. Use specific primary antibody to bind the protein 
attached to the membrane 4. Use the enzyme conjugate secondary antibody to 
bind the protein-primary antibody complex, such as, horseradish peroxidase 
(HRP); 5. The isolated protein bands can be imaged in the presence of ECL 
substrate and dye (Liu et al., 2014; Mahmood and Yang, 2012). WB is considered 
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to be the preferred technique among immunoassay methods that studying protein 
expression due to its accuracy, easy of analysis, translation of results, and 
reasonable cost (Westermeier and Marouga, 2005). The density of the bands is 
proportional to the concentration of the protein of interest (Mahmood and Yang, 
2012). WB also possesses excessive ability to indicate the presence of such 
protein by size or through the binding of an antibody, which increases the capability 
of the WB method to follow protein fractions throughout the protein purification 
procedure. This allows observing protein expression from different cells or the 
response of specific proteins after treatment by a particular drug. WB has been 
used to study the effect of the chemotherapeutic agent Adriamycin (doxorubicin) on 
BRCA1 and PARP-1 expression in MCF-7 breast cancer cells, thus proteins are 
playing essential roles in DNA repairing pathways, and this study allowed them to 
follow the drug impact and if there is a resistance to doxorubicin (Wang et al., 
2014). WB is a lengthy procedure with several manual phases including protein 
assay, gel electrophoresis [SDS–PAGE], protein transfer, and detection, which 
might increase the possibility of a higher error rate(Gibbons, 2014; Mahmood and 
Yang, 2012). The WB technique was introduced recently to detect the genotoxicity 
of nanoparticles (Kumar et al., 2014). 
1.20 Aim 
The main aim of this work is to study the DNA protective effect of two well-known 
NSAIDs namely ibuprofen and aspirin in bulk form and as nanoparticles. Some 
previous studies have demonstrated that regular intake of either drugs results in 
protection against certain tumours such as colorectal, lung and breast cancer. 
However, these studies did not investigate the effect of these agents at the DNA 
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level. Consequently, this work aims to examine the effect of both agents on DNA 
damage using lymphocytes obtained from breast cancer patients and comparing 
the result with healthy females as controls. Two different particle sizes were 
selected and used in this study namely NPs and bulk forms to analyse the effect of 
size difference on DNA damage. Comet and micronucleus assays were used as 
techniques to assess the extent of DNA damage. The Comet repair assay was also 
chosen for monitoring DNA damage repair, after challenging lymphocytes using a 
damaging agent bleomycin and allows the DNA repair in the presence and 
absence of aspirin and ibuprofen. Furthermore, the role of both NSAIDs on the 
expression of XRCC3 and p53 proteins was studied by WB. Finally, the influence 
of aspirin and ibuprofen in both nano and bulk forms on p53, COX1 and COX2 
genes expression in lymphocytes from BC patients compared to the those from 
healthy females volunteers using real-time PCR were studied.  
.  
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Chapter 2 - Material and Methods 
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2. Material and Methods 
2.1 Material 
The chemicals and reagents that were used in this work, as well as their sources and 
CAS numbers are summarised in the following Table (1, 2 and 3). 
Chemicals Supplier Product or CAS number  
Bis-acrylamide, 30% solution Sigma, UK 110-26-9. 
Aspirin (SLS) Sigma-Aldrich UK 50-78-2 
Bleomycin sulfate Sigma UK 9041-93-4 
Western ECL Substrate, 200 ml Bio-Rad 1705060 
Cytochalasin-B Sigma-Aldrich UK 14930-96-2 
DMSO BDH, UK 67-68-5 
Ethanol Sigma, UK 64-17-5 
Ethidium bromide Sigma, UK 1239-45-8 
Fast SYBR® Green Master Mix Life Technologies 4385610 
Fetal Bovine serum Sigma, UK n/a 
Foetal Bovine Serum GIBCO Invitrogen UK 10270 
Hydrogen peroxide Sigma, UK 7722-84-1 
Ibuprofen USP Albermarle sprt 15687-27-1 
 Reverse Transcription System Promega A3800 
Low melting point (NMP) 
agarose 
Invitrogen, UK 39346-81-1 
Lymphoprep Axis-Shield Norway 66720-17-0 
Mitomycin C Sigma-Aldrich UK 50-07-7 
Na2EDTA·2H2O Sigma, UK 6381-92-6 
NaCl Sigma, UK 7647-14-5 
NaOH BDH, UK 1310-73-2 
Normal melting point 
(NMP)agarose 
Invitrogen, UK 9012-36-6 
PBS phosphate buffered saline Sigma, UK n/a 
Phytohaemagglutinin  , Liquid GIBCO Invitrogen UK 9008-97-3 
QIAamp® RNA Blood Mini  Qiagen 52304 
 Bradford Protein Assay Kit 1 Bio-Rad 5000201 
RPMI-1640 Medium Sigma-Aldrich UK n/a 
Trition X-100 Sigma, UK 9002-93-1 
Trizma Base Sigma, UK 77-86-1 
Trypan blue Sigma, UK 72-57-1 
Table 1 Chemicals with their corresponding sources and CAS numbers. 
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Primer Company Sequince or ID 
P53 primer Qiagen QT00050785 
COX1 primer Qiagen 
 
QT00210280 
COX2 primer Qiagen QT00040586 
Table 2 List of primers 
 
Antibodies Source Company 
Anti- p53 antibody ABCAM ab1431 
Anti-beta Actin antibody ABCAM ab189073 
Anti-XRCC3 antibody ABCAM ab58467 
Donkey Anti-Rabbit IgG H&L  ABCAM ab6802 
Table 3 primary and secondary antibodies 
 
2.2 Blood samples  
Whole blood was collected by venepuncture after receiving the consent from both 
healthy non-smoking female volunteers and breast cancer patients. The breast 
cancer samples were provided by the Ethical Tissue Bank using licence12191. The 
blood was collected in labelled lithium heparin coated tubes. Ethical approval was 
granted by the University of Bradford’s Sub-Committee for Ethics in Research 
involving Human Subjects (Reference no.: 0405/8). Control samples were also 
taken under IRAS/NRES application 12/YH/0464. The Research Support and 
Governance Office Bradford Teaching Hospital NHS Foundation granted the Re 
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DA number: 1202. Blood was collected in labelled lithium heparin coated tubes. 
Samples were diluted 1:1 with RPMI-1640 medium and then 10% DMSO was 
added. The diluted blood samples were divided and transferred to labelled 
Eppendorf® tubes, which were tightly closed and stored in a -80°C freezer. 
However, fresh blood samples were used in the micronucleus assay, qPCR, and 
western blot analysis. The data shown in the appendix 2 and the confound are 
discussed following it. 
2.3 Aspirin and ibuprofen 
2.3.1 Preparation of aspirin and ibuprofen nanoparticles   
Aspirin and Ibuprofen were suspended 3% and 4% (w/w) respectively with solid 
loads in special suspension media, which was prepared from melting 
polyvinylpyrrolidone K-30 (0.5% w/w), hydroxypropyl methylcellulose (HPMC) 
(0.5% w/w), and sodium lauryl sulphate (0.1% w/w) in deionised water. The Lena 
nanoceutics technology DM-100 machine was utilised for milling the suspensions. 
150 ml of 0.2 mm yttrium was used to mill 250 ml of each suspension in the 
presence of stabilised zirconium beads (Glen mills, USA). Recycling the 
suspension in the milling machine took 60 min before being discharged and 
transferred to an impervious glass bottle. The suspensions were stored in a 4°C 
fridge. 
2.3.2 Measuring of nano-suspension particle size 
The size of aspirin and ibuprofen particles was regularly measured to confirm no 
significant alteration in particle size occurred for the duration of the Comet assay, 
MN, qPCR, and western blot experiments. The particle size distribution of aspirin 
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and ibuprofen nano-suspensions were measured using the dynamic light scattering 
technique of the Zetasizer Nano ZS (Malvern instruments, UK). Both aspirin and 
ibuprofen particles were measured at room temperature 25 °C using 2 ml unused 
cuvettes. All measurements were done in triplicate. However, the bulk particle 
sizes of aspirin and ibuprofen powder were measured utilising the laser diffraction 
technique (Sympatec Helos, UK).  For each drug 20 mg were transmitted into the 
sample vial and 4 bar primary pressure was selected while the feeder speed was 
adjusted to 40mm/s. Three samples of each compound were determined using an 
R2 lens (0.25/0.45, 87.5 µm). 
Images were captured using a transmission electron-microscope (TEM) (Estop et 
al., 1993). Specimens were prepared by adding a drop of the drug suspension 
(aspirin or ibuprofen) on the TEM carbon grid. After 10 min the grid was rinsed by 
immersion in water. A drop of uranyl acetate was floated on the grid for 10 min 
then rinsing again in water. After drying, the grid was placed in the TEM and 100, 
000x magnification power was used, and the 60 kV and 40 kV beam intensity were 
chosen for aspirin and ibuprofen sample respectively. 
2.3.3 Zeta potential analysis of nano suspensions 
The zeta potential for the suspensions was determined using Zetasizer Nano ZS 
(Malvern instruments, UK). The suspensions were diluted 1:100 using deionised 
water and measured at room temperature. Disposable zeta cells were used. 
Measurement extent was set as automatic between 10 and 100 runs maximum. All 
measurements were repeated three times. 
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2.3.4 Aspirin and Ibuprofen Doses 
In this project two different sizes of ibuprofen and aspirin were used (NPs and 
Bulk) using the same concentrations of both NPs and Bulk sizes. The ibuprofen 
concentration used was 250 µg/ml, whereas, 500 µg/ml was chosen for aspirin. 
These doses were selected according to the differences in properties between the 
two drugs and appropriate doses were used so that they did not lead to cytotoxicity 
and cell apoptosis.  
2.4 Lymphocyte isolation from whole blood 
Whole blood was mixed 1:1 in Falcon tubes with saline (0.9% NaCl), which was 
prepared by dissolving 4.5 g of NaCl in 500 ml of distilled water. In a Falcon tube, 6 
ml of diluted blood were carefully overlaid on 3 ml of Lymphoprep which has the 
same density as lymphocyte cells, then transferred to centrifuge at room 
temperature (RT) for 20 min at 600 g. After the centrifugation, the white layer of 
lymphocytes was obtained from the top of the Lymphoprep within the plasma 
interface of the sample and washed with saline in an universal tube. Then, the 
suspension was centrifuged at 375 g for 15 min at RT, and the centrifugation the 
supernatant was treated with 2% virkon, then discarded. The pellet was 
resuspended in 1800 μl of foetal bovine serum (FBS), then, 450 μl of the 
suspension transferred to each of 4 Eppendorf tubes, which contained each 50 μl 
of dimethyl sulfoxide (DMSO) 100%. The tubes were tightly closed and gently 
mixed and stored overnight at -20 °C before being transferred into -80 °C freezer 
for prolonged storage. 
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2.5 Comet assay 
2.5.1 Cell treatment 
 The stored blood samples were allowed to thaw at room temperature. After that, 
100 μl of blood suspension was added to 890 μl RPMI-1640 media in Eppendorf® 
tubes, which contained 10μl of NC (control negative) (chemical solvent), PC 
(control positive) (50 μM H2O2) and test agents. In this project, chemicals 
examined were ibuprofen and aspirin in NPs and bulk sizes. The final volume in 
the Eppendorf® tubes was 1000 μl. The cells were incubated for 30 min at 37°C. 
The tubes were centrifuged for 5 min at 705 g. After the centrifugation, 900 μl of 
the supernatant was discarded, and 100 μl of 0.5% low melting point agarose 
(LMP) was added to the cell pellet and re-suspended. After that 100 μl of cell 
suspension was layered onto 2 duplicate slides pre-coated with 1% of normal 
melting point agarose (NMP). The slides were covered with cover-slips and 
transferred on to an ice tray for 5 min. 
2.5.2 Cell lysis 
In this step, after removal of the cover slips, the slides were immersed overnight in 
cold lysing solution at 4°C, which was always freshly prepared. The lysis solution 
consisted of 100 mM EDTA, 2.5 M NaCl, 10 mM Trizma base, 10% DMSO and 1% 
Triton X-100, pH 10. The lysis solution contained a high concentration of salt and a 
detergent. Proteins and their bonding and RNA were disrupted by aqueous salts. 
The cell membrane was dissolved by the detergent.   
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2.5.3 Electrophoresis 
After cell lysis, the slides were placed horizontally in a gel electrophoresis tank with 
a fresh alkaline buffer (10M NaOH and 200mM EDTA, pH >13). The slides 
remained for 30 min at 4°C to allow unwinding of DNA before starting the 
electrophoresis. The electrophoresis was then run for 30 min at 25 volts/32 cm 
(0.78 v/cm) and 300 mA using a compact power supply. 
2.5.4 Neutralization  
The slides were removed from the electrophoresis tank and placed in a horizontal 
position, then covered with neutralising buffer (0.4 M Tris-HCl, pH 7.5) three times 
for 5 min each. For long term storage slides can be run through a dehydration 
process, by immersing them in methanol for 30 min at 4°C. The dehydrated slides 
can be rehydrated by placing them in chilled water for 30 min in order to rehydrate 
the gel, and the cells can be stained. 
2.5.5 Staining and comet scoring 
Ethidium bromide (20 μg/ml) stain was used for DNA staining; 60 μl of the dye was 
added on the top of each slide and covered with a cover slip. To avoid the drying of 
cells, they were kept in a damp and closed container. The cells were scored by 
using a fluorescence microscope equipped with CCD camera and connected with 
image computer software. Objectives of 200 x magnification were utilised in the 
evaluation of each dose. 100 cells were selected randomly and analysed from 
each slide. The mean of each set of the experiment's data was utilised in the 
statistical analysis. A significance level of p<0.05 was considered as statistically 
significant. Two comet data parameters Olive tail moment (OTM) and % tail DNA, 
were used to quantify DNA damage. OTM (the fraction of DNA in the tail multiplied 
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by the tail length) and % tail DNA (the percentage of DNA in the tail) are 
recommended to be the most reliable comet measurements with OTM being the 
most statistically significant (Kumaravel and Jha, 2006). of these two parameters, 
OTM is the more commonly used to measure DNA damage, however, it is 
recommended to provide in parallel with % tail DNA (Tice et al., 2000).  
Additionally, OTM and % tail DNA clearly indicate the comet demonstrating a linear 
relationship with the DNA break frequency over a wide range of levels of damage.  
Both OTM and % tail DNA can be used for scientific purposes. However, OTM 
values can change extensively among laboratories with different software 
packages; furthermore, for all studies that use different electrophoresis runs. It is 
advisable that % Tail DNA be used to eliminate the variability in the results. % Tail 
DNA is considered as appropriate for regulatory or inter-laboratory comparison 
studies (Hartmann et al., 2003; Kumaravel et al., 2009). 
2.6 Micronucleus assay 
2.6.1 Preparation of basic culture medium 
Basic culture medium was prepared in the extraction laminar flow hood under 
sterile conditions. 15% of foetal bovine serum (FBS) and 1% of penicillin-
streptomycin solution were added to the Roswell Park Memorial Institute medium 
(RPMI-1640) that contained l-Glutamine amino acid and 25 mM HEPES buffer. 4.5 
ml of prepared medium was transferred into each of 25 cm³ Corning culture flasks. 
The flasks were then stored in a -20 °C freezer. 
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2.6.2 Lymphocyte cell culture 
Before starting the culture the T25 cm³ flasks containing 4.5 ml of frozen prepared 
media were placed in a 37°C incubator (5% CO2) for 30 min to adjust for 
temperature. Sterile materials and solutions were used when performing 
lymphocyte culture which lasted for 72h. 
2.6.3  Culture start  
At 0 h 500 μl of fresh blood obtained from healthy volunteers or from breast cancer 
patients were added to each flask containing 4.5 ml of basic medium. Then, 100 μl 
of phytohaemagglutinin (PHA final concentration 2%) were added to each flask. 
After 24h incubation 50 μl of 40 µM mitomycin C (end concentration 0.4 µM) was 
added to the positive control flask, 250 ng/ml ibuprofen and 500 ng/ml aspirin were 
added to different lablled flasks (Table 4). Then the cultures were incubated at 
37°C in the presence of 5% CO2. 
Flasks  No.  Type Blood  PHA  compound RPMI 
Flask 1 Untreated cells 500 μl 100 μl 50 μl 4350 μl 
Flask 2 PC 500 μl 100 μl 50 μl 4350 μl 
Flask 3 Ibuprofen NPs 500 μl 100 μl 62.5 μl 4337.5 μl 
Flask 4 Ibuprofen bulk 500 μl 100 μl 50 μl 4350 μl 
Flask 5 Aspirin NPs 500 μl 100 μl 83 μl 4317 μl 
Flask 6 Aspirin bulk 500 μl 100 μl 50 μl 4350 μl 
Table 4 Six different treatments which were used in the CBMN assay 
*Maximum volume of treating stock added was 1% of culture volume i.e. 50 µl 
2.6.4 Cytokinesis block  
After 44 h of incubation, 30 µl of 6 µg/ml Cytochalasin B were added to each flask. 
This step is essential in this assay as the Cyto B inhibits the formation of actin 
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filaments that network strongly and this in turn leads to inhibition of cytoplasmic 
division and therefore, halts the cells in the bi-nucleated form. 
2.6.5 End of cell culture 
 After 72 h the flasks were removed from the incubator and the flask content 
transferred to labelled 15 ml Falcon tubes. 
2.6.6  Cell hypotonic shock treatment  
The Falcon tubes containing the culture were placed in a centrifuge and 
centrifuged for 8 minutes at 107 g. After that a vacuum pump was used to remove 
the supernatant with retention of 500 µl. The tubes were agitated gently to re-
suspend the pellet. To allow hypotonic treatment of cells 5 ml of cold 110 mM 
potassium chloride was added to each tube, and then the tubes were stored for 15 
minutes in the refrigerator (4°C). Again the tubes were centrifuged for 8 minutes at 
107 g and a vacuum pump was used to discard the supernatant with retention of 
500 µl. Tubes were agitated gently to re-suspend the cell pellets. 
2.6.7 Fixation of cells 
Carnoy’s solution (3 parts of methanol and 1 part of glacial acetic acid) and 38% 
formaldehyde were used 3 times for fixation of the cells. 
2.6.7.1 Fixation 1 
 In this step 5 ml of Carnoy’s solution (freshly prepared) was added to each tube 
gently and drop wise over the vortex followed by 3 drops of formaldehyde (38 %). 
The Falcon tubes were placed in a centrifuge and centrifuged for 8 minutes at 107 
g. The vacuum pump was utilised to discard the supernatant with retention of 500 
µl. Tubes were agitated gently to re-suspend the pellet. 
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2.6.7.2 Fixation 2 & 3 
 The fixation 1 step was repeated twice except for the addition of formaldehyde 
38%. 
2.6.8 Preparation, staining and slide fixation 
After centrifugation the supernatant was discarded while retaining 100 µl. 
Depending on the amount of cells around 300-600 µl of freshly prepared Carnoy’s 
solution was added and the pellet re-suspended. 20 µl of cell suspension was 
transferred twice onto new and clean slides in centre right and centre left. The 
slides were left to dry overnight. Two slides were prepared for each tube. The cells 
were stained in Giemsa stain for 20 minutes. Altered 5% Giemsa solution in 
Sorenson buffer (51 ml 0.2 M NaH2PO4 with 49 ml 0.2 M Na2HPO4). The slides 
were washed and left to dry and were fixed by adding DPX. Finally 24 mm x 50 
mm coverslips were added on the top.   
2.7  Comet assay on BLM with and without recovery 
2.7.1 Reagents 
The reagents were purchased including aspirin and ibuprofen as described in 
section 2.1. Bleomycin sulfate was purchased from Enzo Life Sciences Ltd, Exeter, 
United Kingdom. The stock solutions of BLM was prepared using deionized 
distilled water (ddH2O) and stored in a freezer at -20°C. Working solutions 
(different concentrations) were also prepared using ddH2O and stored at 4°C. 
2.7.2 Cell treatment of Whole blood cells  
 Seven Eppendorf® tubes were chosen and labelled for the Comet repair assay; 
one negative control (untreated cells), two positive controls: BLM without allowing 
repair (BLM) and BLM with allowing repair (BLMR) which contained only bleomycin 
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and four treatments challenged with bleomycin and allowing repair individually in 
the presence of aspirin bulk, aspirin nano, ibuprofen bulk or ibuprofen nano. This 
was to demonstrate the effects of aspirin and ibuprofen (both forms) on DNA 
repair. Bleomycin was utilised as a genotoxic agent to induce DNA damage. Cells 
in each Eppendorf® tube were treated for 30 minutes in a first incubation at 37°C 
and then the cells were left for a further 30 minutes incubation at 37°C except the 
positive control 1 (BLM). The cells in BLM treatment were challenged for 30 
minutes incubation at 37°C before being embedded in 5% low milting point (LMP) 
agarose on slides pre-coated with agarose, no time for repair being allowed. The 
BLMR was treated in the same manner as the BLM, but the cells were left for the 
second incubation (30 minutes) without any treatment with NSAIDs to allow DNA 
self-repair. 
2.7.3 Treatment over duration of 1h  
Time point 0 hrs: 100 µl of whole blood cells were added to each tube in the 
presence of 890 µl RPMI medium. 10 µl of 0.75 mg/ml bleomycin (final 
concentration 7.5 µg/ml) were added to each tube except the negative control, 
where 100 µl of whole blood cells added to 900 µl RPMI medium.  All 7 tubes were 
incubated for 30 min at 37°C. After the incubation all tubes were removed from the 
incubator and centrifuged at 110 g for 3 min.  
For BLM treatment, 900 µl of supernatant was removed, 100 µl of 0.5 % LMP 
agarose was added to cell pellet and mixed gently. The suspension was 
immediately embedded on two pre-coated slides with 1% normal melting point 
(NMP), 100 µl each and covered with cover-slips then transferred on an ice tray for 
5 min. The slides were transferred in lysis buffer after removing cover slips.  
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2.7.4 Supplementation with NSAIDs during recovery 
For the negative control, BLMR, and the other four treatment concentrations, 900 
µl of supernatant was discarded and cell pellet were washed three times with 900 
µl of fresh 1640-RPMI medium. Cell pellets were very gently mixed and centrifuged 
at 110 g for each wash.  
For the negative control and BLMR tubes, after the centrifugation 900 µl of 
supernatant was discarded and 900 µl of fresh RPMI was added to the washed cell 
pellet of each tube and gently mixed. To the remaining 4 tubes after last washing 
900 µl  of supernatant was discarded and treated as showed in the table 5, 
 RPMI aspirin 
bulk 
aspirin 
nano 
ibuprofen 
bulk 
ibuprofen 
nano 
End conc of 
NSAIDs 
Tube 1 890 µl 10 µl 0 µl 0 µl 0 µl 500 µg/ml 
Tube 2 883.4µl 0 µl 16.6 µl 0 µl 0 µl 500 µg/ml 
Tube 3 890 µl 0 µl 0 µl 10 µl 0 µl 250 µg/ml 
Tube 4 887.5 µl 0 µl 0 µl 0 µl 12.5 µl 250 µg/ml 
Table 5 Second incubation for all 6 tubes incubated for 30 min at 37 °C. 
2.7.5 Embedding of cells in agarose 
After the second incubation allowing repair, all the Eppendorf® tubes were 
centrifuged for 5 min at 110 g and 900 µl supernatant was discarded. 100 µl of 
agarose LMP was added to the remaining cell pellet and mixed gently. The cell 
suspension was layered on slides pre-coated with NMP agarose, two slides for 
each treatment. The slides were transferred onto a cold surface for 5 min. Then the 
coverslips were removed and the slides were placed overnight in a jar of cold lysis 
solution to remove cell membranes and denatured protein. The freshly prepared 
lysis solution consisted of 100 mM EDTA, 2.5 M NaCl, 10 mM Trizma base, 10% 
DMSO and 1% Triton X-100, pH 10.  
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2.7.6 DNA unwinding and electrophoresis  
Following the lysis step, the slides were placed horizontally in electrophoresis tank 
in presence of electrophoresis buffer (300 mM NaOH and 1 mM EDTA, pH > 13). 
Slides remained in a tank for 30 min at 4°C for DNA unwinding, then 
electrophoresis was started for 30 min at 290-300 mA, at a constant voltage of 25 
V  (0.78v/cm). 
2.7.7 Neutralisation 
The cells and below were then neutralised three times for 5 min each using a 
neutralising buffer (0.4 M Tris-Hcl, pH 7.5). Cells were then stained with 20 µg/ml 
ethidium bromide reagent and covered with cover-slips in a dark place. 
2.7.8 Scoring of Slides  
Before scoring, all slides were double blinded and 100 cells were evaluated on 
each slide using a fluorescence microscope connected to a CCD camera and 
Computer system (Andor Technology Ltd, Belfast, UK). Data were analyzed to 
measure olive tail moment and % Tail DNA using kinetic imaging software (Andor 
Technology Ltd, Belfast, UK). Experiments were repeated for 15 healthy 
individual’s samples and for 15 BC female patients’ samples. 
2.8 PCR 
2.8.1 RNA Extraction 
1ml of human whole blood was mixed with 5ml of Buffer EL (erythrocyte lysis 
buffer) in a 15 ml Falcon tube. The mixture was incubated for 15 min on ice and 
vortexed briefly 3 times throughout the incubation. After the incubation, the mixture 
was centrifuged at 400 x g for 10 min at 4°C, and the supernatant completely 
removed and discarded. 2 ml of Buffer EL were added to the pellet which was then 
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re-suspended by brief vortexing. The suspension was again centrifuged at 400 x g 
for 10 min at 4°C, and the supernatant removed completely and discarded. 350 µl 
of lysis Buffer (10 µl ß-mercaptoethanol per 1 ml Buffer RLT) was added to the 
pellet while vortexing. The lysate was directly pipetted in a QIAshredder spin 
column placed in a 2 ml collection tube and centrifuged for 2 min at full speed to 
homogenize. After the centrifugation the QIAshredder spin column was discarded 
and the collection tube containing homogenized lysate saved. The homogenized 
lysate was mixed with 350 µl 70% ethanol and carefully pipetted with any formed 
precipitate in a new QIAamp spin column placed in a 2 ml collection tube without 
wetting the rim, and was centrifuged for 15 s at 8000 x g. The QIAamp spin column 
was transferred into a new 2 ml collection tube. 700 µl of Buffer RW1 (a guanidine 
salt and ethanol) was applied to the QIAamp spin column and centrifuged for 15 s 
at 8000 G for washing. The QIAamp spin column placed in a new 2 ml collection 
tube. In this step 500 µl of Buffer RPE was pipetted into the QIAamp spin column 
and centrifuged for 15 s at 8000 x g. An additional 500 µl of buffer RPE was added 
and centrifuged again at maximum speed for 3 min. In the final step the QIAamp 
spin column was transferred into a 1.5 ml microcentrifuge tube and 50 µl of RNase-
free water was directly pipetted in the middle of QIAamp membrane and 
centrifuged for 1 min at 8000 G to elute. The extracted RNA was stored at -80°C 
2.8.2 Preparation of cDNA 
The cDNA was prepared by the following steps. Mixture 1 was generated by mixing 
2 µl of random hexamer primers with 8 µl of isolated RNA and heated by using 
PCR machine at 70°C for 5 min to denature the RNA. Meanwhile, mixture 2 was 
prepared by mixing 4 µl of Improm- ɪɪTM Reaction buffer, 2.4 µl of MgCl2 (25 mM), 
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1 µl of dNTP (10 mM), 1.1 µl nuclease-free water, 0.5 µl of Recombinant RNasin 
(ribonuclease inhibitor), and 1 µl of Improm ɪɪ RT (reverse transcriptase). In the 
final step, mixture 2 was added to the mixture 1 and transferred to a PCR machine. 
and incubated  for 5 min in 25 °C then for 60 min at 42 °C and finally for 15min at 
70 °C. After finishing the incubation the prepared cDNA was stored at - 20 °C. 
2.8.3 Quantitative real time PCR analysis 
The primers were optimised for their annealing temperature. For each reaction, ten 
μl of Fast SYBR® Green Master Mix, two μl of primer, 0.5 μl of cDNA and 7.5 μl of 
UltraPure™ DNase/RNase-Free distilled Water were mixed. The mixture was 
placed in a 96 well PCR reaction plate and sealed using a MicroAmp® Optical 8-
Cap Strips; the mixture was directly vortexed then twirl down using a plate spinner 
to accumulate the solution at the bottom of the plate well ensuring no air bubbles 
were present. The reaction plate was placed into a quantitative real-time PCR 
machine, and the intended protocol was run. The reaction was done in triplicate 
wells. For each experimental condition, β actin was used as a housekeeping gene 
where levels were unaltered at different conditions. The CT value was generated 
for the reaction as soon as the PCR had run.  From the CT values generated, a 
ΔCT value was calculated from the housekeeping gene (the expression of the 
gene of interest normalised against β actin); from that a ΔΔCT was further created 
to ensure that the expression could be obtained. For consistent purposes, 
expression was normalised against β actin. In the comparative or ΔΔCt method of 
qPCR data analysis, the Ct values from two different experimental RNA samples 
are directly normalised to a housekeeping gene and then compared. First, the 
difference between the Ct values (ΔCt) of the gene of interest and the 
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housekeeping gene is calculated for each sample. Then, the variance of the ΔCt 
values between the experimental and control samples ΔΔCt is calculated. 
2.9 Western blot 
2.9.1 Cell culture and protein isolation 
 After lymphocyte isolation from whole blood, the cells were counted and cultured 
in two of 6 well cell culture plates. Each well contained 5 ml of prepared RPMI and 
70 µl of PHA (106cells/well) for 24 h. After 24 h the cells were treated with aspirin 
and ibuprofen (both forms) individually. Plate 1 was treated for 8 hrs and plate 2 for 
24 hrs. Once the treatment time finished the medium was pipetted from the wells, 
and each well washed twice with 5ml sterile PBS. Then, 2 ml of lysis buffer were 
added to lyse and de-attach cells using a plastic scrubber. The isolated protein was 
transferred to Eppendorf tubes. The protein was heated at 90°C in a water bath for 
10 min and stored in the - 20 °C freezer. The Bradford protein assay was used to 
measure the total protein in each sample (Bradford, 1976; Ernst and Zor, 2010). 
2.9.2 Total protein evaluation 
The protein concentration of samples was evaluated with the Bio-Rad Bradford 
assay kit following the manufacture’s guidelines. The Bradford protein assay 
principle is based on colorimetric alterations resulting in binding of Coomassie 
Brilliant Blue G-250 dye to proteins. The unbound reagent is in the protonated red 
cationic form which is converted to an unprotonated blue coulor when bound to 
proteins. Five different standard concentrations were used (1 mg/ml, 0.5 mg/ml, 
0.25 mg/ml, and 0.125 mg/ml). 5 µl of each standard and sample (in triplicate) were 
pipetted into separate wells of 96 well plates, and 250 µl of diluted Bio-Rad dye 
reagent were added to each well. The mixtures were incubated at 25°C for 5 min 
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and absorbance evaluated spectrophotometrically at 595 nm with a microplate 
reader. Concentrations were calculated depending on standards concentrations. 
2.9.3 SDS-PAGE gel preparing and electrophoresis 
Cassettes and glasses were washed with water and dried, then fixed together. 
Each cassette was covered by a glass plate and fitted into a casting frame, and 
secured by turning the hinge around and placed in the Perspex rack holder. Five 
ml of spreading gel (5 ml ddH2O, 6.67 ml 30% acrylamide, 4 ml 1.5 M Tris pH 8.8, 
160 µl 10% SDS, 160 µl 10% APS and 16 µl TEMED) were pipetted between 
cassettes and plates, by utilizing 1 ml pipette until brought to the green lane. The 
spreading gel was left to solidify completely, then a 1 ml pipette was used to add 
the stacking gel (5.3 ml ddH2O, 2 ml 30% acrylamide, 2.5 ml 1.5 M Tris pH 8.8, 
100 µl 10% SDS, 100 µl 10% APS and 10 µl TEMED) to the top of each plate. A 
comb was introduced to each plate and this was done promptly before the gel sets. 
Cassettes filled with gel were removed from the plate holder and transferred to the 
electrophoresis plate holding rack. Cassettes held by the holding rack were placed 
in the electrophoresis tank and the combs were removed. The tank was filled with 
running buffer (30.29 g Tris base 25 mM, 142.63 g glycine190 mM and 10.0 g SDS 
0.1%  in 1L distilled water) then 30 µl of each prepared sample was added into one 
of the wells. Samples were mixed with laemmli buffer (4% SDS, 10% 2-
mercaptoethanol, 20% glycerol, 0.004% bromophenol blue and 0.125 M Tris-HC)   
at a rate dependent on the concentration of total protein in each sample.The 
electrophoreses was run at 200 V for 1 h. 
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2.9.4 Protein transfer from the gel to the membrane  
The Polyvinylidene difluoride (PVDF) membrane was cut in the same gel size and 
activated by placing it in methanol for 30 seconds, then placed in transfer buffer 
(3.02 g Tris base 25 mM, 14,26 g glycine 190 mM, 200 ml methanol in 1L distilled 
water) for 5 minutes on a rotator at room temperature. The gel containing the 
electrophoresed protein was removed from the plate and assembled to a 
transferring cassette. Gel and membrane were assembled in the transfer 
sandwich. The air bubbles trapped in the sandwich were removed. The blot was on 
the cathode, and the gel was at the anode. Each component was soaked in 
transfer buffer for a few seconds before assembly to keep the membrane moist, 
this step was carried out in a tray containing transferring buffer. The cassette was 
closed and positioned in the tank already filled with transfer buffer and ice block, 
then run at 100 V for 1 h. 
2.9.5 Antibody staining  
 After the transferring process the membrane was removed and transferred to a 
tray with Blocking buffer (NaCl 2g + KCl 50mg + Trisma Base 57mg were dissolved 
in 250 ml dH2O and the pH adjusted to 7.4 then added to 250 µl of Tween 20 and 
PSA 9g 4%) and placed on a rotator in a cold room for 1 h. The primary antibody 
was diluted in blocking buffer to the appropriate concentration depending on the 
antibody type, and then the membrane was transferred to a plate containing 10ml 
of diluted primary antibody and incubated overnight on a rotator in the cold room 
(4°C). After that the membrane was washed for three washes with washing buffer 
(PBS/0.05%-0.1% Tween-20), for 5 min each. The membrane was incubated with 
 64 
 
the recommended dilution (1:2000) of a conjugated secondary antibody using 
blocking buffer at room temperature for 1 h under rotating at room temperature. 
2.9.6 Signal development 
Three washes were performed each for 5 minutes with washing buffer in a tray 
under rotation. Before the last wash was commenced, the equipment and reagents 
for signal development were prepared in the dark room following the kit (ECL) as 
recommended by Bio-rad. The membrane was transferred on plastic wrap and 
covered with ECL reagent. Images were captured utilizing darkroom development 
techniques for chemiluminescence, or normal image scanning methods for 
colorimetric examination. 
2.9.7 Western blot membrane stripping for restaining  
The membrane was incubated for 10 min with 35 ml of stripping buffer (15 g 
glycine 200 mM, 1g SDS 0.1% and 10 ml Tween20 1%, pH adjusted to 2.2 before 
bring the volume 1L). Then the membrane incubated twice with 35 ml of PBS for 
10 min each. After that the membrane transferred in 35ml of TSBT solution (NaCl 
2g + KCl 50mg + Trisma Base 57mg) were dissolved in 250 ml dH2O and the pH 
adjusted to 7.4 after which was added to 250 µl of Tween 20 and PSA 9g 4%) for 5 
min, this step was repeated two time. After that the western blot steps started from 
the blocking step to the end as described earlier in western blot method.  
2.10 Cell viability  
The cell viability assessment was evaluated for the fresh lymphocyte cells after 30 
min of treatment with ibuprofen (NPs, bulk) 250 ng/ml or aspirin (NPs, bulk) 500 
ng/ml. The cells were centrifuged in the micro-centrifuge at 1250 g for five minutes 
at room temperature. Then 0.4% of Trypan blue solution was mixed with treated 
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cells 1:1, 100 cells were recorded. Trypan blue permeation into the cell occurs after 
the breakdown of the cell membrane, which is associated with cell death. 
2.11 Statistical analysis  
 Twenty different samples of healthy individuals and 20 samples of BC patients 
were used in the Comet assay and 5 samples of healthy individuals with 5 samples 
of BC patients in CBMN assay. In Comet repair assay 15 samples were used from 
each group BC patients and healthy female individuals. However, 3 samples from 
each group for western blot and qPCR. The means of group data were calculated 
with standard errors. For qPCR the ΔΔCT method was used which is a convenient 
way to analyse the relative changes in gene expression from real-time quantitative 
PCR experiments. The normality of distribution of the data were tested through the 
Kolmogorov-Smirnov and Shapiro Wilk’s test to select the appropriate parametric 
statistics which could be used. The normality of distribution of the data were 
evaluated using the One Way ANOVA test between healthy control and BC blood 
samples. Normality was violated so non-parametric statistics were considered for 
data analysis. The differences between groups were tested using the Kruskal-
Wallis test and Mann-Whitney U-test. Dose response correlations were determined 
by Pearson’s test for both NSAIDs.  A value of p ≤ 0.05 value was chosen as 
statistically significant. All analyses were generated using SPSS for windows 
statistical package (version 18.0). Graphpad prism 6 was used to draw graphs.  
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Chapter 3 – The Comet assay in peripheral blood 
lymphocytes after treatment with the NSAIDs, 
ibuprofen and aspirin. 
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3. Comet assay studies 
3.1 Introduction 
Many studies have been done to examine the relationship between the level of 
NSAID (ibuprofen, aspirin) intake and the incidence of various malignancies 
including the most prevalent types: lung, prostate, colon, and breast cancer 
(Agrawal and Fentiman, 2008; Harris et al., 2005; Neill et al., 2013). The 
concentration-response curve of those studies showed an inverse relationship 
between NSAIDs intake and cancer risk. Moreover, there was a significant 
exponential decline in the emergence of cancer, when compared with the increase 
of NSAIDs (primarily aspirin or ibuprofen). It has been found that the daily intake of 
NSAIDs, generally aspirin led to risk reductions of breast cancer (39%), 63% for 
colon cancer, and 39% for prostate cancer. After five years of use, the NSAIDs 
impact became apparent, and this effect was more evident with increasing duration 
of use (Harris et al., 2005; Langley et al., 2011; Neill et al., 2013). Most studies 
concentrated on the role of inflammation in breast cancer, specifically the role of 
the cyclooxygenase enzyme COX-1 and COX-2 with drugs that inhibit COX-2 in 
several cancer types including breast cancer. The anti-inflammatory drugs study 
showed promising findings in the treatment and reduction of colon and breast 
cancer. Aspirin and ibuprofen were among the NSAIDs included in these studies. 
COX-1 is present in healthy cells, whereas, the COX- 2 can be found in high 
concentrations in inflammatory processes.  It has been found that COX-2 has a 
role in some cancers including breast cancer. COX-2 has a role in the production 
of prostaglandins which in turn leads to increase the production of oestrogen. The 
oestrogens stimulate breast cell proliferation and finally increase the breast cancer 
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risk (Komen, 2004; Neill et al., 2013). Methodologies that can identify and evaluate 
DNA damage have been developed in the last two decades. The Comet assay or 
single cell gel electrophoresis assay is a technique that was designed to follow and 
measure DNA damage in individual cells including lymphocytes and sperm, 
especially double-strand breaks (Wu and Jones, 2012). In this assay, lymphocytes 
are embedded in the agarose gel and are transferred to an electrophoresis tank in 
the presence of an alkaline condition (pH> 13). The DNA fragments with a negative 
charge move through the gel towards the anode (+ve). The pieces move much 
faster than undamaged DNA, and this gives the appearance a comet under 
florescence. The Comet assay is used to analyse DNA damage in lymphocytes in 
two ways using Olive tail moment and % of Tail DNA (Wu and Jones, 2012).  
In these experiments, the effect the ibuprofen a non-steroidal anti-inflammatory 
drug and aspirin a non-opioid analgesic (acetylsalicylic acid) NSAIDs in both NPs 
and bulk sizes were assessed for DNA damage in human blood lymphocyte cells. 
There were obtained from healthy female volunteer and breast cancer patients 
using the single cell gel electrophoreses method. Here, the classic genotoxic 
compound hydrogen peroxide (H2O2) (50 µM) was used as a positive control. 
Different experiments were conducted with fixed doses of both compounds 
(ibuprofen 250 ng/ml and aspirin 500 ng/ml) in NPs and bulk states respectively. 
These doses are not toxic. After doing these experiments, the data were analysed, 
to help to determine the effect of these two agents on reducing DNA damage and 
DNA integrity. 
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3.2 Materials   
The materials that were used in this project are listed and described in section 2.1. 
3.3 Methods 
Blood collection and preparation including lymphocyte isolation have been 
described in section 2.2. The alkaline Comet assay protocol and all its steps have 
been described in section 2.5. NSAIDs (aspirin and ibuprofen) doses are described 
in section 2.3.4. 
3.4 Scoring and data statistical analysis 
 After finishing experiments, coded slides were scored using a florescence 
microscope connected to a camera and computer system equipped with Komet 6 
software (Andor Technology Ltd, Belfast, UK). A Description can be found in 
section 2.5.5. SPSS statistics (version 18) were used to determine significance and 
data distribution from Olive tail moment and % tail DNA values. 
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3.5 Results 
3.5.1 Ibuprofen NP and bulk forms concentration responses on 
lymphocytes DNA from female healthy volunteers  
 
Figures 13 and 14 illustrate the concentration response of both NP and bulk sizes 
of Ibuprofen on lymphocyte DNA from healthy volunteers using Olive tail moment 
and % Tail DNA. It was clear from the histogram in Figure 13 that the effect of 
Ibuprofen on lymphocyte DNA was non-significant compared to the untreated, 
similarly to % Tail DNA (Figure14). Using the ANOVA test when making a 
comparison of ibuprofen NP and Ibuprofen bulk against untreated cells showed 
non-significant (ns) effect on lymphocyte DNA. Whereas, H2O2 (positive control) 
(50 µM) showed high significance ***p ≤ 0.001. It shows non-significance when 
comparing the nano with bulk form (ns†).  
 
Figure 13 Concentration response of ibuprofen 250 ng/ml (NPs and bulk), SE, and significance on 
lymphocytes DNA from healthy volunteers using Olive tail moment. (N = 20) 
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Figure 14 Concentration response of ibuprofen 250 ng/ml (NPs and bulk), SE, and significance on 
lymphocytes DNA from healthy volunteer using % Tail DNA. (N = 20) 
 
3.5.2 Ibuprofen NP and bulk forms concentration response in 
lymphocytes DNA from BC patients  
 
Figures 15 and 16 demonstrate the concentration response of both NP and bulk 
sizes of Ibuprofen on DNA in lymphocytes from BC patients using Olive tail 
moment and % Tail DNA. It was evident from the histograms in Figures 15 and 16 
that Ibuprofen reduced the damage in lymphocyte DNA compared to the untreated 
cells. All controls and Ibuprofen were normally distributed. Using the ANOVA test 
represents the comparison of Ibuprofen NP and Ibuprofen bulk against untreated 
cells where there was no significant (ns) effect on lymphocyte DNA. Whereas, the 
positive control showed high significance ***p ≤ 0.001. Additionally, there was no 
difference when compared the nano with bulk form (ns†). 
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Figure 15 Concentration response of Ibuprofen (NPs and bulk), SE  and significance on 
lymphocyte DNA from BC patients using Olive tail moment. (N = 20) 
 
Figure 16 Concentration response of Ibuprofen (NPs and bulk), SE and significance on lymphocyte 
DNA from BC patients % Tail DNA. (N = 20) 
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3.5.3 Comparison of Ibuprofen NP and bulk forms for concentration 
responses on lymphocytes DNA from BC patients and healthy 
volunteers 
Figure 17 and 18 showed the concentration response of both NP and bulk forms of 
ibuprofen in lymphocyte DNA from both BC patients and normal healthy volunteers 
using Olive tail moment and % Tail DNA. It was evident from the chart that 
ibuprofen reduced the damage in lymphocyte DNA from BC patients compared to 
untreated cells but the reduction was not significant (ns). The normal healthy cells 
showed a non-significant DNA damage increase compared to untreated cells. Both 
aspirin and ibuprofen showed non-significance increase when comparing the Bulk 
with Nano form (ns†). 
 
Figure 17 Comparison of ibuprofen concentration responses, SE, and significance on lymphocytes 
DNA from both healthy volunteers and BC patients using Olive tail moment. (N = 20) 
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Figure 18 Comparison of ibuprofen concentration responses, SE, and significance on lymphocytes 
DNA from both healthy volunteers and BC patients using % Tail DNA. (N = 20) 
 
3.5.4 Aspirin NP and bulk forms concentration responses on 
lymphocytes DNA from healthy volunteers  
Figure 19 and 20 demonstrates the concentration responses of both NP and bulk 
forms of aspirin on lymphocyte DNA from healthy volunteers using Olive tail 
moment and % Tail DNA. It was clear from the histogram in Figure 19 and 20 that 
the effect of aspirin on lymphocyte DNA was weak and non-significant compared to 
untreated cells. Using the ANOVA test aspirin NP and bulk forms against untreated 
cells were compared and no significant (ns) impact on lymphocytes DNA was 
observed, whereas, H2O2 (50 µM) showed high significance ***p ≤ 0.001. No 
significant difference in response was seen when the nano form was compared 
with the bulk (ns†). 
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Figure 19 Concentration response to aspirin (NPs and bulk), SE, and significance in lymphocyte 
DNA from healthy volunteers using Olive tail moment. (N = 20) 
  
Figure 20 Concentration response to aspirin (NPs and bulk), SE, and significance in lymphocyte 
DNA from healthy volunteers using % Tail DNA. (N = 20) 
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3.5.5 Aspirin NP and bulk forms concentration responses in 
lymphocyte DNA from BC patients  
 
Figure 21 and 22 illustrated the concentration response of both NPs and bulk forms 
of aspirin on lymphocyte DNA from BC patients using Olive tail moment and % Tail 
DNA. It was evident from the histogram that the aspirin reduced the damage on 
lymphocyte DNA compared to the untreated cells. All controls and aspirin insert 
data were normally distributed. By using the ANOVA test, aspirin NP and bulk 
against untreated cells showed significant reduction in lymphocyte DNA damage 
**p ≤ 0.01 and *p ≤ 0.05 respectively. H2O2 (positive control) (50 µM) showed a 
significance increase in DNA damage ***p ≤ 0.001 when compared to untreated 
cells. There was a non-significant difference in effect when the nano-form was 
compared with the bulk form (ns†).  
 
Figure 21 Concentration responses of aspirin (NP and bulk), SE and significance in lymphocyte 
DNA from breast cancer patients using Olive tail moment. (N = 20) 
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Figure 22 Concentration responses of aspirin (NP and bulk), SE and significance in lymphocyte 
DNA from breast cancer patients using % Tail DNA. (N = 20) 
 
3.5.6 Comparing aspirin NP and bulk forms concentration responses 
in lymphocyte DNA from BC patients and healthy volunteers  
 
Figure 23 and 24 demonstrate the concentration response of both NP and bulk 
forms of aspirin in lymphocyte DNA from BC patients and normal healthy 
volunteers using Olive tail moment and % Tail DNA. It was apparent from the 
histogram in Figure 23 and 24 that the both forms of aspirin significantly reduced 
the damage to lymphocyte DNA from BC patients compared to the untreated cells. 
However, normal healthy cells exhibited a weak and non-significant damage 
increase compared to the untreated cells. Both aspirin and ibuprofen showed non-
significance when comparing the bulk with nano form (ns†). 
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Figure 23 Comparison of the aspirin concentration responses, SE, and significance in lymphocyte 
DNA from both healthy volunteers and BC patients using Olive tail moment. (N = 20) 
 
Figure 24 Comparison of the aspirin concentration responses, SE, and significance in lymphocyte 
DNA from both healthy volunteers and BC patients using % Tail DNA. (N = 20) 
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Figure 25 Typical comet image showing control lymphocyte cells (undamaged DNA) 
 
 
 
Figure 26 Typical comet image showing damage in lymphocytes cell DNA where the head 
represents undamaged DNA and tail reflects damaged DNA. 
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3.6 Discussion 
The single cell gel electrophoresis assay (Comet assay) has become one of the 
most influential and standard assays to assess damage to DNA (Azqueta and 
Collins, 2013; Hoffmann et al., 2005; Vijaya Lakshmi et al., 1999). In studying DNA 
strand breakage, the Comet assay is already established to be the most sensitive 
technique available at present; it has many advantageous features including 
speed, ease and the fact that the DNA damage is evaluated at the level of a single 
cell (Collins et al., 1997; Wu and Jones, 2012). Lymphocytes obtained from human 
peripheral blood are used in different assays to assess genotoxicity. Lymphocytes 
are often utilised from workers who have been exposed to cytotoxic agents to 
follow chromosomal abnormality changes, sister chromatid exchanges, mutations, 
and after in vitro exposure (Anderson et al., 1991; Najafzadeh et al., 2012). 
Isolated and thawed lymphocytes obtained from both healthy volunteers and BC 
patients were treated in vitro separately, with ibuprofen NP 250 ng/ml, ibuprofen 
bulk 250 ng/ml, aspirin NP 500 ng/ml, and aspirin bulk 500 ng/ml individually for 30 
min at 37°C. H2O2 (50 µM) was used as PC. After treatment, the lymphocytes were 
scored for Olive tail moment and % DNA tail. Healthy volunteer lymphocyte 
samples treated with ibuprofen and aspirin showed minor and non-significant 
damage in DNA. However in lymphocytes obtained from BC patients, both 
ibuprofen and aspirin (NP and bulk) displayed a decrease in DNA damage 
compared to the untreated cells. By using the ANOA test, these reductions were 
shown to be significant for aspirin NP and bulk *p ≤ 0.01 and *p ≤ 0.05 
respectively, whereas, this decrease was non-significant when comparing the 
aspirin bulk with nano form. For both ibuprofen NP and bulk, the reduction was 
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non-significant compared to untreated cells. The Comet assay incubation time was 
30 min, and this could be too short a time for ibuprofen to act and reduce DNA 
damage significantly. The aspirin outcomes demonstrated that the aspirin NP effect 
was stronger than the bulk form. When comparing the aspirin and ibuprofen 
results, it was shown that the aspirin response was faster and greater than that of 
ibuprofen. 
Many studies suggest that NSAIDs such as ibuprofen and aspirin have the 
potential to reduce the probability of breast cancer development (Horn and 
Fentiman, 2010; Kwan et al., 2007). In this present study the Comet assay 
experimental outcomes corresponded to the previous suggestion that ibuprofen 
and aspirin have the ability to reduce DNA damage and therefore developing 
cancer (Baron and Sandler, 2000; Ghosh et al., 2010).     
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Chapter 4 – Anti genotoxic effects of ibuprofen and     
aspirin treatment in lymphocytes in the 
micronucleus assay 
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4. Micronucleus assay results 
4.1 Introduction 
The results from the ibuprofen (NPs and bulk) and aspirin (NPS and bulk) 
experiments in the previous chapter showed the potential of these compounds to 
reduce DNA damage. This was evident as seen by the significant decrease of 
Olive tail moment and % DNA tail using the Comet assay. Both ibuprofen and 
aspirin showed an ability to reduce the DNA damage; however, aspirin had a more 
significant impact. The Comet assay can demonstrate a compound’s effect at a 
genomic level. From these findings, it is clear that another technique is needed, 
which can investigate the compounds’ impact at a cytogenetic level. In this chapter 
results of the cytokinesis-block micronucleus (CBMN) are shown studying the 
effect of both agents in the micronucleus assay using somatic cells, i.e. 
lymphocytes.  The definition of the cell growth cycle is the vital processes that 
allow the cell to proliferate into daughter cells by replicating their DNA and finally 
when becoming senescent reach apoptosis, also called programmed cell death, at 
the end of their lives. The cell cycle occurs over a 24 h period in eukaryotic cells 
and consists of four stages: Gap 1 phase (G1 phase), the synthesis of DNA (S 
phase), gap 2 phase (G 2 phase), and the mitotic phase (M phase) (Bertoli et al., 
2013; Collins et al., 1997). In the first stage, G1 phase, the cell starts to prepare 
itself for progressing into S phase by synthesising protein required for DNA 
replication. In S phase, chromosomes are replicated to produce two identical 
copies of each chromosome. All components that are required for cell division and 
M phase are being prepared in G2 phase. The M phase is an essential stage in 
which nuclear division takes place and this stage can be divided in 5 different sub-
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stages prophase, prometaphase, metaphase, anaphase, and telophase (Bertoli et 
al., 2013; Norbury, 1992). Eventually, cytokinesis occurs in which the cell divides 
into two daughter cells (Kim et al., 2012; Vermeulen et al., 2003). The CBMN 
technique utilises once divided cells; these cells are characterised by the presence 
of two nuclei in cells known as binucleated cells (BiNC). These binucleated cells 
are a result of a blocking cytokinesis with cytochalasin B (cyto B), which inhibits the 
formation of the actin filaments network. These filaments are crucial to complete 
the cytokinesis stage. During cell division, the chromosome structure can be 
changed and separation can be interfered with by so many chemicals and 
exogenous agents, and this may lead to a variety of genetic mutations (Fenech, 
2007; Ionescu et al., 2011). The formation and presence of micronuclei (MNi) are a 
consequence of chromosomal breaks. These are fragments or whole 
chromosomes which can be scattered after the anaphase stage of mitosis. The 
presence of MNi in BiNC cells reflects precisely the cytogenetic damage. MNi can 
also be found in mononucleated (MonoNC) cells and multinucleated (MultiNC) 
cells; the presence of MNi in BiNCs exhibit the primary cytogenetic level; however, 
the MNi in MonoNC and MultiNC could be a result of different cell cycle kinetics 
(Fenech, 2006; Ionescu et al., 2011; Torres-Bugarín et al., 2014). Recently, 
research has demonstrated that the CBMN assay can as well measure 
nucleoplasmic bridges (NPBs) and nuclear buds (NBUDs) (Figure 10, 11). NPBs 
can be described as a small, very thin bridge between the two nuclei in BiNC. 
Occurrence of NPBs shows the presence of dicentric chromosomes which appear 
as a result of DNA mis-repair or telomere end-lesions. The importance of NPBs lies 
in its ability to measure some chromosomes rearrangements, which cannot be 
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shown by scoring the MNi alone (Fenech et al., 2011). Gene amplification can be 
detected via NBUDs as a biomarker. These NBUDs persist attached to the original 
nuclei throughout the nucleoplasm. NBUDs are similar to MNi, the only difference 
being  that NBUDs are physically connected to the nucleus (Fenech, 2007; Luzhna 
et al., 2013). MNi induction in lymphocytes has been well recognised in the CBMN 
assay (Fenech, 2000). The CBMN assay was selected and performed to evaluate 
MNi induction following NSAIDs (aspirin and ibuprofen) exposure. Two doses, 500 
µg/ml and 250 µg/ml, were chosen for aspirin and ibuprofen, respectively. As 
positive control 0.4 µM of mitomycin C was selected. MNi, NBPs, and NBUDs were 
scored in BiNC up to 1000 cells. One thousand other cells were scored to calculate 
the percentages of each type of cells’ MonoNCs, BiNC, and MultiNC. After the 
scoring proportions of 3 cell types were used to calculate the nuclear division index 
(NDI). The NDI is essential to measure the rate of mitotic division as it reflects 
cytostatic effects (Fenech, 2007). 
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4.2 Materials and Methods  
4.2.1  Materials  
All materials that have been used in these experiments are mentioned and 
described in section 2.1  
4.2.2  Methods  
The collection of whole blood samples was described in section 2.2. The CBMN 
assay protocol was described in section 2.6. Treatment groups, including MMC, 
ibuprofen (NPs and bulk), and aspirin (NPs and bulk) per each experiment were 
described in section 2.6.3. (See Table 4).  
4.2.3  Statistical Analysis  
Slides were coded and scored using Fenech’s protocols (Fenech, 2007). The 
determination of NDI was obtained by using NDI = (M1) + 2 (M2) + 3 (M3) /N 
formula, where, M1 = mononucleated cells, M2 = binucleated cells, M3 = 
multinucleated cells and N = the total number of viable cells scored.  The ANOVA 
test was used to determine the significance of each group compared to the 
untreated cells. 
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4.3 Results 
4.3.1 Results of CBMN Assay following ibuprofen and aspirin (NPs 
and bulk) exposure to lymphocytes 
Table 6 and 7 showing various cytological scoring parameters, including cell mitotic 
status (BiNC, MonoNC, MultiNC), MNi frequency, NDI and chromosomal 
damage/instability parameters in the form of NPBs and NBUDs.  Lymphocytes 
from 5 female volunteers and 5 BC patients were used.  The cells were treated 
with 250 µg/ml of ibuprofen and 500 µg/ml of aspirin (NPs and bulk) individually. By 
using the ANOVA test. There were no differences in MNi frequency in lymphocytes 
from healthy volunteers compared to an treated cells. However, the positive control 
showed an increased the MNi frequency significantly ***p ≤ 0.001 compared to the 
untreated cells.  In lymphocyte from BC patients, the frequency of MNi in BiNC was 
reduced significantly after the treatment with ibuprofen and aspirin. Moreover, both 
forms of aspirin and ibuprofen showed ***p ≤ 0.001, whereas, ibuprofen bulk 
showed **p ≤ 0.01 compared to the untreated cells.
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Table 6 Various cytological scoring parameters, including cell mitotic status (BiNC, MonoNC, MultiNC), NDI and chromosomal damage/instability 
parameters in the form of NPBs and NBUDs in lymphocytes from 5 healthy female volunteers  following exposure to ibuprofen and aspirin (NPs 
and bulk). (N = 5) 
NDI = the nuclear division index  
BiNC = Binucleated cells, % BiNC, is % expressed out of all types of 1000 cells scored.   
MultiNC = Multinucleated cells % MultiNC and MonoNC= Mono nucleated cells %MonoNC. The % expressed out of all types of 500 cells scored. 
MNi = Micronuclei score/1000 cells each of BiNC 
Where * is used to compare all groups to the untreated lymphocytes.  *** p  ≤ 0.001 and ns = not significant.  
 
 
 
Treatment 
 
Chemical 
concentration 
 
NDI (mean) 
 
% BiNC 
 
MNi per 
1000 BiNC 
mean 
 
NPBs mean 
 
NBUDs 
mean 
 
%MonoNC 
 
% MultiNC 
 
untreated 
lymphocytes 
  
1.9 
 
67.4 
 
3 
 
1 
 
1 
 
21 
 
11.6 
 
PC 
 
0.4 µM 
 
2.0 
 
73.8 
 
24 *** 
 
3 
 
6 
 
11.2 
 
15 
 
Ibuprofen 
NPs 
 
250 ng/ml 
 
1.8 
 
70.1 
 
2  (ns) 
 
0 
 
0 
 
15.1 
 
14.8 
 
Ibuprofen 
bulk 
 
250 ng/ml 
 
2.0 
 
60 
 
3  (ns) 
 
0 
 
0 
 
29.4 
 
10.6 
 
Aspirin NPs 
 
500 ng/ml 
 
2.0 
 
69.4 
 
2  (ns) 
 
0 
 
0 
 
13 
 
17.6 
 
Aspirin bulk 
 
500 ng/ml 
 
1.9 
 
74 
 
2  (ns) 
 
0 
 
0 
 
14.4 
 
11.6 
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Treatment 
group 
Chemical 
concentration 
NDI (mean) % BiNC  BiMNi per 
1000 BiNC 
mean 
BiNPB 
mean 
BiBuds 
mean 
%MonoNC % MultiNC 
 
NC 
  
2.0 
 
67.9 
 
11.4 
 
1.4 
 
1 
12.1  
20 
 
PC 
 
0.4 µM 
 
1.9 
 
69.1 
      
 17.6 ** 
 
2.4 
 
2.4 
17.6  
13.3 
 
Ibuprofen 
NPs 
 
250 ng/ml 
 
1.8 
 
67.5 
  
   5 *** 
 
0 
 
0 
23.9  
8.6 
 
Ibuprofen 
bulk 
 
250 ng/ml 
 
1.8 
 
65.3 
 
6 ** 
 
0 
 
0 
28.3  
6.4 
 
Aspirin NPs 
 
500 ng/ml 
 
1.8 
 
65.8 
     
 3.2 *** 
 
0 
 
0 
26  
8.2 
 
Aspirin bulk 
 
500 ng/ml 
 
1.9 
 
67.6 
   
   3.4 *** 
 
0 
 
0 
23.1  
9.3 
 
Table 7 Various cytological scoring parameters, including cell mitotic status (BiNC, MonoNC, MultiNC), NDI and chromosomal damage/instability 
parameters in the form of NPBs and NBUDs in lymphocytes from 5 BC patients  following exposure to ibuprofen and aspirin (NPs and bulk). 
NDI = the nuclear division index 
BiNC = Binucleated cells, % BiNC, is % expressed out of all types of 500 cells scored.   
MultiNC = Multinucleated cells % MultiNC, is % expressed out of all types of 500 cells scored.  
MNi = Micronuclei score/500 cells each of BiNC  
Where * is used to compare all groups to the untreated lymphocytes. ** p  ≤ 0.01 and *** p  ≤ 0.001.
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4.3.2 Ibuprofen and aspirin (NPs and bulk size) concentration response on 
MNi induction in lymphocytes from healthy female individuals.  
Figure 27 illustrates the concentration response of both ibuprofen and aspirin 
(NP and bulk) on lymphocytes from healthy volunteers. Using the ANOVA test, 
both NSAIDs (nano and bulk) showed no significant (ns) change in lymphocyte 
MNi frequency compared to the untreated cells. Whereas, 0.4 µM MMC (PC) 
showed a significant increase in MNi frequency ***p ≤ 0.001 compared to the 
untreated cells. There was no significant difference between both nano and bulk 
forms in either aspirin or ibuprofen (ns†). 
 
Figure 27  MN frequency in lymphocytes from healthy females exposed to ibuprofen and aspirin 
including SE and significance. (N=5)
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4.3.3 Ibuprofen and aspirin (NPs and bulk size) concentration 
response on MNi induction in lymphocytes from BC patients  
 
Figure 28 illustrates the concentration response of both ibuprofen and aspirin (NP 
and bulk) in lymphocytes from breast cancer patients to induce MNi in BiNC. The 
histogram in Figure 28 shows that the ibuprofen and aspirin significantly reduced 
the frequency of MNi in lymphocytes of BC patients in vitro when compared to 
untreated cells. Using the ANOVA test, results showed a significant decrease ***p 
≤ 0.001 in MNi for ibuprofen nano, aspirin nano and aspirin bulk. However, 
ibuprofen showed **p ≤ 0.01 compared to the untreated cells. Furthermore, 0.4 µM 
MMC (PC) showed a significant increase in MNi ***p ≤ 0.001 compared to the 
untreated cells. Both bulk and nano-forms of aspirin and ibuprofen had similar 
effects ns†.
 
Figure 28  MN frequency in lymphocytes from BC patients exposed to ibuprofen and aspirin 
including SE and significance. (N=5) 
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4.3.4 Comparing ibuprofen and aspirin (NPs and bulk) concentration 
response on MNi frequencies in lymphocytes from BC patients 
and healthy females volunteers  
 
Figure 29 demonstrates the dose response of both NPs and bulk sizes of aspirin 
on MNi frequencies in lymphocytes from breast cancer patients and normal healthy 
volunteers. The histogram in Figure 29 shows that the ibuprofen NP ***p ≤ 0.001, 
ibuprofen bulk **p ≤ 0.01, aspirin NP ***p ≤ 0.001 and aspirin bulk ***p ≤ 0.001 
significantly reduced MNi numbers in lymphocyte from breast cancer patients 
compared to the high baseline frequency of MNi in the untreated cells; by contrast, 
in lymphocytes from healthy individuals both drugs had no effect in either form 
when compared to the relatively low MNi frequency in the untreated cells. 
 
Figure 29 Comparison between MN frequencies in lymphocytes from healthy females and BC 
patients exposed to ibuprofen and aspirin including SE and significance. (N = 5) 
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              Figure 30 shows (A) Binucleated, (B) Mononucleated, and (C) Multinucleated cells. 
 
                  Figure 31 shows binucleated cells (A) with one MN and (B) with two MNi. 
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4.4 Discussion 
Micronuclei are small extra-nuclear chromosomal fragments that can be observed 
in the cytosol after anaphase through nuclear division. MNi may originate from 
acentric chromosomal fragments or entire mis-segregated chromosomes which are 
usually not incorporated into either of the daughter nuclei (Fenech, 2007; Fenech 
et al., 2011; Torres-Bugarín et al., 2014). The roles of ibuprofen and aspirin in both 
sizes, NP and bulk, and their influence on MNi frequencies in binucleated 
lymphocytes was analysed in this study. The lymphocytes were obtained from both 
healthy females and breast cancer patients. Many studies recently suggested that 
regular intake of NSAIDs especially ibuprofen and aspirin have a role in cancer 
prevention (Johannesdottir et al., 2012). Concentrations of 250 ng/ml of ibuprofen 
NP, 250 ng/ml of ibuprofen bulk, 500 ng/ml of aspirin NPs, and 500 ng/ml of aspirin 
bulk were used in these experiments. As a PC 0.4 µM of MMC was used. 
Lymphocytes from both groups were exposed to both drugs in either form and 
cultured for 72 hours. Cyto-B was added to each culture after 44 hours to block cell 
cytokinesis by inhibiting the microfilament formation and cell division. At 72 hours, 
the cells were extracted, fixed, applied to glass slides, stained, and then scored 
(Fenech, 2007; Fenech et al., 2011). Our results showed (Tables 6 and 7) that the 
NDI values of all experiments were within the normal range (1.3 – 2.2) which 
indicates that the majority of viable cells had completed one cell division. Between 
10% - 17% of healthy lymphocyte cells and 6% - 20% of lymphocyte cells from 
breast cancer patients were multinucleated showing a low proportion of the cell 
population had already have progressed to the second mitosis in the presence of 
Cyto-B. In experiments using lymphocytes from healthy individuals, ibuprofen and 
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aspirin showed no effect on MNi frequencies when compared to the untreated 
cells, i.e. the number of MNi within the untreated cells and the drug-treated cells 
were in the same range at about 2-3 per 1000 BiNC. Only the PC increased the 
MNi frequency sharply 2-fold compared to the untreated cells ***p ≤ 0.001. 
Different results were obtained from experiments using lymphocytes from BC 
patients. It is clear that both drugs reduced cytogenic damage. Both drugs (see 
Table 7) showed an apparent reduction in MNi frequency compared to the 
untreated cells, in particular: ibuprofen NP ***p ≤ 0.001, ibuprofen bulk **P ≤ 0.01, 
aspirin NP ***p ≤ 0.001 and aspirin bulk ***p ≤ 0.001. This was due to the 2-folds 
higher baseline damage in lymphocytes from BC patients when compared to those 
from healthy individuals. By comparing the two drugs, it became clear that aspirin 
was more effective than ibuprofen (Figure 29) reducing the high cytogenetic 
baseline damage in lymphocytes of BC patients.  Furthermore, the effects of NP of 
both ibuprofen and aspirin on MNi frequencies were stronger compared to bulk-
sized drugs supporting the theory that NP have the ability to penetrate inside the 
nucleus faster than bulk sizes (Singh et al., 2009). From this work, it is clear that 
the outcome from BC patients corresponds to recent studies that suggested the 
ibuprofen and aspirin have the ability to reduce DNA damage which in turn may 
have a role in prevention of many  cancer types (Ali, 2014) 
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Chapter 5 - Comet assay on BLM with and without 
recovery 
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5. Comet repair assay 
5.1 Introduction 
The Comet assay is a method used for direct assessment of DNA damage in 
mammalian cells (Azqueta and Collins, 2013). The Comet assay in recent years is 
a method of choice to measure genotoxic DNA damage in lymphocytes due to its 
time/cost efficiency, simplicity and high sensitivity (Kapka-Skrzypczak et al., 2011). 
The assay is using as a molecular biomarker for simultaneous monitoring to 
evaluate chemical genotoxicity in DNA damage and repair (Alvarez-Moya and 
Reynoso-Silva, 2015; Costa and Teixeira, 2014). Monitoring the repair of DNA is 
essential to assess cancer susceptibility (Gaivão and Sierra, 2015). All cells 
possess repair pathways for various types of DNA damage to avoid permanent 
changes being made to the DNA. The method used to assess DNA repair progress 
is also known as the challenge assay (Azqueta et al., 2014). The In-vitro cellular 
repair assay is a technique monitoring DNA repair process; this approach is also 
called the mutagen challenge assay. In this test, a genotoxic element such as 
MMC, doxorubicin, or BLM is utilised to challenge cells generating DNA damage. 
To provide the ability to monitor the DNA single strand breaks manner to re-join 
after repairing them (Azqueta and Collins, 2013; Azqueta et al., 2014). After 
incubation, cells are then transferred into a fresh buffer to eliminate the bleomycin 
genotoxic effect. A further incubation of cells is used with short time intervals (30 
min) to allow the DNA to repair. In the next step, the DNA damage level is 
measured from samples at the end of the repair process then it is compared to the 
control samples (untreated cells). The Olive tail moment and % tail DNA 
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parameters are used for analysis and comparison with the DNA damage repair 
ability. The repair of single strand breaks can be monitored by observing other 
DNA lesions, such as oxidised bases which repair by using the base excision 
repair pathway. Additionally, altered bases can be evaluated, by using specific 
enzymes which have the capability to distinguish these lesions and consequently, 
alter these lesions to strand breaks (Azqueta and Collins, 2013; Azqueta et al., 
2014).  
The principle of the present study depends on the previous methodology described 
above. Cells from healthy female individuals and BC patients were challenged 
using the genotoxic agent bleomycin and then cells washed with RPMI and allowed 
to repair DNA damage in the absence of BLM. A group of samples were allowed to 
repair DNA damages in the presence of aspirin and ibuprofen (both nano and bulk 
forms) individually. This step was chosen due to previous work on the NSAIDs 
(aspirin and ibuprofen) using the Comet assay. This study is designed to examine 
whether these two compounds (both forms) increase the repair of DNA in the 
presence of the genotoxic agent (BLM). 
BLM was chosen in this research as it was used in other repair studies. Various 
studies have examined DNA damage and repair mechanisms in lymphocyte cells 
obtained from patients with different cancer types after bleomycin exposure, such 
as lung cancer, mastocarcinoma patients, nasopharyngeal carcinoma, and 
oesophagus cancer (Laffon et al., 2010; Wei et al., 2005; Zhang and Gu, 2013). 
DNA damage resulting from BLM treatment is repaired through HRR, NHEJ and 
BER mechanisms (Wei et al., 2005). Bleomycin is a radiomimetic drug commonly 
used as part of chemotherapy for treatment of  various solid tumours, especially for 
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cutaneous and subcutaneous tumours such as testicular carcinomas, lymphomas, 
and head and neck tumours (Chen and Stubbe, 2005; Gibot et al., 2013; Wang et 
al., 2013; Yu et al., 2013). Bleomycin induces DNA damage by binding to the 
transition metal iron (Fe(II)) or/ and oxygen to produce ROS which cause DNA 
damage (single and double-strand) in the presence of an electron reductant. 
Bleomycin can also cause lipid peroxidation and mitochondrial DNA damage (Chen 
and Stubbe, 2005; Wang et al., 2013). The most common cellular responses to 
BLM exposure are cell-cycle arrest, senescence, mitotic cell death, and apoptosis 
(Wang et al., 2013) 
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5.2 Materials and Methods  
5.2.1 Materials 
The materials required for this study have been described in section 2.1 
5.2.2 Methods 
The treatment of whole blood cells treatment has been described in section 2.2. 
The Comet assay was prepared under alkaline conditions. Treatment groups for all 
samples and treatment with NSAID compounds were described in sections 2.7.2, 
2.7.4 and 2.7.5. Embedding of cells in LMP agarose, DNA unwinding and 
electrophoresis, and neutralisation have been described in sections 2.7.5, 2.7.6, 
and 2.7.7 respectively. Scoring of cells and statistical analysis has been described 
in sections 2.7.8 and 2.11. 
This study was conducted to evaluate the DNA repair ability of lymphocyte cells, 
following BLM exposure for 30 min from healthy female control individuals and 
breast cancer patients. Cells were allowed to carry out DNA repair in the presence 
of aspirin and ibuprofen (NP and bulk forms), to determine the impact of these two 
compounds on cell DNA repair using the Comet assay technique. The results were 
compared to the treated and untreated cells and self-repaired cells without NSAIDs 
treatment (BLMR).  
All slides were coded before the scoring, and 100 cells were scored using a 
microscope equipped with a CCD camera and Computer system using Comet 
Kinetic Imaging Software© 6.0, Liverpool/Andor Technology, Belfast, UK. Each 
experiment used blood from BC patients or healthy individual were repeated fifteen 
times. Mean data were calculated with standard errors. 
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5.2.3  Statistics 
Data from both Olive tail moment and % Tail DNA were used to accomplish SPSS 
Statistics (Version 18). Most of the data were normally distributed. The normality of 
distribution was checked using the Kolmogorov-Smirnoff and Shapiro Wilk’s test. 
One-Way ANOVA test (>three variables) and t-test (two variables) were used 
determine the difference between healthy individuals’ samples and BC samples. 
Different kinds of significance were determined, all samples were compared to the 
untreated cells, including the BLM sample where DNA repair was not allowed to 
proceed (disallowed) ***p = ≤ 0.001, **p = ≤ 0.01, *p = ≤ 0.05 and ns (not 
significant).  
The Second comparison was among treated with BLM and allowed to repair 
(BLMR) in the presence of NSAIDs (ASP B, ASP N, IBU B & IBU N) and the 
sample that was treated with BLM and disallowed DNA repair against the sample 
treated with BLM with allowing DNA self-repair without any of NSAIDs †††p = ≤ 
0.001, ††p = ≤ 0.01, †p = ≤ 0.05 and ns† (not significant). 
Finally, the different forms of each NSAIDs were compared with each other. ASP N 
was compared to ASP B and IBU N was compared to IBU B ˄˄˄p = ≤ 0.001, ˄˄p = ≤ 
0.01, ˄p = ≤ 0.05, ns˄ (not significant).  
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5.3 Results 
5.3.1 Aspirin and ibuprofen concentration response on lymphocyte 
from healthy female volunteers treated with bleomycin 
In figures 32 and 33 showed the concentration response of aspirin and ibuprofen 
both forms on lymphocytes DNA from healthy volunteers treated with BLM using 
Olive tail moment and % Tail DNA, standard errors SE and significance. Using the 
one-way ANOVA It was clear from the histogram in the Olive tail moment figure 
(32) that treatments showed significant increases in DNA damage compared to 
untreated cells, BLM, BLMR and ibuprofen-bulk **p ≤ 0.001 and ASP-bulk **p ≤ 
0.01. However, both aspirin and ibuprofen NPs were not-significant (ns*) compared 
to untreated cells. Comparing to the BLMR treatment BLM, ibuprofen and aspirin 
NPs showed †††p ≤ 0.001, aspirin bulk ††p ≤ 0.01, whereas, ibuprofen bulk was 
(ns†). Another comparison was made between NPs and bulk forms of aspirin and 
ibuprofen; aspirin NP showed significance ^p ≤ 0.05 compared to the bulk form 
where there were no significance (ns^) between the two ibuprofen forms. In % Tail 
DNA figure (33) all treatments showed significance against untreated cells ***p ≤ 
0.001 except aspirin NP it was not-significant. In comparing with BLMR all 
treatments were significant (BLM, IBU bulk, IBU NP, ASP bulk and ASP NP) †††p  ≤ 
0.001. The effect of both ibuprofen and aspirin were significant when compared the 
NPs with bulk forms ^^^p ≤ 0.001. 
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Figure 32 illustrates the comparison of the aspirin and ibuprofen (both forms) concentration-
response, (±SE), on lymphocyte DNA from healthy female volunteers treated with bleomycin using 
Olive tail moment (n = 15). 
BLM = without repair 
BLMR = repair allowed 
† = comparison with BLMR 
^ = comparison between nano and bulk 
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Figure 33 illustrates the comparison of the aspirin and ibuprofen (both forms) concentration-
response, (±SE), on lymphocyte DNA from healthy female volunteers treated with bleomycin using 
% Tail DNA (n = 15). 
BLM = without repair 
BLMR = repair allowed 
† = comparison with BLMR 
^ = comparison between nano and bulk 
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5.3.2 Aspirin and ibuprofen concentration response on lymphocyte 
from BC patients treated with bleomycin 
In figures 34 and 35 are displayed the concentration responses of aspirin and 
ibuprofen both forms on lymphocyte DNA from BC patient treated with BLM using 
Olive tail moment and % Tail DNA, standard errors SE and significance. Using the 
one-way ANOVA It was clear from the chart for Olive tail moment figure (34) that 
BLM, BLMR and BLMR + IBU bulk treatments showed a significant increase in 
DNA damage compared to untreated cells, BLM and BLMR  ***p ≤ 0.001 and 
BLMR + IBU bulk *p ≤ 0.05. However, BLMR +ASP NPs, BLMR + IBU NPs and 
BLMR + ASP bulk were ns*. Furthermore, Comparing the treatments with BLMR 
BLM, BLMR + ASP bulk and BLMR + IBU bulk showed no-significance, whereas, 
BLMR + IBU NP  †p ≤ 0.05 and BLMR + ASP NP ††p ≤ 0.01. Another comparison 
was made between NPs and bulk forms of aspirin and ibuprofen, where there was 
no significance (ns^) between forms for both compounds. In % Tail DNA figure (35) 
BLMR + IBU NP, BLMR + ASP bulk and BLMR + ASP NP treatment showed (ns*) 
non-significance against untreated cells. By comparing treatments with BLMR, 
BLM and BLMR + IBU bulk were (ns†) not-significant. However, there was 
significance with BLMR + ASP NP ††p ≤ 0.01 and both IBU NP and ASP bulk †p ≤ 
(0.05). Both ibuprofen and aspirin were not-significant when comparing the NPs 
with bulk forms (ns^). 
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Figure 34 Comparison of the aspirin and ibuprofen (both forms) concentration-response, SE, and 
significance on lymphocyte DNA from BC patients treated with bleomycin using Olive tail moment 
(n=15) 
BLM = without repair 
BLMR = repair allowed 
† = comparison with BLMR 
^ = comparison between nano and bulk 
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Figure 35 Comparison of the aspirin and ibuprofen (both forms) concentration-response, SE, and 
significance on lymphocyte DNA from BC patients treated with bleomycin using % Tail DNA (n=15) 
BLM = without repair 
BLMR = repair allowed 
† = comparison with BLMR 
^ = comparison between nano and bulk 
 
 
 
 
 
 
U n tr e a te d
 c e lls
B L M B L M R B L M R
+ IB U  B U L K
B L M R
+ IB U  N P s
B L M R
+ A S P  B U L K
B L M R
+ A S P  N P s
0
5
1 0
1 5
2 0
2 5
T re a tm e n t
%
 T
a
il
 D
N
A
* * *
* * *
*
n s *
n s *
n s *
n s †
n s †
†
†
††
ns^
ns^
 108 
 
 
5.4 Discussion 
An interesting study was carried out by Kirkland and Speit (2008). They showed 
from studies, interalia Comet-assays, on 67 compounds that are classified 
carcinogens but showed negative or equivocal results in the micronucleus assay; 
90 % were positive in the comet assay. Furthermore, 78 % of non-carcinogens 
were negative. The comet assay has been used since the very earliest days to 
monitor the repair of DNA damage.  Thousands of DNA lesions per cell can be 
repaired in a matter of half an hour in conventional cultured mammalian cells 
(Azqueta and Collins, 2013). Milić and Kopjar (2004) confirmed the high sensitivity 
of the alkaline comet assay for evaluating bleomycin genotoxicity to human 
lymphocytes. It has also elucidated the advantages of the alkaline comet assay as 
one of the primary screening technique for in vitro investigations of drug-DNA 
interactions, particularly in assessing mechanisms of action of new drugs. 
In this study, aspirin and ibuprofen have shown a chemo-protective influence 
against DNA damage induced by BLM in human lymphocytes obtained from BC 
patients and healthy female individuals using Comet assay. Aspirin and ibuprofen 
reduced the DNA damage in blood lymphocytes challenged with BLM. Both aspirin 
and ibuprofen exhibited a protective effect at concentrations of 500 µg/ml and 250 
µg/ml respectively. 
Data from all treatments illustrated that all samples challenged with BLM had high 
levels of DNA damage in both OTM and % tail DNA. This damage was, significant 
compared to the untreated cells **p ≤ 0.01 or ***p ≤ 0.001.  Aspirin and ibuprofen 
NPs showed ns compared to untreated cells in most samples especially in % tail 
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DNA after 30 minutes incubation with these two compounds. Non-significance 
implies that DNA was highly repaired and reduced to normal when compared to 
other treatments against untreated cell.  
For healthy individuals, the decrease in DNA damage was obvious in the cells 
exposed to BLM and repaired in the absence of both NSAIDs (BLMR), compared 
to the cells treated with BLM and scored without repair incubation. Both aspirin and 
ibuprofen treatments showed higher reductions in DNA damage when compared to 
the BLM treatment with no repair. BC patients cells in general showed the same 
pattern as healthy individuals. Using  OTM parameter in BC patients cells, the BLM 
treatment, BLMR + IBU bulk, and BLMR + ASP bulk were unable to show a 
significance reductions in DNA damage compared to the BLMR treatment, 
however, in % tail DNA parameter BLMR + ASP bulk treatment showed 
significance reduction in DNA damage †p ≤ 0.05. When cells treated in the 
presence of NSAIDs, the ASP, and IBU NPs demonstrated greater reductions in 
DNA damage compared to the bulk forms. This result showing the importance of 
both compounds nano-forms in inducing DNA repair especially with the increased 
active surface area of nanoparticles, as a result of their large surface area to 
volume ratio. 
It is interesting to combine NSAIDs with chemotherapy agent such as BLM; this 
combination suggested the possibility of enhancing the efficiency of the cancer 
chemotherapy and reducing toxicity on healthy cells. BLM is inducing the 
genotoxicity and pathogenesis by generating Oxidative stress and inflammation, 
which have a role in DNA damage, chromosome impairment, and mutagenesis 
(Arab et al., 2015; Zhou et al., 2014). 
 110 
 
 
 
 
 
 
 
Chapter 6 - Investigation of XRCC3 and P53 
proteins in Lymphocytes obtained from Healthy 
Female Individuals and BC Patients and Treated 
with Both forms of Aspirin and Ibuprofen Using 
Western Blot Technique 
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6. Western blot study 
6.1 Introduction 
The western blot technique is frequently used in research to isolate and identify 
proteins. In this method, a mixture of proteins is separated depending on molecular 
weight, during gel electrophoresis. The proteins are then transferred to a 
PVDF/nitrocellulose membrane producing a band for every protein. The membrane 
is then incubated with antibodies specific to the protein of interest (Liu et al., 2014; 
Mahmood and Yang, 2012). The unlinked antibody is rinsed off leaving only the 
linked antibody linked to the target protein. The bound antibodies are then 
identified by imaging the membrane. As the antibodies are only bound to the 
protein of interest, only specific bands should be visible. The thickness of the band 
correlates to the amount of protein present; thus a known standard can be used to 
indicate the quantity of protein present (Mahmood and Yang, 2012).  
Use of non-steroidal anti-inflammatory drugs NSAIDs is correlated with a minor 
reduction in BC occurrence (de Pedro et al., 2015). However, it is not obvious 
whether NSAIDS can improve the outcome of patients already diagnosed with BC. 
Given that there are is an increase of 2.5 million BC survivors in the USA only, and 
that aspirin and other NSAIDs are frequently consumed medications, their 
influence on BC prognosis has significant clinical importance (Sutton et al., 2016). 
However, epidemiological studies on NSAIDs intake and BC prevalence have not 
yielded consistent results (Ou et al., 2013). Case–control studies globally show a 
small reduction in BC with NSAIDs use. Moreover, a protective effect of NSAIDs 
was verified in 13 studies (de Pedro et al., 2015), while only 7 papers 
demonstrated a higher risk of BC among NSAIDs medication users (de Pedro et 
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al., 2015; Vinogradova et al., 2011). A non-significant effect was determined in one 
case–control study (Kirsh et al., 2007). Furthermore, the vast majority of 
observational studies depended on the self-reported consumption of NSAIDs, 
generally obtained as over-the-counter medications; the few exemptions were 
studies based on prescriptions, which constitute a safer strategy to assess NSAIDs 
consumption. Finally, another prospective explanation for the contrast in results 
may lie on the theory that some NSAIDs inhibits COX-2 more intensely than 
others, which leads to different risk reductions (de Pedro et al., 2015). 
XRCC3 is classified as one of the DNA repair genes that encodes for a protein that 
has an essential role in repairing the double-strand breaks, cross-link repair and 
the stability. XRCC3 has been associated with the emergence of Rad51 as a key 
component of the homologous DNA repair (HR) pathway (Bei et al., 2015; Han et 
al., 2006). Cells with XRCC3 disorders demonstrated defects in Rad51 genesis, 
which leads to genetic instability and increased sensitivity to DNA-damaging 
agents (Griffin, 2002; Zhao et al., 2013). People carrying the abnormal allele of 
XRCC3 Thr241Met had relatively high DNA adduct rate in lymphocyte DNA, 
demonstrating that this polymorphism was correlated with relatively low DNA repair 
capacity(Han et al., 2006; Matullo et al., 2001). Therefore, XRCC3 has been of 
substantial interest as a candidate susceptibility gene for cancer (Bei et al., 2015). 
A large number of molecular epidemiological studies have been conducted to 
assess the role of XRCC3 polymorphisms on several neoplasms, such as breast, 
lung, bladder, head and neck cancer (Figueiredo et al., 2004). Nevertheless, the 
outcomes remain apparently conflicting rather than decisive. As a result of this 
discrepancy among studies, it has been suggested that polymorphisms might play 
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a different role in different tumour sites. Also, even at the same cancer site, 
considering the prospective small effect size of these genetic polymorphisms to 
tumour and the relatively small specimen size in several studies. The contradiction 
will become evident since some single studies may have been underpowered to 
detect a small effect but real association (Bei et al., 2015; Peng et al., 2014). 
The TP53 tumour suppressor gene encodes the p53 protein, which is an essential 
molecular decision maker of stress control in human cells (Horn and Vousden, 
2007). Functioning within a complex signalling pathway, p53 senses excessive 
stress signals resulting from deregulated oncogenes expression, such as DNA 
damage, metabolic disorders or telomere erosion. The p53 signalling reaction is 
dependent on the cellular state and the type of oncogene. P53 triggers self-cell 
death (apoptosis), DNA repair, fugacious or permanent cell cycle arrest and 
metabolic homoeostasis maintenance (Li et al., 2012). P53 activation–inactivation 
depends on an accumulation of posttranslational modifications (PTMs) and 
interferes with proteins that induce p53 activation and subcellular relocation, 
allowing it to induce expression of appropriate sets of genes needed in the 
signalling pathway (Walerych et al., 2012). P53 alters cellular response to stress 
via either  transcriptional or post-transcriptional pathway (Kelly et al., 2009). 
A number of genomic studies in mouse models have shown that lack of p53 
function leads to tumour formation and that restoration of p53 leads to a rapid and 
effective retraction of established, in situ tumours, providing vigorous evidence for 
designing chemotherapy that restores p53 function (Shangary and Wang, 2009).  
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In this study, we examined the expression of XRCC3 and P53 proteins in 
lymphocyte cells obtained from healthy females and BC patients, after treating clls 
using ibuprofen and aspirin, both forms individually. The Western blot technique 
was utilised in this study, to evaluate the impact of two NSAIDs on the expression 
of both proteins XRCC3 and P53. 
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6.2 Material and methods 
Please refer to Chapter 2 Material and Methods section (2.1, 2.2 and 2.9). 
6.3 Results 
6.3.1 XRCC3 expression in lymphocyte from healthy female 
individuals treated with both forms of aspirin and ibuprofen 
individually  
XRCC3 protein expression in lymphocytes from healthy volunteers treated with 
both forms of aspirin (500µg) and ibuprofen (250 µg) was quantified using the 
Western blot assay. Two different incubation times were used 8 and 24 h 
individually. Untreated cells were used as a control to determine the value of 
XRCC3 expression for comparison. As depicted in Figure (36), the expression of 
XRCC3 was significantly increased after 8 h incubation for ASP bulk ***p ≤ 0.001 
and ASP nano ***p ≤ 0.01, whereas the IBU nano was non-significant (ns). The 
IBU bulk showed a decrease in expression compared to the untreated cells. 
Following 24 h treatment, the XRCC3 expression decrease compared to 8h 
incubation in ASP nano and bulk treatment where it showed a non-significant 
increase compared to untreated cells. IBU bulk and nano showed no effect on 
XRCC3 expression after 24 h incubation.   
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Figure 36 showing the effect of aspirin and ibuprofen both forms on XRCC3 protein expression in 
lymphocytes from healthy female individuals incubated for 8 and 24 h individually. (A, B) Developed 
bands of XRCC3, and β-actin by immunoblotting. β-actin was used as a control. (C, D) 
demonstrating relative expression of XRCC3 after treatment with aspirin and ibuprofen both forms 
individually, SE, and significance comparing to untreated cells. (N=3) 
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6.3.2 XRCC3 expression in lymphocyte from BC patients treated with 
aspirin and ibuprofen both forms  
We were prompted to investigate the expression of XRCC3 in lymphocytes from 
breast cancer pateints treated with aspirin (500µg) and ibuprofen (250 µg) both 
forms (NPs, Bulk) for either 8 or 24 h. Untreated cells were used as a control to 
determine the basal level of XRCC3 expression for comparison. The results in 
Figure 37 showed that the expression of XRCC3 was decreased for all treatments 
ASP NPs *p ≤ 0.05 ASP Bulk (ns), IBU NPs *p ≤ 0.05 and IBU Bulk **p ≤ 0.01. 
However, the expression remained unchanged (ns) for ASP NPs, ASP Bulk and 
IBU NPs following 24 h incubation, whereas, IBU Bulk showed a significant 
decrease compared to untreated cells.  
 
Figure 37 Western Blot validation results illustrating the effect of aspirin and ibuprofen both forms 
on XRCC3 protein expression in lymphocytes obtained from BC patients incubated for 8 and 24 h 
individually. (A, B) Images displaying Western blot results of XRCC3, β-actin was used as a control. 
(C, D) Graph displaying relative expression of XRCC3 after treatment with aspirin and ibuprofen 
both forms individually, SE, and significance comparing to untreated cells. (N=3) 
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6.3.3 P53 expression in lymphocyte from healthy female individuals 
treated with both forms of aspirin and ibuprofen individually  
P53 protein expression in lymphocyte from healthy volunteers treated with both 
forms of aspirin (500µg) and ibuprofen (250 µg) were assessed using Western blot. 
As shown in Figure 38, the expression of p53 was not changed (ns) in either 
incubations 8 hrs or 24 h with ASP bulk, IBU nano and IBU bulk. Likewise, ASP 
NPs caused non significance change in p53 protein expression compared to the 
untreated cells.  
 
Figure 38 Western Blot verification results demonstrating the effect of aspirin and ibuprofen both 
forms on P53 protein expression in lymphocytes obtained from female healthy control incubated for 
8 and 24 h individually. (A, B) Images displaying Western blot results of p53 and β-actin which was 
used as a control. (C, D) Graph displaying quantitative analysis of P53 relative expression after 
treatment with aspirin and ibuprofen both forms individually, SE, and significance comparing to 
untreated cells. (N=3) 
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6.3.4 P53 expression in lymphocyte from BC patients treated with 
aspirin and ibuprofen both forms  
In studying the effect of aspirin and ibuprofen (bulk and NP) on p53 protein 
expression in lymphocyte from BC patients. The cells were treated individually with 
both forms of aspirin (500µg) and ibuprofen (250 µg) for 8 or 24 h, and p53 protein 
expression evaluated by western blot. Untreated cells were used as a control to 
quantify the value of the p53 expression for comparison. As depicted in Figure 39, 
the expression of p53 protein showed non-significant (ns) change when treated for 
8 h with ASP NPs, ASP bulk and IBU NPs. By contrast, the IBU bulk showed 
significant downregulation *p ≤ 0.05 when compared with untreated cells in 8 h 
incubation.  In 24 h incubation both forms of aspirin (NPs and bulk) upregulated the 
expression of P53 significantly **p ≤ 0.01 and *p ≤ 0.05 respectivily. However, in 
ibuprofen nano and ibuprofen bulk treatment there was no difference in p53 
expression compared to untreated cells.  
 
Figure 39 Western Blot validation results demonstrating the effect of aspirin and ibuprofen both 
forms on p53 protein expression in lymphocytes obtained from BC patients incubated for 8 and 24 h 
individually. (A, B)  Western blot results show representative examples for expression of p53, as 
well as β-actin which served as an internal control. (C, D) Eexhibiting relative expression of p53 
after treatment with aspirin and ibuprofen both forms individually, protein levels were expressed as 
means in bar graphs including SE and significance comparing to untreated cells. (N=3) 
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6.4   Discussion 
Genomic DNA is exposed daily to a considerable number of damaging agents. In 
healthy cells, the cellular repair mechanisms are generally controlling the damage 
very efficiently, with only sporadic breaks or errors. Dysfunctional repair 
mechanisms may lead to genetic and/or multifactorial disorders. This effect 
depends on whether it occurs on germline or somatic cells, which allows for 
making an alteration in the genome that comprises one of the major motivations in 
evolution. Even amongst healthy individuals of similar species, however, the lack of 
protection against DNA damage including removal of lesions in DNA or the rate of 
unrepaired damage may vary (Chakarov et al., 2013). It is well known that genes 
and environmental elements are exceedingly engaged in the stages of the majority, 
common non-hereditary cancers. Regardless, the age at the first child's birth, 
nullparity and a family history are classified as most common risk factors but in the 
majority of BC cases, the cause of the disease remains unclear. The potential role 
for DNA erroneous repair in cancer development, namely in BC has been the 
subject of supplemental studies since it has been declared that BC patients might 
be deficient in one of the key DNA repair pathways (Ralhan et al., 2007). 
The XRCC3 protein participates in homologous recombinational repair pathway 
(HRR) and is considered a member of a family of Rad-51-related proteins that 
probably participate in HRR to maintain chromosome stability. The XRCC3 (Ex8-
5C > T, T241M, rs861539) polymorphism was studied in various case-control 
studies to clarify its role in susceptibility to breast cancer (Silva et al., 2010). And 
the results showed that there was an association between XRCC3 and BC risk 
(Fan Chai et al., 2015; Xu et al., 2016).  
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Responses to DNA damage are mediated through highly protected DNA damage 
checkpoint pathways that are essential for tumour suppression by arresting cell 
cycle development or triggering cellular senescence and programmed cell death. 
P53 is a vital participant in the tumour-suppressive pathway. p53 is mutated and 
inactivate in almost 50% of human cancers (Reinhardt and Schumacher, 2012). 
Recent studies propose that p53 not only antagonises oncogenic transformation 
but moreover regulates non-cell-independent responses to DNA damage by 
mediating liquidation of cells with damaged DNA through the native immune 
system. Additionally, p53 also dominates genes that are correlated to lifespan 
extension (Feng and Levine, 2010). 
The present work studied the expression of XRCC3 and p53 protein in lymphocyte 
cells obtained from BC patients and healthy female individuals. Cells were treated 
with 250 ng/ml of ibuprofen (NPs and bulk) or 500 ng/ml of aspirin both forms for 
either 8 or 24 h. The results showed that, both aspirin and ibuprofen have effect on 
XRCC3 and p53 expression. 
For XRCC3 protein expression, healthy cells treated for 8h had significant increase 
in its expression for both ASP bulk and ASP nano ***p ≤ 0.001. However in both 
IBU treatments (NPs and Bulk) there was a non-significant change in XRCC3 
protein expression compared to the untreated cells. Following 24 h treatment, all 
treatments displayed non-significant change compared to the untreated cells. In 
cells obtained from the BC patients, the expression exhibited a different trend, 
where ASP bulk increased the expression non-significantly in 8 h treatment. Both 
ASP nano and IBU nano showed significant decrease *p ≤ 0.05 compared to 
untreated cells in 8 h treatment, however, ASP bulk remained unchanged in either 
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8 or 24 h incubation.  IBU bulk followed the similar trend in both incubations, where 
it reduced the expression of XRCC3 significantly **p ≤ 0.01 compared to untreated 
cells. It is clear from the above that there is a difference in XRCC3 protein 
expression between the cells from healthy and BC patients. 
In this study, it is clear that the treatment with NSAIDs produced a significant 
increase in XRCC3 protein expression in healthy lymphocytes. However, in BC 
patient’s lymphocytes both ibuprofen and aspirin seemed to decrease the 
expression. Limited studies have been conducted to determine the relationship 
between NSADs intake and XRCC3 expression in different types of cells including 
cell lines from different tumours and healthy cells. Moreover, the results of two 
different studies in this area have been inconsistent or controversial (Dibra et al., 
2010; Dibra et al., 2011). 
The expression of p53 protein in healthy lymphocytes in either 8hrs or 24 h 
incubation was non-significantly (ns) changed for ASP bulk, ASP nano, IBU nano 
and IBU bulk compared to the untreated healthy lymphocytes.   
Treatment with both forms of aspirin bulk and nano caused a significant increase in 
the expression of p53 protein *p ≤ 0.05 and *p ≤ 0.01 respectively in lymphocytes 
from BC patients incubated for 24 h. However, this increase was non-significant in 
8 h treatment. for ibuprofen nano treatment the increase in protein expression was 
not significant at either incubation times. The ibuprofen bulk caused a significant 
decrease in protein expression *p ≤ 0.05 after 8 h treatment, whereas, in 24 h 
incubation showed no change compared to untreated lymphocytes from BC 
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patients. The p53 protein expression was different between the two NSAIDs used 
in this study. 
Our results are consistent with previous outcomes of studies displaying a 
protective effect on the part of NSAIDs in patients with High-grade dysplasia 
(HGD). However, their effect on the development of cancer cells is less clear 
(Vaughan et al., 2005). A number of studies suggested that the protective effect of 
NSAIDs initiates from the activating gene-1 (NAG-1), which acts as cox inhibitor. 
NAG-1 is a macrophage inhibitory cytokine-1 and a member of the transforming 
growth factor β family. Furthermore, increase in the expression of tumour 
suppressor protein p53 mediates the activation of NAG-1 (Baek et al., 2001; Kang 
et al., 2013).  
Figueroa et al. (2009), studied the relation between several NSAIDs and p53 
protein overexpression by examining 170 cases of esophageal adenocarcinomas, 
147 gastric cardia adenocarcinomas, 220 non-cardia gastric adenocarcinomas, 
and 112 esophageal squamous cell carcinomas, using immunohistochemistry. 
They recorded the overexpression of p53 in 72% of esophageal adenocarcinoma, 
69% of gastric cardia adenocarcinoma, 52% of non-cardia gastric 
adenocarcinoma, and 67% of esophageal squamous cell carcinoma.  Bardia et al. 
(2016), suggested that only aspirin has an inverse correlation with breast cancer 
risk after multivariate analysis. However, there was no association for other (non-
aspirin) NSAIDs with BC.   
Further research is needed to identify the NSAIDs protective mechanisms of 
NSAIDs on BC.  
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Chapter 7 - Investigation of P53, COX1 and COX2 
genes expression in lymphocytes from healthy 
females and BC patients treated with both forms of 
aspirin and ibuprofen using Real-Time PCR 
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7. QPCR study 
7.1 Introduction 
Real-Time PCR is a technique that allows for the logarithmic amplification and 
detection of a short sequence of specific nucleic acids in “real-time” by the 
measuring of fluorescent probes. In theory, a single copy of a particular DNA 
sequence can be amplified and identified by the use of proper primers and probes, 
with a direct relationship linking the starting target and the quantity of product at a 
given cycle (Zuo et al., 2010). The probe attaches to the target DNA sequence and 
cleaves, performing a fluorescence that is recognised by a qPCR machine after 
each thermal cycle is finished. This procedure is utilised for the  detection and 
quantification of different viruses and parasites in various specimen mediums 
(Valasek and Repa, 2005). 
Prostaglandin (PG) endoperoxide synthetase is also known as cyclooxygenase 
(COX) which plays an essential role in the inflammatory progression through 
altering the synthesis of prostaglandins from arachidonic acid (Gao et al., 2014). 
Higher COX expression in BC was first proposed on account of elevated PG 
production in BC cell lines (Brandão et al., 2013). To date there are two isoforms of 
cyclooxygenase: COX-1 and COX-2 (Gao et al., 2014). COX1 and COX2 are 
catalyse prostanoid biosynthesis in the same committed step with similar 
capabilities. However,  the two COXs are encoded by different genes located on 
distinct chromosomes, and they differ considerably in their expression pattern 
(Nagao et al., 2013). COX1 is strongly expressed in most tissues and is 
accountable for the biosynthesis of PGs involved in different housekeeping 
functions, including the platelet function, gastrointestinal and regulation of renal 
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functions. However, COX-2 can be promptly inducible by inflammatory stimuli and 
a significant number of mitogenic and pro-inflammatory cytokines which lead to 
increased levels of prostaglandins which can impact on cell proliferation, apoptosis 
and angiogenesis, and finally contributing to neoplastic genesis and development 
(Kuroda and Yamashita, 2002). 
Moreover, many studies have suggested that genetic polymorphisms in COX1 and 
COX2 might be associated with the liability to develop cancer or effect drug 
efficacy in humans. To date, various studies have investigated associations of the 
changes in expression of the COX1 and COX2 genes and NSAID consumption on 
cancer risk; Nevertheless, these studies have produced contradictory outcomes 
(Nagao et al., 2013). 
In BC, different studies have indicated that moderate to high COX-2 expression is 
correlated with the formation of mammary tumour and its expression is related to 
parameters of aggressive BC with large tumour mass, positive axillary lymph node 
metastases, and positive human epidermal growth factor (HER2) (Gao et al., 
2014). Inhibition of COX-2 expression could prevent the proliferation of BC cell 
lines in vitro (Dai et al., 2012). Genetic polymorphisms in COX-2 have shown 
alteration in its expression and influence the susceptibility to various carcinomas, 
including breast cancer (Yu et al., 2010). 
The p53 tumour suppressor gene encodes the p53 protein, which is a fundamental 
molecule that is considered as the “decision maker of stress control” in human cells 
(Horn and Vousden, 2007).  Functioning through a complicated signalling 
mechanism, p53, discriminates excessive stress signals emerging from regulating 
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oncogene expression, for instance, DNA damage, telomere erosion or metabolic 
disorders. The p53 signalling response relies on the variety of oncogenes and the 
cellular state. P53 induces apoptosis (self-cell death), DNA repair processes, 
perpetual or fugacious cell cycle arrest and metabolic equilibrium maintenance (Li 
et al., 2012). P53 activation–inactivation depends on an accumulation of 
posttranslational modifications (PTMs) and interacts with proteins that trigger p53 
activation and relocates the subcellular, which in turn induces the expression of 
relevant sets of genes required in the signalling pathway (Walerych et al., 2012).  
The aim of this study is to investigate the impact of aspirin and ibuprofen both 
forms on the expression of p53, COX1 and COX2 genes in lymphocytes from BC 
patients and compare them with those from healthy female individuals using the 
quantitative PCR technique. 
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7.2 Material and Methods  
Please refer to Chapter 2 Material and Methods section (2.1, 2.2 and 2.8). 
7.3 Results 
7.3.1 P53 mRNA abundance in lymphocytes from healthy female 
individuals treated with both forms of aspirin and ibuprofen 
individually.  
P53 gene expression changes in lymphocyte from healthy volunteers treated with 
both forms of aspirin (500µg) and ibuprofen (250 µg) was quantified using 
quantitative PCR. Five different incubation times were used 0, 2, 4, 6 and 8 h 
individually. 0 h incubation was used as a control to determine the value of the p53 
expression for comparison. All expressions were normalised against β actin using 
the ΔΔCT method. Preview results Figure 40 showed that there was no significant 
(ns) change in p53 expression in all four treatments aspirin bulk, aspirin nano, 
ibuprofen bulk and ibuprofen nano. This non-significant alteration was seen in all 
four incubation times 2, 4, 6 and 8 h compared to 0 hr incubation. 
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Figure 40 Real-time PCR (qPCR) results expressed in relative changes of p53 mRNA over the 
control, using β actin as an endogenous housekeeping gene in lymphocytes from healthy female 
volunteers. (A) Relative expression level of P53 mRNA in ASP BULK treatment. (B) Relative 
expression level of P53 mRNA in ASP NPs treatment. (C) Relative expression level of P53 mRNA 
in IBU BULK treatment. (D) Relative expression level of P53 mRNA in IBU NPs. Results are 
expressed as mean ± SEM and significance compared with the 0 h treatment. (N=3) 
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7.3.2 P53 mRNA abundance in lymphocytes from BC patients treated 
with both forms of aspirin and ibuprofen individually. 
To assess whether both forms of aspirin (500µg) and ibuprofen (250 µg) have an 
influence on the expression of p53 gene, qPCR analysis on cDNA from RNA 
extracted from lymphocytes from BC patients was performed. Five different 
incubation times 0, 2, 4, 6 and 8 h were chosen for this experiment. 0 h incubation 
was used as a control to determine the value of the P53 expression for 
comparison. All expressions were normalised against β actin using the ΔΔCT 
method. Real-time PCR results Figure 41 showed that the increase of p53 
expression in aspirin bulk was not- significant (ns) at 2, 4 and 6 h, however, the 
increase was significant **p ≤ 0.01 at 8 h compared to the 0 h incubation. In cells 
treated with aspirin nano the p53 expression was non-significant (ns) at 2 and 4 h 
incubation, whereas, this expression was significant in 6 and 8 h *p ≤ 0.05 and ***p 
≤ 0.001 respectively. In contrast, the ibuprofen bulk had no significant (ns) 
influence on the expression of p53 in all four treatments against 0 hr treatment, 
although, increase of expression can be seen in the graph 41C at 2 and 4 h. 
Ibuprofen nano showed significant increase *p ≤ 0.05 at 6 and 8 h treatment 
compared to the 0 h treatment.   
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Figure 41 Real-time PCR (qPCR) results expressed in relative changes of P53 mRNA over the 
control, using β actin as an endogenous housekeeping gene in lymphocytes from BC patients. (A) 
Relative expression level of P53 mRNA in ASP BULK treatment. (B) Relative expression level of 
P53 mRNA in ASP NPs treatment. (C) Relative expression level of P53 mRNA in IBU BULK 
treatment. (D) Relative expression level of P53 mRNA in IBU NPs. Results are expressed as mean 
± SEM and significance compared with the 0hr treatment. (N=3) 
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7.3.3 COX1 mRNA abundance in lymphocytes from healthy female 
volunteers treated with both forms of aspirin and ibuprofen 
individually  
COX1 gene expression in lymphocytes from healthy female volunteers treated with 
both forms of aspirin (500µg), and ibuprofen (250 µg) was identified by quantitative 
PCR. Five different incubation times were namely 0, 2, 4, 6 and 8 h. Leave out 
individually. 0 h incubation was utilised as a control to determine the value of the 
COX1 expression for comparison. All expressions were normalised against β actin 
using the ΔΔCT method. It is evident from the Figure 42 that both forms of aspirin 
and both forms of ibuprofen down-regulated the expression of the COX1 gene. In 
aspirin bulk the decrease was significant *p ≤ 0.05 at 2 h treatment and was ***p ≤ 
0.001 at 4, 6 and 8 h. for aspirin nano, ibuprofen bulk and ibuprofen nano the 
expression was decreased significantly ***p ≤ 0.001 at all four incubations 
compared to the zero hour treatment.  
 
 
 133 
 
 
Figure 42 Real-time PCR (qPCR) results expressed in relative changes of COX1 mRNA over the 
control, using β actin as an endogenous housekeeping gene in lymphocytes from female healthy 
volunteers. (A) Relative expression level of COX1 mRNA in ASP BULK treatment. (B) Relative 
expression level of COX1 mRNA in ASP NPs treatment. (C) Relative expression level of COX1 
mRNA in IBU BULK treatment. (D) Relative expression level of COX1 mRNA in IBU NPs. Results 
are expressed as mean ± SEM and significance compared with the 0hr treatment. (N=3) 
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7.3.4 COX1 mRNA abundance in lymphocytes from BC patient  
treated with both forms of aspirin and ibuprofen individually  
The quantitative PCR technique determined expression patterns of COX1 in 
lymphocyte from BC patients treated with both forms of aspirin (500µg), and 
ibuprofen (250 µg). Five different incubation times were namely 0, 2, 4, 6 and 8 h. 
Leave out individually. 0 h incubation was used as a control to evaluate the value 
of the COX1 expression for comparison. All expressions were normalised against β 
actin with the ΔΔCT method. QPCR results showed Figure 43 the expression of 
COX1 was downregulated in the presence of aspirin or ibuprofen. In aspirin bulk 
treatment the expression was significantly decreased at 2 and 4 h incubation *p ≤ 
0.05 and ***p ≤ 0.001 respectively. However, there was no statistical difference at 
6 h incubation and the expression increased in 8 h **p ≤ 0.01. Aspirin nano 
downregulated the COX1 expression in all incubations where the significance was 
*p ≤ 0.05 at 2 h incubation and **p ≤ 0.01 at 4, 6, and 8 h. In ibuprofen bulk and 
nano the decrease was *p ≤ 0.05 at 2 h and ***p ≤ 0.001 at 4, 6, 8 h.   
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Figure 43 Real-time PCR (qPCR) results expressed in relative changes of COX1 mRNA over the 
control, using β actin as an endogenous housekeeping gene in lymphocytes from BC patients. (A) 
Relative expression level of COX1 mRNA in ASP BULK treatment. (B) Relative expression level of 
COX1 mRNA in ASP NPs treatment. (C) Relative expression level of COX1 mRNA in IBU BULK 
treatment. (D) Relative expression level of COX1 mRNA in IBU NPs. Results are expressed as 
mean ± SEM and significance compared with the 0hr treatment. (N=3) 
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7.3.5 COX2 mRNA abundance in lymphocytes from healthy female 
individuals treated with both forms of aspirin and ibuprofen 
individually.  
COX2 gene expression changes in lymphocyte from healthy female volunteers 
treated with both forms of aspirin (500µg), and ibuprofen (250 µg) was specified 
using quantitative PCR. Five different incubation times were used 0, 2, 4, 6 and 8 h 
individually. 0 h incubation was used as a control to evaluate the value of the 
COX2 expression for comparison. All expressions were normalised against β actin 
using the ΔΔCT method. Preview results Figure 44 showed that there was no 
significant (ns) change in COX2 expression in all four treatments aspirin bulk, 
aspirin nano, ibuprofen bulk and ibuprofen nano. The non-significant (ns) changes 
were seen at all four incubation times 2, 4, 6 and 8 h compared to 0 h incubation. 
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Figure 44 Real-time PCR (qPCR) results expressed in relative changes of COX2 mRNA over the 
control, using β actin as an endogenous housekeeping gene in lymphocytes from female healthy 
volunteers. (A) Relative expression level of COX2 mRNA in ASP BULK treatment. (B) Relative 
expression level of COX2 mRNA in ASP NPs treatment. (C) Relative expression level of COX2 
mRNA in IBU BULK treatment. (D) Relative expression level of COX2 mRNA in IBU NPs. Results 
are expressed as mean ± SEM and significance compared with the 0hr treatment. (N=3) 
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7.3.6 The effects of aspirin and ibuprofen both forms, on the 
expression of COX2 in lymphocytes from BC patients. 
The qPCR technique was used to assess whether the both forms of aspirin 
(500µg) and ibuprofen (250 µg) had an influence on the expression of the COX2 
gene, by evaluating the cDNA from RNA extracted from lymphocytes obtained from 
BC patients. Five different treatment incubations were used 0, 2, 4, 6 and 8 h 
individually. The expression of COX2 was influenced statistically by the presence 
of the aspirin or ibuprofen whether bulk or nanoparticle. Figure 45 the aspirin 
nanoparticle showed a steady, significant decrease ***p ≤ 0.001  at 2, 4, 6 and 8 h 
incubations compared with 0 h. Aspirin bulk illustrated significant change where it 
was **p ≤ 0.01 at the first two hours and ***p ≤ 0.001 at 4, 6, 8 h. Furthermore, 
ibuprofen bulk showed **p ≤ 0.01 at 2 and 4 h then ***p ≤ 0.001 for 6 and 8 h, 
however, ibuprofen nano demonstrated *p ≤ 0.05 at 2 and 8 h then ***p ≤ 0.001 at 
4 and 6 h.  
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Figure 45 Real-time PCR (qPCR) results expressed in relative changes of COX2 mRNA over the 
control, using β actin as an endogenous housekeeping gene in lymphocytes from BC patients. (A) 
Relative expression level of COX2 mRNA in ASP BULK treatment. (B) Relative expression level of 
COX2 mRNA in ASP NPs treatment. (C) Relative expression level of COX2 mRNA in IBU BULK 
treatment. (D) Relative expression level of COX2 mRNA in IBU NPs. Results are expressed as 
mean ± SEM and significance compared with the 0hr treatment. (N=3) 
 
 
 
 
 
 
 
 
 140 
 
7.4 Discussion  
Various epidemiologic and observational studies have investigated the correlation 
between NSAIDs and BC, although the results remain controversial. A high 
proportion of case-control studies suggested that regular intake of NSAIDs is 
protective against BC. However, the majority of cohort studies did not detect this 
correlation. Several studies have dealt with NSAIDs as an entire group or with 
particular drugs, such as aspirin and ibuprofen, but not with NSAIDs subgroups. 
Moreover, limited attention has been given to the effect of NSAIDs on different 
tumour categories, for instance, ductal/non-ductal, stage at diagnosis or presence 
of hormonal receptors (Dierssen-Sotos et al., 2016; Pocock et al., 2004). In the 
predictable Women’s Health Initiative Observational Study, regular use of NSAIDs 
was apparently associated with a reduction in the proportion of BC (van Nes et al., 
2011).  
In our study, we examined the prospective expression of the P53, COX1 and 
COX2 in lymphocytes from BC patients and healthy female volunteers, treated with 
aspirin and ibuprofen individually. 
Our data demonstrated that aspirin and ibuprofen had no significant effect on p53 
expression in lymphocytes from healthy female individuals either in the nano or 
bulk forms treatments including all incubations compared to 0 h incubation. In 
lymphocytes from BC cancer patients, both drugs impact was uneven depending 
on the compound and whether it was in the bulk or nano form. Aspirin bulk 
increased the expression of p53 significantly only after 8 h of incubation, whereas, 
in aspirin nano treatment, the statistical change was from 6 to 8 h. Interestingly, the 
ibuprofen bulk showed a non-significant change in gene expression. However, this 
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change was significant at 6 and 8 h for ibuprofen nano. Similar results were 
proposed by Tofiq (2015), that NSAID (Sulindac sulfone) increased the p53 activity 
in Hela cells. 
The expression of the COX1 gene was significantly downregulated in lymphocyte 
from both healthy female and BC cancer patients when treated with either aspirin 
or ibuprofen. Furthermore, both forms were similar in decreasing the expression of 
COX1 gene. Aspirin and ibuprofen are nonselective COX inhibitors, which have 
illustrate a similar impact for both COX-1 and COX-2. Their inhibition of COX-1 
leads to the decreased biosynthesis of homeostatic, cytoprotective, and hemostatic 
PGs, which further resulted in gastric ulcers and bleeding. Moreover, the inhibition 
of COX-1 in kidneys induced excessive water and sodium retention, which in turn 
reduced blood flow (Regulski et al., 2016).     
In BC, the prognostic influence of COX2 expression varied widely among studies, 
and was emphasised by the fact that the majority of these studies did not stratify 
patients under study according to systemic therapy. Furthermore, in most of these 
studies, patients were given some forms of systemic therapy, so that the 
prognostic influence data of COX2 in the absence of systemic therapy was 
incomplete. This is especially the case  for endocrine therapy, as COX2 stimulates 
the diversion of arachidonic acids into prostaglandins which catalyse aromatase 
and therefore the formation of oestrogens (van Nes et al., 2011). 
In our study, we investigated and assessed the impact of both the NSAIDs aspirin 
and ibuprofen in nano and bulk forms on the expression of COX2 in lymphocytes 
from healthy females and BC patients. We found that both NSAIDs hade no 
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statistically significant effect on the change in COX2 expression in healthy female 
lymphocytes, and this applies to all treatments with aspirin nano, aspirin bulk, 
ibuprofen nano and bulk, regardless of the incubation times. However, this impact 
was completely different in the lymphocytes of BC patients , where both drugs 
downregulated the COX2 expression significantly. The expression decrease was 
comparatively small with aspirin bulk, ibuprofen bulk and nano, whereas, 
expression was sharply reduced with aspirin nano treatment. 
Some studies suggested that there is an inverse correlation between p53 and 
COX2. Kim et al., (2010), found that inhibiting the expression of p53 by Pifithrin-α, 
led to upregulation of the COX-2 expression through a MAPK-Dependent Pathway 
in Breast and fibrosarcoma cells (Kim et al., 2010). By contrast, a previous study 
demonstrated that the anti-proliferative impact of NSAIDs was associated with an 
increased level of p53 acetylation and this effect appeared to be a COX-
independent pathway (Tofiq, 2015). 
Similar outcomes have been reported in some larger epidemiological studies 
examining NSAIDs, where it has a protective effect on BC. Furthermore, they have 
a role in inhibiting the expression of COX1 and COX2. The mechanisms behind 
these functions still need further investigation (Zhang et al., 2014). 
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Chapter 5 – General Discussion 
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8. General Discussion 
Many studies recently suggested that regular intake of some NSAIDs have a 
protective effect against several types of tumours including BC. The protective 
effect of NSAIDs is thought to be mediated by the regulation of different pathways 
including inhibition of COX1, COX2 and expression of some tumour suppressor 
genes such as p53. Although, ibuprofen and aspirin are the most commonly used 
NSAIDs in these studies (Agrawal and Fentiman, 2008; Harris et al., 2005), none 
of the previous studies have investigated the effect of both drugs on DNA damage, 
specifically, damage to lymphocyte obtained from BC patients. Therefore, in this 
present study different sizes of ibuprofen and aspirin (NPs and bulk) were used to 
examine their protective effect on DNA damage of BC patients using lymphocytes 
as surrogate cells. Lymphocytes were selected for this study because they are 
exposed to different environments within the body by travelling in the bloodstream, 
and hence they can reflect DNA damage induced by endogenous and exogenous 
genotoxins from chemical and physical agents (Najafzadeh et al., 2012).  NPs, on 
the other hand, have stable and known chemical and physical properties in their 
normal size. However, the smaller size of NPs allows them to penetrate the cell 
membrane by different mechanisms and finally they can diffuse through the 
nuclear membrane. In mitosis, NPs can become surrounded by the nucleus 
because the nuclear membrane disintegrates during mitosis. This can in turn lead 
to a direct interaction between the NPs and chromosomes that can subsequently 
promote contact with DNA (Singh et al., 2009). This fact was behind the selection 
of ibuprofen and aspirin NPs alongside the bulk size in this study.    
 Lymphocytes were treated with H2O2 and MMC which were used as a positive control 
to induce DNA damage in the Comet and micronucleus assays, respectively. 
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Suspending buffer was used as a negative control in both assays since it has no 
effect on DNA damage. BC patients lymphocytes and healthy volunteer lymphocytes 
were both treated with NPs and bulk forms of both drugs and the results were 
compared to the untreated controls.  
8.1 Effect of aspirin and ibuprofen on DNA damage using the Comet 
assay 
The Comet assay is a micro-electrophoretic method that facilitates the direct 
visualisation and measurement of DNA damage in several types of mammalian 
cells (Azqueta and Collins, 2013; Ostling and Johanson, 1984). The Comet assay 
has many advantages that make it the preferred technique for assessing DNA 
damage, because of, for example, simplicity, time efficiency, and low cost of the 
assay (Anderson et al., 1997; Anderson et al., 1998; Anderson et al., 1991). The 
Comet assay can recognise and follow the damage in single or double DNA 
strands and alkali labile sites. The principle of a Comet assay is based on 
investigation and measurment of the ratio between the head and tail of DNA where 
the head represents intact DNA while the tail corresponds to damaged DNA (Tice 
et al., 2000).  
In this present study, lymphocytes were treated in vitro, with ibuprofen and aspirin 
(NP and bulk) individually for 30 min at 37°C followed by lymphocyte scoring.  The 
lymphocyte nuclei displayed an increase in head DNA ratio after exposing the 
lymphocytes to the following doses: ibuprofen NP 250 ng/ml, ibuprofen bulk 250 
ng/ml, aspirin NP 500 ng/ml, and aspirin bulk 500 ng/ml. In the case of 
lymphocytes from healthy volunteers, we observed minor and insignificant damage 
to DNA Figure 13, 14, 19 and 20. Lymphocytes obtained from BC patients, by 
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contrast, showed a decrease in DNA damage compared to the untreated cells. 
This decrease was significant for both aspirin forms (NP and bulk) ***p ≤ 0.001 and 
**p ≤  0.01, respectively Figures 21 and 22. Despite the fact that there was a 
reduction in DNA damage observed with both forms of ibuprofen, this decrease 
was insignificant when data were analysed using ANOVA test Figures15 and 16. 
The insignificant effect of ibuprofen to protect against DNA damage perhaps may 
be attributed to the short incubation time (30 min) used with this assay. The short 
incubation might not be sufficient to cause significant DNA damage reduction. The 
result also showed that aspirin showed a greater reduction of the DNA damage 
compared to ibuprofen. Aspirin NP greater more significant DNA damage reduction 
compared to aspirin bulk form. This emphasises the theory  that NPs have a better 
ability to penetrate into the nucleus compared to bulk size (Singh et al., 2009). 
8.2 Ibuprofen and aspirin effect on MNi induction in the micronucleus 
assay 
Detecting the effects of ibuprofen and aspirin on genomic DNA damage was 
established in lymphocyte cells using the Comet assay. Thereafter, micronucleus 
technique was used to study the influence of these drugs on lymphocytes at the 
cytogenetic level. During the cell cycle and growth many disorders at the stage of 
mitosis can lead to the appearance of MNi, which are smaller and separate extra 
nuclear fragment (Fenech, 2006, 2007). A MN is formed when the chromosomes 
fail to interact with spindle fibres in the mitosis phase. MN consists of acentric parts 
or whole chromosome, and MN presence results from chromosomal damage and 
cell damage. In this study, MNi were chosen over  several types of cell 
abnormalities, to reflect and emphasise chromosomal breakage, rearrangement, 
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loss, and apoptosis (Fenech, 2007). In all experiments, the NDIs were within 
normal range Tables 6 and 7. The BiNC percentages after scoring 1000 cells in 
each experiment were within normal percentage range in lymphocyte cultures. The 
low % of multiNC in cell cultures indicated that the cyto B was efficient in blocking 
further cell division after one cell cycle (Fenech, 2007; Sgura et al., 1997).    
 In this assay ibuprofen and aspirin were also used in both NP and bulk forms, and 
lymphocytes from fresh blood were used. The cells were exposed to both ibuprofen 
and aspirin and cultured for 72 h. Cyto B was then added to the culture after 44 h 
to block cytokinesis during cell division. Lymphocytes were scored for the presence 
of MNi which indicates the chromosomal abnormality. Compared to the untreated 
cells, both ibuprofen and aspirin showed an insignificant effect on lymphocytes 
from healthy female volunteers Table 6 and Figure 27. By contrast, a significant 
reduction of MNi formation was observed on lymphocytes from BC patients with 
both ibuprofen and aspirin (NP and bulk) compared to untreated cells Table 7 and 
Figure 28. However, aspirin caused a greater reduction of MNi formation compared 
to ibuprofen. Furthermore, NPs of both drugs showed the superior reduction in MNi 
formation compared to their bulk forms Figure 29. Using the ANOVA test, aspirin 
NP, aspirin bulk and ibuprofen NP showed a significant ***p ≤ 0.001 reduction in 
MNi formation compared to ibuprofen bulk **p ≤ 0.01. 
8.3 Comparing Comet and micronucleus assays results 
Both aspirin and ibuprofen caused a reduction in DNA damage and micronucleus 
formation in lymphocytes from BC patients. Both aspirin bulk and NP forms 
showed a significant decrease in both the Comet and micronucleus assays. By 
contrast, ibuprofen showed a significant reduction with the micronucleus test but 
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not with the Comet assay. This discrepancy might be due to the difference in the 
exposure time of both assays since the Comet assay has an incubation time of 
only 30 minutes, whereas, the micronucleus assay has a longer incubation period 
of 72 hours. Therefore, long exposure makes the cells more exposed to ibuprofen, 
and this perhaps explains the significant reduction with the micronucleus but not 
with Comet assay. 
The genotoxicity induced by ibuprofen has been debated in recent years. However, the 
controversy still exists as, for instance, the genotoxicity of ibuprofen on Salmonella 
strains did not result in conclusive and satisfactory results (Tripathi et al., 2012). 
Philipose et al. (1997), on the other hand demonstrated a genotoxic effect of ibuprofen 
in a mouse model where it caused a weak genotoxic effect observed on sister 
chromatid exchange. This is in line with our finding of minor DNA damage seen in 
healthy lymphocytes exposed to ibuprofen in the Comet assay. However, the dissimlar 
results were found when Ghosh et al. (2010) found that ibuprofen had no genotoxic 
effect over a two weeks’ period. Conversely, Tripathi et al. (2012) conducted a similar 
study to investigate the genotoxic effect of ibuprofen on bone marrow cells of mice. 
Finally, they concluded that ibuprofen might induce a genotoxic effect in bone marrow 
cells of mice and this effect was more pronounced at 40 and 60 mg/kg bodyweight. 
Although aspirin does not induce a genotoxic effect by itself, its protection against 
genotoxicity was observed when it was combined with the genotoxic anticancer agent 
MMC. Here mice treated with aspirin at 0.5, 5 and 50 mg/kg combined with 2mg/kg 
dose of MMC showed a reduced genotoxic effect. It was observed that aspirin led to a 
dose dependent reduction in the genotoxicity produced by MMC in various organs 
such as liver and spleen and the reduction was in a dose dependent fashion (Baron 
and Sandler, 2000; Niikawa et al., 2008). These findings correspond to this project’s 
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outcomes that aspirin reduced the DNA damage in lymphocytes from BC patients. 
Niikawa et al. (2008) suggested that the mechanism behind the capacity of aspirin to 
reduce the DNA damage is its ability to scavenge or diminish or block different oxygen 
free radicals. 
8.4 Comet assay on BLM with and without recovery 
Our study using the Comet assay and micronucleus assay has demonstrated 
substantial reductions in DNA damage in lymphocytes when treated with the two 
forms of aspirin and ibuprofen, with NP forms causing more reduction. With these 
findings, the study aimed to examine the DNA repair influence in cells challenged 
with a genotoxic agent in the presence or absence of both aspirin and ibuprofen, to 
conclude whether these two NSAIDs induced DNA repair or not. Investigating DNA 
repair disorders has utmost importance in monitoring predisposition to the 
development of cancer (van Gent and Kanaar, 2016). 
Lymphocytes from healthy females and female BC patients were challenged using 
BLM, and cells were allowed to carry out DNA repair without BLM. Some of the 
challenged cells were allowed to repair DNA in the presence of either aspirin or 
ibuprofen, as previously discussed. 
Subsequent exposure to BLM, the greatest capacity for repairing of DNA was 
observed when cells were allowed to repair in the presence of NSAIDs. 
Furthermore, the treatment with nano forms showed higher repair in DNA 
compared to their bulk versions, where DNA damage was reduced to untreated 
cells levels. 
In cells from BC patients, the DNA was still unrepaired in lymphocytes in BLMR, 
where DNA repair was allowed in the absence of either aspirin or ibuprofen 
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compared to untreated cells Figure 34 and 35. The reductions in DNA damage was 
present with the bulk forms of the NSAIDs, and this repair was higher in the 
presence of the NP form in both drugs. These findings illustrated the capacity of 
both compounds to induce the repair processes and reduce the DNA damage. The 
large surface of NPs could be the reason for the difference in DNA repair between 
nano and bulk forms. Where NPs have a large surface area to volume ratio, and 
maybe the nano size allowed for fast penetration to the nucleus compared to the 
bulk size (Huang et al., 2012). 
Our findings were compatible with a study done on lymphocyte from lung cancer 
patients and challenged with BLM. Where the DNA damage was reduced in 
challenged cells in the presence of NSAIDs but not in the absence of aspirin and 
ibuprofen (Ali, 2014). 
8.5 Investigation of XRCC3 and p53 proteins in Lymphocytes from 
Healthy Female and BC Patients Treated with Both forms of 
Aspirin and Ibuprofen using Western Blot 
Mammalian cells have specific mechanisms for the repair of double-strand DNA 
breaks (DSBs): nonhomologous end joining (NHEJ) and homologous 
recombination repair (HRR). HRR is a vertebrate regulated pathway through which 
repair proteins accumulate sequentially at DSBs. In HRR, Rad51 and the five 
paralogues Xrcc3, Rad51B, Rad51C, Rad51D, and Xrcc2 accomplish distinct and 
collaborative functions to repair damage (Loignon et al., 2007). 
Thus, we studied the effect of the two forms of aspirin and ibuprofen on the 
expression of XRCC3 and p53 proteins in lymphocytes from healthy female 
volunteers and BC patients using the western blot technique. Two different 
incubation times 8 and 24 h were chosen for each treatment. In the XRCC3 protein 
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expression experiment in cells from healthy individuals Figure 36, our results 
demonstrated that 8 h incubation with both aspirin nano and bulk significantly 
increased the protein expression. However, both forms of ibuprofen displayed no 
statistical change in XRCC3 expression. Both drugs showed no change in protein 
expression after 24 h incubation. The increase in protein expression after aspirin 
treatment may explain the minor increase in DNA damage that was observed in the 
Comet assay experiments in Chapter 3. Furthermore, aspirin may cause non-
significant DNA damage in the first 8 h of the incubation in normal female 
lymphocytes. In samples from BC patients Figure 37, aspirin bulk showed a non-
significant change in XRCC3 expression after 8 or 24 h incubations. However, 
ibuprofen bulk decreased the expression approximately 2- fold at both 8 and 24 h. 
Both aspirin nano and ibuprofen nano decreased the expression nearly 1-fold in 8 
h incubation, whereas, both drugs in nano forms showed no change in XRCC3 
protein expression after 24 h of incubation.  Both NSAIDs showed a non-significant 
change in p53 expression in lymphocytes from healthy control samples after 8 or 
24 h incubation Figure 38. The p53 expression results in lymphocytes from BC 
patients was varied among treatments Figure 39, where aspirin bulk showed no 
change in 8 h and a significant increase *p ≤ 0.05 at 24 h incubation. However, 
aspirin nano was not significant at 8 h while the statistical  significance **p ≤ 0.01 
at 24 h. Ibuprofen nano had no effect on p53 expression after incubation for 8 or 24 
h. Ibuprofen bulk significantly reduced p53 expression *p ≤ 0.05 at 8 hrs, whereas, 
this change disappeared after 24 h. 
Dibra et al. (2010) proposed that exposure to aspirin (1 mM) for 48 h, caused a 
significant increase in the transcription of XRCC3 in the SW480 colorectal cancer 
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cell line. They suggested that the toxic influence of aspirin on the transcriptional 
machinery could explain this effect. By contrast, our results showed no XRCC3 
overexpression in BC patients lymphocytes when treated with aspirin or ibuprofen. 
Furthermore, both aspirin and ibuprofen nano decreased the protein expression 
significantly *p ≤ 0.05, where, ibuprofen bulk reduced it **p ≤ 0.01, whilst 
considering the difference between BC and colorectal cancer  and the type of cells 
used in both studies.  
A study by Loignon et al. (2007) indicated that the absence of exogenous DNA 
damage, reduced the expression of XRCC3 which then decreased cell proliferation 
by slowing replication. Also, decreasing the XRCC3 expression in lymphocytes 
from BC patients after treatment with aspirin and ibuprofen perhaps means that 
both NSAIDs stimulated DNA repair process.   
8.6 The effect of both aspirin and ibuprofen on COX1, COX2 and P53 
genes expression in lymphocytes from healthy female and BC 
Patients using Real Time PCR 
Many studies have been done recently to assess the ways that aspirin acts against 
BC and many mechanisms have been suggested for the phenomenon. Inhibition of 
cyclooxygenase is the most common known pathway. COX enzymes are enzymes 
that have an important function in the synthesis of some mediators particularly 
prostaglandin-endoperoxide. The prostanoids including prostaglandins are 
essential biological mediators, which serve different biological roles. So far three 
isoenzymes of COX are known COX1, COX2 and COX3. Aspirin and ibuprofen 
can block both COX1 and COX2 (Simmons et al., 2004).  
The main function of COX enzymes Figure 5 to convert the arachidonic acid to 
prostaglandin H2 and finally synthesise the biological form of prostaglandin which 
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has roles  in cell division, migration, angiogenesis, and apoptosis (Ulrich et al., 
2006). In addition, many preclinical studies found that pro-inflammatory 
prostaglandin E2 (PGE2) catalyses the production of oestrogen by increasing the 
expression of the aromatase gene. The latter belongs to the P450 family of 
enzymes and stimulates the production of oestrogen from androgen. Furthermore, 
various studies have found that COX enzymes stimulate PGE2 to catalyse CYP19 
transcription and lead to increases in the aromatase production and activity. These 
findings support the observation of a positive correlation between COX enzymes 
level and CYP19 expression in human breast carcinoma (Elvin et al., 2000). 
Therefore,  the preventative effect of aspirin and ibuprofen observed in BC can be 
linked to inhibition of prostaglandin by these agents and this ultimately stops the 
production of oestrogen from androgen as this conversion needs prostaglandin to 
proceed successfully. This in turn inhibits breast cell proliferation as it needs 
oestrogen to function (Lazzeroni et al., 2013). 
The COX2 signalling pathway has been marked as a fundamental mediator in the 
pathogenesis of a range of malignancies. Consistent with this concept, it has been 
evidenced that the COX2 pathway inhibition can be a key approach to the 
treatment of a variety of cancer models, including BC (Gharghabi et al., 2016). 
Previous studies have described a functional interaction between COX2 and some 
molecular targets, especially p53. Regarding this theory, the role of COX2 
inhibitors as a potential candidate to induce apoptosis through cell death 
machinery has been examined in various reports so far (Corcoran et al., 2005; 
Swamy et al., 2003). 
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In this respect, we examined the effect of NSAIDs aspirin and ibuprofen (nano and 
bulk forms) on the expression of p53, COX1 and COX2 in lymphocytes from BC 
patients and compared responses with those from healthy female volunteers.  
Our results showed a non-significant change in the expression of both p53 and 
COX2 genes in lymphocyte from healthy females after treatment with either aspirin 
or ibuprofen Figure 40 and 44. However, COX1 was downregulated significantly 
Figure 42. In lymphocytes from BC patients, the effect of both drugs was different, 
where; both forms of aspirin and ibuprofen NPs significantly increased the 
expression of p53 Figure 41. In the case of ibuprofen bulk, there was an increase 
in p53 expression but the effect was not statistically significant. However, the 
expression of COX1 and COX2 in patients cells was significantly reduced after 
treatment with both compounds either bulk or nano form Figure 43 and 45.    
 It is evident that the effect of both NSAIDs on the expression of p53 was different 
compared to their impact on COX1 and 2. Moreover, p53 and COX responded to 
this effect differently. This outcome may support the studies suggesting that 
NSAIDs inhibit cyclooxygenase via increasing the expression of tumour suppressor 
gene p53 (Wilson et al., 2003). 
 The nuclear factor of kappa light polypeptide gene enhancer in B cells (NFkB) is 
another mediator that is also inhibited by aspirin and this inhibition has been 
observed in both in vivo and in vitro studies (Lazzeroni et al., 2013). Surprisingly, 
the prevention of NFKB transcription results in an increase in the apoptosis ratio 
and this effect was found to be limited to neoplastic epithelial cells. Among others 
some in vitro studies suggested that aspirin may have a direct impact on elevating 
the levels of some important apoptotic genes namely BAX, BCL2 and caspase-3 
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genes and this eventually results in stimulation of breast tumour cell apoptosis 
(Yan et al., 2013). Aspirin also blocks angiogenesis (formation of new blood 
vessels from the pre-existing blood vessels) by inhibiting the secretion of some 
angiogenic factors and this in turn leads to promote tumour growth and this effect 
was assessed using the 3-dimensional collagen angiogenesis assay, utilising (0.5 
mM) therapeutic aspirin, which showed a reduction in tubule formation (Lazzeroni 
et al., 2013). 
Sun et al. (2012) suggested that the phosphate-ibuprofen has a considerable 
influence on two protein members of thioredoxin (Trx) system, Trx-1 and TrxR. 
phosphate-ibuprofen has the ability to change the Trx-1 to its oxidised form and 
finally reduced the expression of Trx-1. Phosphate-ibuprofen also suppressed the 
activity of TrxR. These findings demonstrated the major inhibition effect of 
Phosphate-ibuprofen on the Trx system through effects on Trx-1 and TrxR. The 
effect of Phosphate-ibuprofen on the Trx system had indirect impacts on signalling 
cascades dependent on the Trx system, for instance NFKB and MAPK. The NFkB 
is predominantly inhibited by oxidation of the Trx system through its Cys62 of p50. 
This oxidation makes NFkB unable to bind the DNA. NFKB regulates the two anti-
apoptotic proteins Bcl-2 and Mcl-1 and the inactivation of NFkB by phosphate-
ibuprofen leads indirectly to suppression of the expression of Bcl-2 and Mcl-1 
proteins. This finally increases the apoptotic process (Mitsiades et al., 2002). The 
phosphate-ibuprofen also has a role in the MAPK pathway regulation, by down-
streaming the Trx-1. This pathway remains inactive as a result of ASK1 bound to 
Trx-1. Once the Trx-1 is oxidised, this activates the pathway by releasing the 
ASK1. Furthermore, phosphate-ibuprofen has the ability to induce apoptosis and 
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suppress proliferation, that is mainly mediated by NF-_B and MAPK (Sun et al., 
2012). 
8.7 Conclusion 
Data from the Comet assay showed that ibuprofen and aspirin (both bulk and NP 
sizes) caused a reduction in DNA damage in lymphocytes from BC patients but not 
in healthy volunteers. However, the reduction of DNA damage was higher for 
aspirin compared to ibuprofen. The results were the same for both parameters 
Olive tail moment and % tail DNA. The micronucleus assay data showed a 
decrease in MNi frequency, which followed a similar pattern the results of the 
Comet assay. In both assays, aspirin was more effective than ibuprofen in reducing 
DNA damage and MNi formation seen in the Comet and micronucleus assays, 
respectively. NPs of both agents were more effective than bulk sizes. In the 
recovery study, the DNA repair process was more effective in the presence of both 
NSAIDs, where the aspirin nano form had the greatest effect compared to aspirin 
bulk, ibuprofen bulk and ibuprofen nano. Also, both forms of aspirin increased the 
expression of p53 protein, and aspirin nano increased the expression of the tumour 
suppressor gene p53. Both aspirin and ibuprofen reduced the expression of the 
COX2 gene. The results of this work are consistent with the view that NSAIDs, 
particularly aspirin and ibuprofen have a promising role in cancer treatment 
including BC. 
8.8 Future work 
From the above discussion, it can be concluded that these findings have to be 
studied extensively and using additional techniques to confirm and prove these 
results. Micronucleus FISH (Fluorescence in situ hybridisation) is one of these 
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techniques which allow the evaluation of the nature of chromosome damage 
lesions.  Since in this project ibuprofen and aspirin were used with lymphocytes 
from BC patients, it would be interesting if this work could be repeated with 
lymphocytes from different types of cancer patients to determine whether the 
results will be similar or different compared to BC. Aspirin and ibuprofen 
downregulated the expression of some genes, and it could be possible to study if 
both NSAIDs have any effect in the formation of micro-RNA (miRNA) perhaps this 
could be an additional protective effect mechanism against cancer. Finally, 
regarding the studies suggesting that aspirin and ibuprofen could have an effect on 
the expression of BAX, BCL2 and caspase-3 genes, it is possible to study this 
effect on these genes in lymphocytes from BC patients and compare them with 
healthy female volunteers.    
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Appendix 2 
Healthy female individuals and Breast cancer patients database details. 
Control 
sample 
No 
Age Ethnicity Smoking 
pack 
year 
Smoking 
history 
Family 
history 
Past Medical 
history 
A1 34 Asian ---- No No No 
M1 40 Asian ---- No No No 
R1 34 Asian ---- No No No 
S1 30 Asian ---- No No No 
K1 44 Asian ---- No No No 
CH1 29 Asian 5 10/d BC No 
SH1 33 Asian ---- No No No 
A18 41 Asian ---- No No No 
O1 36 Asian ---- No No No 
1723 45 Caucasian ---- No No No 
4107 56 Caucasian ---- No No No 
4113 80 Caucasian ---- Ex-smoker Heart 
disease 
Osteoprosis 
4114 45 Caucasian ---- No No No 
4115 45 Caucasian ---- No No Arthritis 
4122 50 Caucasian ---- No No No 
4522 52 Caucasian ---- No No No 
4523 53 Caucasian 21 10/d-42y No Lumbar disc 
4524 60 Caucasian ---- No No No 
4526 61 Caucasian ---- No No No 
4922 53 Caucasian 16 10/d-32y No No 
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BC 
sample 
No 
Age Ethnicity Smoking 
pack 
year 
Smoking 
history 
Family 
history 
Past  Medical 
history 
4796 80 Asian ---- No No No 
4802 51 Caucasian 7.5 15/d No No 
4805 85 Caucasian ---- No No No 
5076 71 Caucasian ---- No No kidney transplant 
5189 41 Asian ---- No No No 
5351 70 Caucasian 10 10/d No IHD, Chol 
5357 81 Caucasian ---- No No HTN, Chol 
5363 47 Caucasian 6 20/d No No 
5364 47 Caucasian ---- No No No 
5372 32 Caucasian 2.1 7/d No N 
5375 65 Asian ---- No No HRT 
5554 36 Asian ---- No No No 
5558 46 Caucasian ---- No No No 
5572 57 Caucasian 4.5 15/d No No 
5604 58 Asian ---- No No No 
5608 50 Caucasian 6 10/d No No 
5723 60 Caucasian ---- No No No 
6003 58 Caucasian 13 20/d-13y BC No 
6010 53 Caucasian 1 10/d-2y Ovarian 
cancer 
No 
6011 55 Caucasian ---- No BC No 
 
Fifteen percent of control individuals and 40% of BC cancer patients were 
smokers. It would appear that smoking and ethnicity did not confound the 
responses due to uniformity of the data collected. The t-test showed no change in 
significance between the two groups (p = 0.337) and (p = 0.489) respectively. In 
both, gender was not an issue since only females were examined. 
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With regard to age: 
Age 20 30 40 50 60 70 80 
Control 1 5 6 5 2 0 1 
BC 0 2 4 7 2 2 3 
 
The difference in the age might contribute some enhancement of response in the 
cancer group, since damage can increase with age. However both control and 
patients fall within the same age range. Therefore, it is unlikely that only age 
contributes to the response. Furthermore, some older patients had lower value 
than those in the ages between forty and fifty. 
 
